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Abstract  
Dysregulation of translation has a direct effect on growth control in mammalian 
cells. The initiation step of translation is an important point of control of gene expression 
and a rate-limiting step for protein synthesis. Initiation requires initiation factors (eIFs) 
that are important for the activation of both mRNA and the recruitment of ribosomal 
subunits. Previously, post-translational modifications (PTMs), such as phosphorylation, 
have been shown to be an important part in fine-tuning translation. SUMOylation is 
another PTM that affects a number of fundamental cellular processes, including the 
response to DNA damage, metabolic regulation and protein trafficking. Many eIFs have 
been identified in proteomic screens as SUMOylated targets, but to date most of these 
modifications have not been confirmed. Preliminary work from the Watts lab indicated 
that some eIFs co-purified with the S. pombe SUMO protease Ulp2. The aim of my project 
was to determine whether components of the eIF4F complex are SUMOylated and to 
initiate studies to investigate the role of this modification. The first results chapter 
investigates eIF4G, eIF3h and Sla1 (the La protein homologue) and demonstrates that 
eIF4G and Sla1, but not eIF3h, are SUMOylated in S. pombe. These experiments were 
then extended to mammalian cells. The effects of stress conditions on protein synthesis 
and SUMOylation in a range of cell lines were first analysed. SUMO localisation was 
altered in response to sodium arsenite (AR) and ionising radiation (IR). In most cell types 
tested, for example, after IR treatment, SUMO1 went to nuclear foci in HeLa cells, but 
was more abundant in the cytoplasm following exposure to AR. Next, in vivo and in vitro 
SUMOylation assays were used to demonstrate that mammalian eIF4G and eIF4A are 
both SUMOylated. Mass spectrometric analysis identified the SUMOylation sites in 
eIF4G, as K1386 and K1588. Those of eIF4AI and eIF4AII are K225 and K226, 
respectively. Mutated eIF4AII was introduced into cells to investigate the role of 
SUMOylation of this factor. Colocalisation of eIF4A/eIF4G and SUMO1 shows that, in 
AR-treated cells, SUMO1 colocalises with eIF4A and eIF4G in the cytoplasmic stress 
granules, especially at their edges. In contrast, in IR-treated cells, the colocalisation of 
eIF4G/eIF4A with SUMO1 is much more in the nucleus, compared to that in untreated 
cells, suggesting that eIF4G/eIF4A and SUMO1 may have a cellular role in some aspects 
in response to AR and IR. 
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Chapter 1  
Introduction 
 
This work is a study on the SUMO modification of eukaryotic translation initiation 
factors (eIFs) from both the fission yeast Schizosaccharomyces pombe (S. pombe) and humans. 
This chapter will provide some information involving protein synthesis, in particular 
translation initiation and translational regulation. This chapter also includes post-
translational modification, specifically SUMOylation. In addition, previous studies from 
the Watts lab will be described as preliminary results have demonstrated a number of 
eIFs to be potential SUMO targets.  
1.1 Protein synthesis  
Protein synthesis is the cellular process that produces new proteins. Eukaryotic 
transcription occurs in the nucleus and converts the information in DNA into messenger 
RNA (mRNA) by DNA-directed RNA polymerase II. Pre-mRNA is capped by 7-methyl 
guanosine triphosphate (m7GTP), spliced and then polyadenylated in the nucleus before 
being translocated to the cytoplasm. During translation, spliced mRNA associates with 
ribosomes and transfer RNA (tRNA) in order to generate proteins (Sonenberg and 
Hinnebusch, 2009; Jackson et al., 2010). Following protein synthesis, post-translational 
modification (PTM) can occur; these are mostly reversible and modulate the function of 
proteins. Thus, PTMs have important roles in biological processes. There are several 
types of PTMs which depend on a characteristic feature of proteins such as 
ubiquitylation, ubiquitin-like modification, acetylation, methylation, phosphorylation and 
glycosylation (Walsh et al., 2005; Prabakaran et al., 2012).  
Regulation of gene expression or protein synthesis occurs at multiple steps, for 
example, from the process of transcription initiation to PTM of the polypeptide chain. 
Translational regulation is widely used to control gene expression: there are two main 
mechanisms, namely global regulation and mRNA-specific regulation (Gebauer and 
Hentze, 2004; Preiss, 2005; Le Quesne et al., 2010). Dysregulation of this process may 
cause a range of diseases such as diabetes, neurological disease and some cancers (Gingras 
et al., 1999; Hollams et al., 2002; Le Quesne et al., 2010) 
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1.2 Basic mechanism of eukaryotic translation initiation  
Translation can be divided into three main stages: initiation, elongation and 
termination. The initiation stage is understood to be the main point of control of 
translation (Jackson et al., 2010). Translation initiation is a process in which an initiator 
tRNA-ribosome complex is formed and recruited to the start codon (usually AUG) on 
mRNA (Figure 1.1). The formation of the eukaryotic translation initiation apparatus 
requires a large number of proteins termed eukaryotic initiation translation factors (eIFs) 
(Sonenberg and Hinnebusch, 2009; Jackson et al., 2010). Eukaryotic translation is initiated 
by a Met-tRNA, known as initiator Met-tRNA (Met-tRNAi), which interacts specifically 
with an eIF2-GTP complex, also known as eIF2 ternary complex (Jackson et al., 2010). 
eIF3, eIF1, eIF1A and eIF5 are recruited to the small (40S) ribosomal subunit 
(Hinnebusch, 2006). Subsequently, the eIF2 ternary complex attaches to the ribosomal P 
site of 40S ribosomal subunits, bound to eIF3, eIF1, eIF1A and eIF5, to form as 43S 
pre-initiation complexes (PIC) (Pestova et al., 2001; Hinnebusch, 2006; Jackson et al., 
2010).  
To load 43S PIC onto mRNA requires the collective action of eIF4F and eIF4B or 
eIF4H, which unwind the 5’ mRNA cap of the mRNA: this structure contains m7GpppN 
(7-methylguanosine-triphospho-5’-ribonucleoside) (Jackson et al., 2010). This process 
prepares the mRNA for the attachment of ribosome. The complex of eIF4F consists of 
the cap-binding protein eIF4E, the DEAD-box RNA helicase eIF4A and the scaffold 
protein eIF4G, which binds eIF4E, eIF4A, poly(A)-binding protein (PABP), eIF3 and 
Mnk1, leading to the association of the eIF4F and the mRNA. The 43S PIC is then 
attached to the eIF4F-mRNA complex (Pestova et al., 2001; Silvera et al., 2010), becoming 
48S complex.  
The 48S complex scans along the mRNA, and secondary structures in the 
untranslated region (UTR) are unwound by eIF4A helicases (Sonenberg and Hinnebusch, 
2009). When a start codon (usually AUG) is recognized, it base-pairs with the anticodon 
of the initiator tRNA, allowing 60S ribosomal subunit to join with 40S subunit. For them 
to form an 80S ribosome, eIF5B effectively dissociates eIFs from the complex 
(Hinnebusch, 2006; Jackson et al., 2010). Then the joining of a 60S ribosomal subunit and 
the 40S ribosomal subunit produces an active 80S ribosome for the elongation phase 
(Meric and Hunt, 2002; Jackson et al., 2010). 
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Figure 1.1 Mechanism of eukaryotic initiation translation. This shows the 
formation of 43S preinitiation complex (PIC) which requires ternary complex (eIF2–
GTP–Met-tRNAi) and multifactor complex. Then 48S complex scans the mRNA in 
order to recognise a start codon. The 40S subunit then joins with the 60S ribosomal 
subunit in a reaction requiring a number of eIFs and GTP. Adapted from Hinnebusch 
(2006). 
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1.3 The composition and function of the eIF4F complex 
There are several eukaryotic initiation translation factors (eIFs) which are required 
in the initiation steps (shown in Table 1.1). This section focuses on the details of 
components of eIF4F complex, namely the 46 kDa helicase eIF4A, the 24 kDa 
phosphoprotein eIF4E and the 220 kDa scaffold protein eIF4G. Formation of the eIF4F 
complex is essential for cap-dependent translation (Gingras et al., 1999; Holcik and 
Sonenberg, 2005; Sonenberg and Hinnebusch, 2009). It is also believed to be the rate 
limiting step of translation initiation (Gingras et al., 1999). 
 
Table 1.1 A list of main eukaryotic initiation translation factors. 
Factors Size (kDa) Function Reference 
eIF1 12 Stimulates binding of eIF2-GTP-
Met-tRNAi to the 40S ribosomal 
subunit and promotes the 
recognition of the start codon  
(Passmore et al., 
2007; Jackson et al., 
2010) 
eIF1A 17 Stimulates binding of eIF2-GTP-
Met-tRNAi to the 40S ribosomal 
subunit and aids eIF1 in the 
recognition of the start codon  
(Passmore et al., 
2007; Jackson et al., 
2010) 
eIF2 125.6 
(3 subunits) 
When associated with GTP, eIF2 
binds Met-tRNAi to form eIF2 
ternary complex  
(Kimball, 1999; 
Kimball, 2002) 
eIF2B 294 
(5 subunits) 
A guanosine nucleotide exchange 
factor that exchanges eIF2-
associated GDP with GTP  
(Gomez et al., 
2002; Jennings et 
al., 2013) 
eIF3 800 
(13 subunits) 
Stabilises the above complex and 
also the cap-binding complex  
(LeFebvre et al., 
2006; Wagner et al., 
2014) 
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Factors Size (kDa) Function Reference 
eIF4A 46 Unwinds the structure of the 
5’UTR  
(Rogers et al., 1999; 
Rogers et al., 2002) 
eIF4B 70 Stimulates the helicase activity of 
eIF4A 
(Raught et al., 2004; 
Rhoads, 2009) 
eIF4E 24.5 Binds the 5’ cap of mRNA  (Rhoads, 2009) 
eIF4G 220 Binds eIF4A, eIF4E, eIF3, PABP 
and mRNA  
(Lamphear et al., 
1995; Willcocks et 
al., 2004; Yanagiya 
et al., 2009) 
eIF4H 25.4 Stimulates the helicase activity of 
eIF4A 
(Rogers et al., 2001) 
eIF5 58 Facilitates the binding of eIF2-
GTP-Met-tRNAi to the 40S 
ribosomal subunit and promotes 
in the AUG recognition  
(Passmore et al., 
2007) 
eIF5B 139 Promotes ribosomal subunit 
joining and displacement of eIF2-
GDP and factors  
(Pestova et al., 
2001; Jackson et al., 
2010; Pisareva and 
Pisarev, 2014) 
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1.3.1 eIF4A  
Eukaryotic translation initiation factor 4A (eIF4A) is a DEAD-box RNA helicase 
(Rogers et al., 2002) that is responsible for unwinding the secondary structure in the 
5’UTR of the mRNA with a requirement for ATP. This allows ribosome subunits to bind 
the mRNA and subsequently scan AUG start codons on the mRNA. (Rogers et al., 1999; 
Oberer et al., 2005; Parsyan et al., 2011). The activity of eIF4A is enhanced by the co-
factors eIF4B and eIF4H (Gingras et al., 1999; Rogers et al., 2001; Raught et al., 2004). 
eIF4A is named a DEAD box helicase because it contains conserved amino acids, namely 
conserved aspartic acid, glutamic acid, alanine and aspartic acid (DEAD) (Rogers et al., 
2002). The amino acid sequence of eIF4A (Figure 1.2) consists of nine motifs, which are 
conserved in the DEAD-box helicase family—namely motif Q, motif I, motif Ia, 
motif Ib, motif II, motif III, motif IV, motif V, and motif VI (Schutz et al., 2008; Lu et 
al., 2014). Motifs Q, I, and II are responsible for ATP hydrolysis, while motifs Ia, Ib, III, 
IV, V and VI are involved in the interaction with, or the binding to RNA (Tanner et al., 
2003; Cordin et al., 2006). 
In humans, there are three eIF4A isoforms characterised namely eIF4AI, eIF4AII 
and eIF4AIII (Parsyan et al., 2011). At the amino acid level, eIF4AI and eIF4AII share 
90-95% sequence identity. These two forms are involved in translational activity 
(Andreou and Klostermeier, 2013). They are defined as being RNA-dependent ATPases 
and as having ATP-dependent activity (Parsyan et al., 2011). For the different functions 
of eIF4AI and eIF4AII, it has been shown that suppression of eIF4AI increases 
transcription of eIF4AII, leading to higher eIF4AII mRNA and protein levels. However, 
there is no significant change in eIF4AI mRNA levels after eIF4AII is knocked down. 
This suggests that there may be differences in the cellular functions of eIF4AI and 
eIF4AII (Galicia-Vazquez et al., 2012; Andreou and Klostermeier, 2013). eIF4AIII shows 
~60% identity with these two isoforms (Li et al., 1999; Lu et al., 2014) and its function is 
not related to translation (Lu et al., 2014). In contrast to the translational function of 
eIF4AI and eIF4AII, eIF4AIII is involved in exon junction complex formation following 
mRNA splicing (Parsyan et al., 2011; Lu et al., 2014). 
 
 
7 
 
Figure 1.2 Alignment of human eIF4AI, eIF4AII and eIF4AIII.  This shows the 
conserved residues (red) and divergent residues (blue). This also shows where each motif 
of eIF4A is. This figures was taken from Lu et al. (2014). 
 
 
8 
1.3.2 eIF4E 
eIF4E is a 24 kDa phosphoprotein that was first identified as binding to the 5’ cap 
of most mRNAs with high affinity during translation initiation (Sonenberg and Gingras, 
1998; Tomoo et al., 2003; Rhoads, 2009). It has roles in controlling cell growth and 
proliferation (Sonenberg and Gingras, 1998). The level of expression of eIF4E is low and 
the amount of expressed eIF4E is the lowest compared to the amount of other eIFs in 
most cell types (Gingras et al., 1999). Crystallographic and NMR studies have been used 
to analyse the structure of eIF4E and the mRNA cap from yeast (Matsuo et al., 1997) and 
murine proteins (Marcotrigiano et al., 1997). In 2003, the crystal structures of human 
eIF4E bound to the cap analogues, m7GTP and m7GpppA, were elucidated (Tomoo et 
al., 2003) and revealed that the shape of eIF4E is like a cupped hand or baseball glove 
(Marcotrigiano et al., 1997; Matsuo et al., 1997). The 5’ cap of the mRNA is bound in the 
concave surface of eIF4E (Marcotrigiano et al., 1997; Matsuo et al., 1997; Tomoo et al., 
2003).  
The cap-binding ability of eIF4E is negatively regulated by interaction with its 
protein inhibitors, the eIF4E binding proteins (4E-BPs) (Gingras et al., 2001; 
Hinnebusch, 2012). There are three isoforms of 4E-BPs in mammals, comprising 4E-
BP1, 4E-BP2, and 4E-BP3 (Yanagiya et al., 2012). eIF4E associates with a specific 
binding motif on the 4E-BPs (YXXXXLΦ, where X is any amino acid and Φ is Leu, 
Met, or Phe). This motif is also present on eIF4G, which is able to interact with eIF4E 
(Marcotrigiano et al., 1997; Rhoads, 2009). Thus the 4E-BPs are involved in translational 
regulation by association with eIF4E which then leads to the inhibition of eIF4E bound 
to eIF4G in order to form the eIF4F complex (Hinnebusch, 2012). The association of 
eIF4E and the 4E-BPs is controlled by mammalian target of rapamycin (mTOR)-
dependent phosphorylation which is activated by extracellular stimuli e.g. hormones, 
growth factors, or mitogens (Gingras et al., 2001). Briefly, hypophosphorylated 4E-BP1 
can bind strongly to eIF4E while eIF4E-binding 4E-BP1 is phosphorylated at Thr37 and 
Thr46 residues, priming the phosphorylation of Thr70 and Ser65 in order to release free 
eIF4E to interact with other factors in the eIF4F complex (Gingras et al., 2001; Sonenberg 
and Hinnebusch, 2009). 
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1.3.3 eIF4G 
eIF4G is a 220 kDa scaffold protein that possesses docking sites for interaction 
with its partners. There are three characterised forms of mammalian eIF4G; eIF4GI, 
eIF4GII and eIF4GIII (DAP5, death-association protein 5). The first two isoforms share 
46% homology (Coldwell et al., 2012). eIF4GI is the most abundant form of eIF4G 
(approximately 85% of eIF4G). Each eIF4G isoform has a different biochemical activity 
(Coldwell et al., 2004; Coldwell and Morley, 2006; Hinton et al., 2007). eIF4GI consists 
of 1,600 amino acids (Bradley et al., 2002; Fraser, 2009) and contains binding sites for 
several binding partners (Figure 1.3). The N-terminus of eIF4G interacts directly with 
poly-A binding protein (PABP) and eIF4E (Coldwell et al., 2012). PABP is a translation 
initiation protein, involved in mRNA circularisation (Sonenberg and Hinnebusch, 2009). 
PABP associates with the 3’ poly(A) tails (Kahvejian et al., 2005), and this increases the 
affinity of eIF4E for m7GTP cap structures (Borman et al., 2000; Kahvejian et al., 2005). 
The conserved middle region of eIF4G contains a binding site for eIF4A 
(Lamphear et al., 1995; Imataka and Sonenberg, 1997; Marintchev and Wagner, 2004) and 
another site for interaction with eIF3 (Lamphear et al., 1995; Morino et al., 2000; LeFebvre 
et al., 2006). This central region of eIF4G also possesses RNA-binding activity (Yanagiya 
et al., 2009). Its crystal structure demonstrates that it folds into 5 HEAT motifs 
(Marcotrigiano et al., 2001). The C-terminal region of eIF4G contains a second, 
independent binding site for eIF4A (Imataka and Sonenberg, 1997; Korneeva et al., 2001) 
and a MAPK signal integrating kinase (Mnk1)-binding domain (Lamphear et al., 1995; 
Pyronnet et al., 1999). Mnk1 is one of a member of serine/threonine kinases which can 
bind to the C-terminus of eIF4G (Joshi and Platanias, 2014). Once the association of 
eIF4G and Mnk1 occurs, Mnk1 phosphorylates eIF4E on S209, leading to a decrease of 
its binding to the 5’ cap of mRNA (Scheper et al., 2002).  
PTMs such as phosphorylation have been shown to form an important part in fine-
tuning translation. For example, phosphorylation of eIF4GI at Ser1186 by protein kinase 
Cα (PKCα) can modulate the binding of eIF4G to Mnk1 which is an eIF4E kinase. 
Mutation of the specific eIF4GI phosphorylation site affects binding to Mnk1. This 
mutation leads to the failure of translational control through the phosphorylation cascade 
of eIF4E and other eIF4G partners (Dobrikov et al., 2011). 
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Figure 1.3 Schematic representation of eIF4GI, eIF4GII and DAP5. This shows 
regions of binding sites of other components of the translation initiation machinery. This 
also shows different forms of eIF4GI which come from different start codons (AUG) 
(f-a). Several cleavage sites of caspase-3, viral proteases (L/2A) and HIV-1 proteases are 
indicated which provide different fragments of eIF4G during apoptosis or some viral 
transfection. Modified from Coldwell et al. (2012).  
1.4 Regulation of translation 
There are several mechanisms involved in controlling translation initiation. Some 
translational regulation involves the availability of eIFs, while in other cases regulation is 
at the level of the mRNA itself. Some examples of translational regulation are described 
below.  
1.4.1 eIF2 and eIF2B regulation 
As described in section 1.2, a complex of eIF2 and GTP specifically interacts with 
Met-tRNAi to bring about interaction with the 40S ribosomal subunit by the formation 
of the eIF2 ternary complex, and is released as an inactive complex (eIF2-GDP). As 
shown in Figure 1.4, the α-subunit of eIF2 is phosphorylated on Ser51 by 
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serine/threonine kinases during stress (Kimball, 2002). Phosphorylated eIF2α is a 
competitive inhibitor of eIF2B (act as a guanine-nucleotide exchange factor, GEF), 
which is required to exchange GDP for GTP (Sonenberg and Hinnebusch, 2009; Le 
Quesne et al., 2010). Thus, Met-tRNAi binding to eIF2-GTP is decreased, resulting in an 
inhibition of 43S PIC formation that subsequently arrests protein synthesis (Kimball, 
2002; Le Quesne et al., 2010). This is consistent with overexpression of a non-
phosphorylatable form of eIF2α (Ser51Ala), which can cause malignant transformation 
(Donze et al., 1995). This suggests that regulation of eIF2 and eIF2B is an important 
mechanism for global protein synthesis and cell homeostasis (Klann and Dever, 2004; 
Hershey, 2010). 
 
 
Figure 1.4 Translational regulation via eIF2 and eIF2B. The activity of the eIF2 
ternary complex (eIF2-GTP-Met-tRNAi) is controlled by the guanine nucleotide 
exchange factor eIF2B, which exchanges eIF2-associated GDP with GTP. There are four 
mammalian kinases, namely GCN2, HRI, PKR, and PERK that phosphorylate the α-
subunit of eIF2 at serine 51. (Klann and Dever, 2004; Hershey, 2010). This figure is taken 
from Klann and Dever (2004). 
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1.4.2 eIF4E regulation  
In eukaryotes, controlling the rate of translation initiation is dependent on the cap 
binding activity of eIF4E. There are several mechanisms involved (reviewed in 
Sonenberg and Hinnebusch, 2009). For example, one of the mechanisms is a cap-binding 
ability of eIF4E which is inhibited by the members of the 4E-BP family (Figure 1.5). This 
mechanism involves the competition of 4E-BPs with eIF4G for association with eIF4E 
and results in translational repression as described in section 1.3.2. Specifically, 4E-BP1 
which is hypophosphorylated can bind strongly to eIF4E, while 4E-BP1 which is highly 
phosphorylated via the PI3K/AKT/mTOR pathway releases free eIF4E, allowing it to 
interact with other factors in the eIF4F complex (Sonenberg and Hinnebusch, 2009). In 
another regulatory process, eIF4E is phosphorylated on Ser209 by Mnk1 that binds to 
the C-terminus of eIF4G. Mnk1 is activated through the MAP kinase/ERK pathway. 
This phosphorylation cascade can occur even if eIF4E binds to 4EBP1 (Waskiewicz et 
al., 1999). Another example is the competition of eIF4E homolog (4E-HP) that binds 
directly to the 5’ cap structure of mRNA. This competitively prevents eIF4E from 
binding to the cap structure, resulting in translational repression of specific mRNAs 
(Sonenberg and Hinnebusch, 2009). 
 
 
Figure 1.5 Translational regulation via eIF4E and 4E-BPs. Hyper-
phosphorylation of 4E-BPs is activated via the PI3K/AKT/mTOR pathway, leading to 
release free eIF4E. This allows the association of eIF4E with other factors in the eIF4F 
complex. Modified from Ma and Blenis (2009).  
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1.4.3 Translational control by miRNAs (microRNAs)  
MicroRNAs (miRNAs) are short non-coding RNAs containing ~21 
oligonucleotides (Hershey, 2010; Jackson et al., 2010). miRNAs bring about another 
mode of translational repression. In the mammalian genome, there are 800–1,000 genes 
transcribed into miRNAs, suggesting that they are important regulators of gene 
expression (Sonenberg and Hinnebusch, 2009; Hershey, 2010). miRNAs and associated 
proteins (called an RNA-induced silencing complex (RISC)) interact with a 
complementary site in a mRNA which is usually in the 3’ UTR. This complex functions 
to inhibit translation from specific mRNAs (Hutvagner and Zamore, 2002). However, 
recent studies have provided models to describe how miRNA regulates translation. For 
example, a miRNA-mediated translational repression is proposed to occur through the 
recruitment of eIF4AII (Figure 1.6) (Izaurralde, 2013; Meijer et al., 2013). This involves 
the interaction of eIF4AII with NOT1 in the CCR4-NOT deadenylase complex and 
miRNA-induced silencing complex (miRISC), consisting of a miRNA associated with an 
Argonaute protein (AGO) and a GW182 protein (Izaurralde, 2013). It is proposed that 
eIF4AII recruited by NOT1 binds to the 5’UTR, and then possibly blocks the start codon 
scanning of 43S PIC (Izaurralde, 2013).  
Another model (Figure 1.7) suggests that miRNA-mediated translational repression 
is involved in the association of the GW182 protein with cytoplasmic poly(A)-binding 
protein 1 (PABPC1). An Argonaute protein (AGO) in the miRISC associates with N-
terminal GW-repeated domain of a GW182 protein. The middle (M) and C-terminal 
silencing domains of GW182 proteins bind to PABPC1, leading to translational 
repression and mRNA degradation. This is because the association of GW182 with 
PABPC1 competitively prevents eIF4G binding to PABPC1, affecting the reduction of 
translation. In addition, miRNA-silenced mRNA is deadenylated by the CAF1–CCR4–
NOT1 deadenylase complex, and the 5′-cap is then removed by decapping protein 2 
(DCP2). To have a fully enzymatic activity, DCP2 requires a decapping protein 1 (DCP1), 
an enhancer of decapping 4 (EDC4) and a putative RNA helicase DEAD-box protein 6 
(DDX6) (Tritschler et al., 2010). 
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Figure 1.6 Translational repression through miRNA-mediated pathway by 
recruiting eIF4AII. Interaction of a subunit NOT1 of CCR4-NOT deadenylase 
complex and miRISC, which consists of Argonaute proteins (AGO) associated with 
miRNAs and GW182 proteins, has a role in the translational repression through the 
recruitment of the DEAD-box RNA helicase eIF4AII (Izaurralde, 2013; Meijer et al., 
2013), suggesting that eF4AII may lock the 5’UTR of the mRNA and possibly prevent 
the ribosomal scanning (Izaurralde, 2013). 
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Figure 1.7 Translational repression through miRNA-mediated pathway by 
interacting of GW182 protein in complex and PABPC1. An Argonaute protein (Ago) 
in the miRISC associates with N-terminus of GW182 protein. The GW182 silencing 
domains, middle (M) and C-terminus (C), bind to PABPC1, leading to translational 
repression and mRNA degradation. It is as a result of the association of GW182 with 
PABPC1 that competitively prevents eIF4G binding to PABPC1. Therefore this leads to 
the translational repression and subsequently deadenylation. Deadenylation of miRNA-
silenced mRNA requires the activity of the CAF1–CCR4–NOT1 deadenylase complex. 
The 5′-cap structure of the silenced mRNA is also removed by decapping protein 2 
(DCP2) with the associated proteins, namely a decapping protein 1 (DCP1), an enhancer 
of decapping 4 (EDC4) and a putative RNA helicase DEAD-box protein 6 (DDX6) 
(Tritschler et al., 2010). 
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1.4.4 Translational control by processing bodies and stress granules 
Cytoplasmic mRNA that is not translated by ribosomes can be present in either 
processing bodies (P-bodies) or stress granules (SGs) through the action of specific 
RNA-binding proteins. The mRNA within both structures is in dynamic equilibrium with 
mRNA in polysomes. In terms of translational regulation, it is observed that stress-
induced translational repression results in decreased mRNA within polysomes, while the 
mRNA increases in P-bodies and SGs (Kedersha and Anderson, 2009; Decker and 
Parker, 2012). 
1.4.5 Translational control by alternative pathways 
Translational regulation by the formation of protein-RNA complexes can also 
occur via the 5’UTR of the mRNA. A well-characterized example is ferritin mRNA. In 
the absence of iron, translation of ferritin mRNA is inhibited by the iron regulatory 
element (IRE)-binding protein (IRP). The association of IRP with ferritin mRNA occurs 
at the 5’ cap structure which strongly inhibits the 43S complex from being loaded onto 
the mRNA (Gebauer and Hentze, 2004; Hershey, 2010). Other examples include 
regulation by specific 3’ UTR-protein interactions and regulation by trans-acting proteins 
[reviewed in Sonenberg and Hinnebusch (2009); Hershey (2010); Jackson et al. (2010)].  
1.5 Translation and cancer  
Tumorigenesis can occur through the disruption of a number of different cellular 
processes, which includes DNA damage repair and protein synthesis (Watkins and 
Norbury, 2002). Hypothetically, a translational apparatus that is moderately repressed can 
create a balance of protein synthesis, allowing cells to regulate their proliferation. In 
contrast, over-activation of translational complexes leads to an imbalance of protein 
production, resulting from "weak" mRNAs being translated relatively more efficiently. 
The “weak” mRNA-encoded proteins are involved in facilitating cell growth and 
proliferation. The dysregulated increase in the levels of those proteins causes cells to 
become malignant (Hershey, 2010). Specifically, the alteration in the levels of eIFs results 
in abnormal translation of specific mRNAs and consequently abnormal cell growth, 
possibly leading to cancer (Yin et al., 2011). Many studies on the control of translation 
have shown a correlation between altered expression of eIFs and tumour formation 
Table 1.2.   
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Table 1.2 Eukaryotic translation initiation factors related to human cancers 
Factor Status Tumour type Reference 
eIF2a Protein increase Non-Hodgkin’s lymphoma 
Gastro-intestinal 
(Wang et al., 1999) 
(Lobo et al., 2000) 
eIF3a Protein increase Lung, Breast, Cervical, 
Esophageal 
(Pincheira et al., 2001) 
eIF3b Protein increase Breast (Lin et al., 2001) 
eIF3c mRNA increase Testicular (Rothe et al., 2000) 
eIF3h mRNA increase Prostate and Breast (Nupponen et al., 
1999) 
eIF4AI mRNA increase Melanoma 
Liver 
(Eberle et al., 1997) 
(Shuda et al., 2000) 
eIF4E mRNA increase  
 
Protein increase 
Liver 
Bladder 
Colon, Head & Neck, Breast 
Bladder, Lung, Prostate, 
Hodgkin’s lymphoma 
(Shuda et al., 2000) 
(Berkel et al., 2001) 
(Wang et al., 1999) 
(Mamane et al., 2006) 
eIF4GI Gene 
amplification 
Squamous cell lung (Gingras et al., 1999; 
Bauer et al., 2002) 
eIF5AII Gene 
amplification 
Ovarian (Guan et al., 2001) 
 
Note: This table is modified from previous publications (Watkins and Norbury, 2002; 
Rajasekhar and Holland, 2004) 
1.6 Post-translational modification 
Post-translational modifications (PTMs) of proteins are biological processes 
occurring after protein synthesis whereby translated polypeptides are modified to achieve 
full function. PTMs involve the addition of functional groups, proteins or peptides. They 
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include phosphorylation, methylation, acetylation, ubiquitylation and small ubiquitin-like 
modification (SUMOylation). PTMs have crucial roles in the regulation of cellular 
processes, altering the biological activities or conformational structures of the 
polypeptides. PTMs related to this study will be described below.  
1.6.1 Phosphorylation 
The first PTM identified and functionally characterized was phosphorylation 
(Burnett and Kennedy, 1954). Phosphorylation is a mainly reversible process that acts by 
adding a phosphate (PO4) molecule to a polypeptide by one of many kinases. It occurs 
in both prokaryotes and eukaryotes. It plays important roles in the control of cellular 
processes such as cell cycle, cell growth, apoptosis and protein synthesis. Enzymes can 
be turned on and off by phosphorylation (kinases) and dephosphorylation 
(phosphatases). For example, phosphorylation can lead to a conformational change in 
protein structure, causing the protein to become activated or deactivated forms. In 
eukaryotic organisms, phosphorylation usually occurs on serine, threonine and tyrosine 
residues. For instance, the phosphorylation of eIF4E at Ser209 decreased the affinity of 
eIF4E for the m7GTP cap structure of the mRNA (Scheper et al., 2002) and is likely to 
be important in regulation of mRNA transport and the transformation activity of eIF4E 
(Topisirovic et al., 2004). 
1.6.2 Ubiquitylation 
Ubiquitin is an 8.5 kDa regulatory protein that is ubiquitously present in almost all 
eukaryotic cells. It is highly conserved in eukaryotes. There are only three amino acid 
differences between human and S. pombe ubiquitin. Ubiquitin can be covalently attached 
through an isopeptide bond to lysine residues in target proteins. Ubiquitylation or 
ubiquitination has roles in proteolysis and modification of protein function. This 
ubiquitin modification can occur as either a single ubiquitin (monoubiquitylation) or by 
an ubiquitin chain (polyubiquitylation). The mechanism occurs via a cascade through the 
activity of a number of proteins, the E1 (ubiquitin activating enzyme), E2 (ubiquitin 
conjugating enzyme) and E3 (ubiquitin ligase) proteins (Figure 1.8). Ubiquitin is 
produced as a precursor protein which needs to be processed to the mature form by 
specific ubiquitin proteases in order to reveal a diglycine (GG) motif at the C-terminus. 
Ubiquitin-GG is then activated in an ATP-dependent reaction by the formation of a 
thioester bond with the E1 activating enzyme. Next, it is passed to an E2 ubiquitin 
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conjugating enzyme to form another thioester bond. In many cases ubiquitin can attach 
directly to target proteins, but in some cases ubiquitin requires one of a large number of 
E3 ubiquitin ligases prior to the attachment with targets since the E3s provides the 
specificity for the modification. Ubiquitin can be removed from targets by the actions of 
deubiquitinating enzymes (DUBs) (Watts et al., 2014).  
 
 
Figure 1.8 Ubiquitylation pathway. E1 ubiquitin activating enzyme, E2 ubiquitin 
conjugating enzyme, E3 ubiquitin ligase, DUB deubiquitylating enzyme. Ubiquitin is 
activated by the formation of an ubiquitin-adenylate before forming a thioester bond 
with a cysteine residue in the E1 ubiquitin activating enzyme. Ubiquitin is passed to an 
E2 ubiquitin conjugating enzyme, again forming a thioester bond. Target proteins are 
recognized by E3 ubiquitin ligases, either directly or via an adaptor, and ubiquitin is 
attached via the formation of an ε-amino bond. Ubiquitin can be attached to target 
proteins either as a monomer, or in the form of ubiquitin chains. Ubiquitin can be 
removed from target proteins by the action of one of a number of DUBs (Watts et al., 
2014). 
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1.6.3 SUMOylation 
SUMO is a small ubiquitin-like molecule that is attached post-translationally to 
target proteins. SUMOylation is an essential process in most organisms including 
eukaryotes such as yeast, plants and animals (Johnson, 2004; Talamillo et al., 2008). 
SUMOylation has roles in the response to DNA damage, cell signalling, cell cycle and 
RNA processing; in particular, SUMOylation can affect protein-protein interactions, 
protein localisation, enzyme activity and protein stability. In humans, there are four 
SUMO proteins; SUMO1, SUMO2, SUMO3 and SUMO4. The expression of SUMO1, 
2 and 3 appears to occur in all tissues while SUMO4 seems to be restrictedly expressed 
in spleen and kidney (Meulmeester and Melchior, 2008). However whether SUMO4 is 
conjugated to target proteins is not clear (Dohmen, 2004; Hay, 2005; Meulmeester and 
Melchior, 2008).  
Like ubiquitin, SUMO is produced as a precursor protein that is cleaved to the 
mature form to reveal a diglycine motif at the C-terminus, by a SUMO-specific protease 
(mammalian: SENP1; yeast: Ulp1) ( 
Figure 1.9 and Table 1.3). It is then activated by the formation of a thioester bond 
with a heterodimeric SUMO E1 activating enzyme (e.g. human: Aos1-Uba2; S. pombe: 
Rad31-Fub2, see Table 1.3) in an ATP-dependent reaction. SUMO is then passed to the 
SUMO E2 conjugating enzyme (human: Ubc9; S. pombe: Hus5, see Table 1.3), forming 
another high energy thioester bond. From here SUMO can be directly attached to target 
proteins by the formation of an isopeptide bond between the C-terminal glycine residue 
and one or more lysine residues on the target. In some, but not all cases, this 
SUMOylation requires the presence of a specific SUMO E3 ligase (human: RanBP2 and 
PIAS family; S. pombe: Pli1, Nse2, see Table 1.3). Like ubiquitin, SUMO is found on 
targets either as monomeric SUMO protein or multimeric chains (Vertegaal et al., 2006; 
Ulrich, 2008). SUMO2/3, but not SUMO1, form SUMO chains (Meulmeester and 
Melchior, 2008). SUMO can be removed from a modified target protein by the action of 
further SUMO-specific proteases such as Ulp1, Ulp2 in yeast or SENP1, 2, 3, 5, 6 and 7 
in mammals (Table 1.3).  
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Figure 1.9 Cycle of SUMOylation. It shows five main steps namely processing, activation, conjugation, ligation and deconjugation. SUMO-
GGxxx represents SUMO precusor, SUMO-GG respresents matured SUMO, E1 respresents SUMO activating enzyme, E2 respresents SUMO 
conjugating enzyme and E3 respresents SUMO ligases. This figure is modified from Hay (2005).  
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Table 1.3 List of components of the SUMOylation pathway in different species. (Adapted from Dr. Brenda Mercer, University of 
Sussex).  
 Component S. pombe S. cerevisiae H. sapiens 
SUMO Pmt3 (Tanaka et al., 1999) Smt3 (Meluh and Koshland, 1995) SUMO1 (Matunis et al., 1996) 
SUMO2/3 (Lapenta et al., 1997) 
SUMO4 (Bohren et al., 2004) 
Activating 
enzyme 
Fub2/Rad31 (Shayeghi et al., 1997)  Aos1/Uba2 (Johnson et al., 1997) SAE1/SAE2 (Gong et al., 1999) 
SUMO conjugating 
enzyme 
Hus5 (al-Khodairy et al., 1995) Ubc9 (Johnson and Blobel, 1997) Ubc9 (Desterro et al., 1997) 
 
Ligases Pli1 (Xhemalce et al., 2004) 
Nse2 (Andrews et al., 2005) 
 
Siz1/2 (Johnson and Gupta, 2001) 
Mms21/Nse2 (Zhao and Blobel, 
2005) 
Zip3 (Cheng et al., 2006a) 
 
PIAS1 (Liu et al., 1998) 
PIAS3 (Chung et al., 1997) 
PIASy (Gross et al., 2001) 
Mms21/Nse2 (Potts and Yu, 2005) 
Pc2 (Kagey et al., 2003) 
RanBP2 (Pichler et al., 2002) 
TOPORS (Weger et al., 2005) 
Protease 
Isopeptidases 
Ulp1 (Taylor et al., 2002) 
Ulp2 (Jongjitwimol et al., 2014) 
Ulp1 (Takahashi et al., 2000) 
Ulp2 (Li and Hochstrasser, 2000) 
SENP1 (Gong et al., 2000) 
SENP2-8 (Gong and Yeh, 2006) 
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1.7 Substrates in SUMOylation  
SUMO is often attached to substrates at a lysine residue in a consensus ΨKXE 
motif (where Ψ is a large hydrophobic residue and X is any amino acid), but to date it is 
clear that lysine residues present in other sequence contexts can be modified by SUMO 
as well. Many SUMO targets have been identified and characterized in several cellular 
processes. In this section, some examples of SUMO targets will be given; specifically 
RanGAP, PCNA, TDG and PML.  
1.7.1 RanGAP 
RanGAP was the first SUMO target to be identified. It is modified by SUMO1 
(Saitoh et al., 1998). RanGAP1 is a trafficking protein that activates the GTPase Ran that 
is involved in nucleocytoplasmic transport of macromolecules and mitotic function. 
SUMOylation of RanGAP1 is required for its localisation at the nuclear pore complex 
and for association with Ubc9 and RanBP2/Nup358 (Johnson, 2004). 
1.7.2 PCNA 
Proliferating cell nuclear antigen (PCNA) is essential for DNA replication, and is 
also required for DNA repair at DNA lesions (Shivji et al., 1992; Moldovan et al., 2007). 
SUMOylation of S. cerevisiae PCNA occurs on K164 and K127. In this yeast, PCNA 
SUMOylation at K164 requires the SUMO ligase E3 Siz1 in vivo and in vitro (Hoege et al., 
2002). SUMOylation of S. cerevisiae PCNA recruits the Srs2 helicase to sites of replication 
in order to prevent the association of Rad51 and homologous recombination (Papouli et 
al., 2005; Pfander et al., 2005; Watts, 2006; Burkovics et al., 2013). This is an example of 
SUMO mediating protein-protein interactions. 
1.7.3 TDG 
The human thymine-DNA glycosylase (TDG) has an important role in the base-
excision DNA repair (BER) of G:U and G:T mismatches. Briefly, when DNA contains 
T or U residues that mismatch with G, they can be recognized and released by TDG, 
resulting in the creation of an abasic (AP) site. To allow the downstream AP endonuclease 
(APE) to bind to damaged DNA, SUMOylation of TDG on K330 is required. This leads 
to C-terminal conformational changes of TDG and decreased affinity of TDG for the 
AP site reduces. Thus the nucleotide is then restored by APE and TDG may be recycled 
 
 
24 
 
 
 
for the next rounds of the recognition of mispaired bases (Huang and D'Andrea, 2006; 
Smet-Nocca et al., 2011).  
1.7.4 PML  
Promyelocytic leukaemia protein (PML) is a nuclear phosphoprotein identified as 
a result of a chromosomal translocation t(15;17), associated with acute promyelocytic 
leukaemia (APL). SUMO modification of PML is essential for formation of PML nuclear 
bodies and recruitment of associated proteins e.g. Sp100, p53, CBP and Daxx. When 
unSUMOylatable mutants of PML are introduced into PML-deleted cells, the aggregation 
of mutant PML occurs. This leads to the failure of PML to localize to PML bodies 
(Zhong et al., 2000). 
1.8 SUMOylation and cancer 
In recent years, several studies have demonstrated that the disruption of 
SUMOylation is associated with a range of different tumours (Jacques et al., 2005; Cheng 
et al., 2006b; Sarge and Park-Sarge, 2009; Driscoll et al., 2010; Zhu et al., 2010). However, 
the relationship between SUMOylation levels and cancer is likely to be complex. For 
example, the SUMO-specific protease SENP1 is over-expressed in both prostate cancer 
(Cheng et al., 2006b) and thyroid oncocytic tumour (Jacques et al., 2005). SENP1 also 
induces the proliferation of prostate epithelial cells (Bawa-Khalfe et al., 2010). The levels 
of SUMO modification increase significantly in multiple myeloma samples, correlating 
with high production of the E1 and E3 enzymes (Driscoll et al., 2010), while the SUMO 
E2 is over-expressed in lung adenocarcinomas (McDoniels-Silvers et al., 2002) and 
ovarian tumours (Mo et al., 2005).  
1.9 Preliminary data and hypothesis 
The Watts lab have been using the fission yeast, S. pombe, as a model organism for 
the analysis of the role of SUMOylation. They have shown that SUMO and SUMOylation 
are required for the response to DNA damaging agents e.g. (Shayeghi et al., 1997; 
Andrews et al., 2005). To further analyse the role of SUMOylation, a complex containing 
the SUMO specific protease Ulp2 was purified (Figure 1.10) (Dr. Min Feng, University 
of Sussex). Interestingly, the protein co-purified with a number of translation initiation 
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factors and proteins required for RNA stability (Table 1.4). Supporting the notion that 
these proteins are affected by SUMOylation are the observations that some of them have 
been found in early screens for SUMOylated proteins in mammalian cells (Hannich et al., 
2005; Xu et al., 2010). Interestingly, the levels of the mammalian homologues of several 
of the translation factors that were identified (eIF2α, eIF3a, eIF3c, eIF3h, eIF4G, 
eEF1A2) are up-regulated in cancer cells (Stumpf and Ruggero, 2011). The preliminary 
data presented a link between these proteins and SUMOylation. Moreover, a significant 
number of translation initiation factors in budding yeast (Saccharomyces cerevisiae, Sc), plants 
(Arabidopsis thaliana), insect cells (Drosophila melanogaster) and/or mammalian cells (human: 
Hs, rat) have been identified in proteomic screens as being SUMOylated (Table 1.5). To 
further analyse the role of SUMOylation of some of the eIFs, this work has been 
focussing on an investigation into whether certain eIFs are SUMOylated and initiating 
studies into determining the role of SUMOylation of one of the proteins in the eIF4F 
complex.  
1.10 Aims of this study 
The aim of this project was to determine whether components of the eIF4F 
complex are SUMOylated and to initiate studies to investigate the role of this 
modification. The first results chapter (Chapter 3) was an investigation of SUMOylation 
of some of the RNA binding proteins in S. pombe, specifically eIF4G, eIF3h and the La 
protein homolog (Sla1), to determine whether they are modified by SUMO in vivo. These 
experiments were then extended to mammalian cells. Before this could be undertaken, 
the effects of stress conditions on protein synthesis and general SUMOylation in a range 
of cell lines were first analysed which will be demonstrated in Chapter 4. Next, in 
Chapter 5 and Chapter 6, in vivo and in vitro SUMOylation assays were used to determine 
whether mammalian eIF4G and eIF4A are modified by SUMO. Immunofluorescence 
analysis was also undertaken to determine whether eIF4G and eIF4A colocalise with 
SUMO in response to stresses. Additionally, studies were initiated to investigate the in 
vivo role of SUMO modification of eIF4AII. 
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. 
Figure 1.10 SDS-PAGE of Ulp2-Tap and associated proteins. TEV = TEV 
protease, used to cleave Ulp2 from TAP tag. Numbers refer to gel slices analysed by mass 
spectrometry (Dr. Min Feng, University of Sussex).  
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Table 1.4 Summary of proteins identified by mass spectrometry that co-
purified with TAP-Ulp2. 
Function Protein 
Translation eIF2a, eIF2b, eIF3a, eIF3b, eIF3c, eIF3c, eIF3h, eIF4G, 
EF1a EF2B, eEF3B, EF2, Pabp 
RNA synthesis Rpa1, Rpa2 
RNA processing Rrp5, SPAC694.02, Exo2, Dhp1, Upf1, SPBC19G7.10C, 
Nop2, Dbp2, Prp19, Sla1 
Ribosome biogenesis aconitate hydrolase/mitochondrial ribosomal protein 
subunit L49, SPAC22G7.05, SPAC1142.04 (Noc2 
predicted), Hsc1/Sks2, Rpl301, Rpl302, Rml2 
DNA metabolism Tcg1, Rfc5 
Other Pfk1, SPBC16h5.12C, glutamate 5-kinase (predicted), 
Gpd1, Gpd3 
 
 
28 
 
 
 
Table 1.5 Proteomic screens identified numerous SUMOylated eIFs. 
Factor SUMO References 
eIF1α Rat SUMO3 (Yang et al., 2011) 
eIF2A Subunit 1 Hs SUMO2 (Blomster et al., 2009) 
eIF2 Subunit α, γ Drosophila SUMO (Nie et al., 2009) 
eIF2B Subunit β Hs SUMO1/2 (Westman et al., 2010) 
eIF2B  Plant SUMO (Miller et al., 2010) 
eIF3A Hs SUMO2 (Blomster et al., 2009) 
eIF3B Hs SUMO2 (Blomster et al., 2009) 
eIF3C Hs SUMO1/2 (Westman et al., 2010) 
eIF3D Rat SUMO3 (Yang et al., 2011) 
eIF3E Hs SUMO1/2 (Westman et al., 2010) 
eIF3I Sc Smt3 (Panse et al., 2004) 
eIF3X Hs SUMO2 (Blomster et al., 2009) 
eIF4AI Drosophila SUMO 
Rat SUMO3 
Hs SUMO2 
(Nie et al., 2009) 
(Yang et al., 2011) 
(Blomster et al., 2009; Bruderer et al., 
2011) 
eIF4AII Hs SUMO1 (Matafora et al., 2009) 
eIF4E Hs SUMO1 (Xu et al., 2010) 
eIF4GI Hs SUMO1/2 (Matafora et al., 2009; Bruderer et al., 
2011) 
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Chapter 2  
Materials and Methods 
2.1 Yeast methods 
2.1.1 Media 
1) Yeast Extract (YE) – an enriched medium 
5 g/l yeast extract 
20 g/l glucose  
200 mg/l  adenine 
100 mg/l  leucine 
100 mg/l  uracil 
100 mg/l  histidine 
100 mg/l  arginine 
25 g/l  Difco (Bacto) agar (for making solid YE agar) 
2) Yeast Nitrogen Base (YNB) – a selective medium  
1.9 g/l YNB (Formedium) 
4 g/l  ammonium sulphate 
20 g/l glucose 
30 g/l  Difco (Bacto) agar for making YNB agar (YNBA) 
0.08 g/l  NaOH for making YNB agar (YNBA)   
3) Extra Low Nitrogen (ELN) – a sporulation medium  
27.3 g/l Formedium Edinburgh Minimal Medium (EMM) 
50 mg/l ammonium chloride 
200 mg/l  adenine 
100 mg/l  leucine 
100 mg/l  uracil 
100 mg/l  histidine 
100 mg/l  arginine 
25 g/l  Difco (Bacto) agar 
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2.1.2 Media supplements 
For some experiments the YNB broth or agar was supplemented. The media may 
contain some or all of supplements e.g. adenine, leucine and uracil, each at 100 mg/l. 
Thiamine was also used at 15 μM for full repression (Cherkasova et al., 2012). 
2.1.3 S. pombe strains 
S. pombe stains used in this study were shown in Table 2.1. 
 
Table 2.1 List of S. pombe strains used in this study. 
Strain Genotype References 
wt501 ade6-704, leu1-32, ura4-D18, h- (Murray et al., 
1991) 
sla1::ura(bs) sla1::ura, ade6-704, leu1-32, ura4-D18, h-  This study 
sla1::ura(bs) sla1::ura, ade6-704, leu1-32, ura4-D18, h+  This study 
sla.wt sla1.wt, ade6-704, leu1-32, ura4-D18, h-  This study 
sla.K106R sla1.K106R, ade6-704, leu1-32, ura4-D18, h-  This study 
sla.K263R sla1.K263R, ade6-704, leu1-32, ura4-D18, h-  This study 
sla.RR sla1.K106R.K263R, ade6-704, leu1-32, ura4-D18, h-  This study 
sla1::kan(bs) sla1::kan, ade6-M210, leu1-32, ura4-D18, h-  This study 
sla1::kan(bs)* sla1::kan, ade6-M210, leu1-32, ura4-D18, h+ This study 
sla1::nat(bs) sla1::Nat, ade6-704, leu1-32, ura4-D18, h-  This study 
ulp2/eIF3h ulp2-myc:kan, eIF3h-HA:Nat, ade6-704, leu1-32, ura4-
D18, h-  
This study 
ulp2/eIF4G ulp2-myc:kan, eIF4G-HA:Nat, ade6-704, leu1-32, ura4-
D18, h- 
This study 
eIF3h-HA eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h-  This study 
eIF4G-HA eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h- This study 
 
* Note: this strain was a kind gift from Dr. Stephanie Schalbetter, University of Sussex. 
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2.1.4 S. pombe plasmids 
Two plasmids used in this study for the integration of mutations into the genome 
were pAW1 and the Cre recombinase expressing plasmid pAW8 (Watson et al., 2008). 
The first plasmid pAW1 was used as PCR template because it contains the ‘loxP–ura4+–
loxM3’ cassette. A pair of PCR primers was designed to amplify the cassette along with 
approximately 80-bp upstream and downstream sequences of target gene within the 
S. pombe genome.  
The second vector pAW8 is derived from pUC19 vector and contains the 
S. cerevisiae LEU2+ gene which is controlled by the nmt41 promoter. In the presence of 
thiamine, gene expression is not induced (no message in thiamine promoter). The 
plasmid also contains the cre gene (expresses bacteriophage P1 recombinase) which is also 
controlled by the nmt1 promoter. Importantly, the plasmid has a multiple cloning site 
flanked by the loxP and loxM into which a coding sequence is cloned. The target gene 
cloned on this pAW8 can be mutated using site-directed mutagenesis.  
2.1.5 Yeast transformation using lithium acetate  
After yeast cells were grown overnight in 10 ml of YE medium, the culture was 
diluted into 40 ml of fresh YE for 3 hours and incubated at 30°C until mid-log phase. 
The culture was harvested by centrifugation at 3,000 rpm for 5 minutes. The pellet was 
washed with 10 ml of water and re-spun for 5 minutes. The pellet was then resuspended 
with 4 ml of 1x LiAc/TE buffer (0.1 M lithium acetate pH 7.5, 10 mM Tris pH 7.5, 
1 mM EDTA). 1 ml of suspension cells was harvested by centrifugation at 13,000 rpm 
for 1 minute and resuspended in 100 µl of 1x LiAc/TE buffer. 20 µl (or 1 µg) of PCR 
product or plasmid was added and incubated at room temperature for 10 minutes. 260 µl 
of 40% polyethylene glycol (PEG) in 1x LiAc/TE buffer was added and the mixture was 
then incubated at 30°C for 1 hour. Subsequently, 43 µl of dimethyl sulfoxide (DMSO) 
was added and the cells were heat shocked at 37°C for 5 minutes. After the cells were 
harvested, the pellet was washed in 500 µl of sterile distilled water and resuspended once 
in 100 µl of remaining supernatant and plated onto YNBA plates supplemented with 
appropriate amino acids. Plates were incubated at 30°C for 3–5 days. 
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2.1.6 Recombination-mediated cassette exchange  
The recombinase-mediated cassette exchange system (Watson et al., 2008) was used 
for this study. To generate a base strain for a non-essential gene, the pAW1 vector was 
used as a PCR template. The PCR product containing the ‘loxP-ura4+-loxM3’ cassette 
flanked by upstream and downstream sequences of the gene was transformed into wild 
type S. pombe using lithium acetate-based yeast transformation following which the PCR 
product was integrated by homologous recombination. To create wild type and mutant 
alleles, a Cre-expression plasmid (pAW8) containing either the non-mutated or point-
mutated gene of interest was used for cassette exchange by homologous recombination.  
2.1.7 Isolation of genomic DNA from S. pombe  
A single colony was grown overnight to saturation in 10 ml of YE medium at 30°C 
with shaking. The pellet was resuspended in 2 ml SP1 buffer pH 5.6 (1.2 M sorbitol, 
50 mM sodium citrate, 50 mM sodium phosphate pH 5.6, 40 mM EDTA) and 1 mg/ml 
of zymolase. After incubation at 37°C for 45 minutes, the harvested pellet was 
resuspended in 900 µl of 5x TE buffer (50 mM Tris pH 8.0, 5 mM EDTA), followed by 
100 µl of 10% SDS for 5 minutes and then 300 µl of 5 M potassium acetate. Samples 
were then incubated for 10 minutes on ice. Tubes were centrifuged at 13,000 rpm for 
5 minutes. The supernatant was transferred to a new 1.5 ml tube containing an equal 
volume of isopropanol. The pellet was obtained by centrifugation at 13,000 rpm for 5 
minutes and then washed with 500 µl of 70% ethanol and dried. The DNA was 
subsequently purified using a mixture of phenol-chloroform, followed by ethanol 
precipitation (Sambrook and Russell, 2001).  
2.1.8 Crossing and random spore analysis  
A loop of S. pombe cells of two different mating types was mixed with 10 μl of sterile 
water and the solution was then dropped on an ELN plate. The plate was incubated at 
30°C for 3–5 days. The crossed cells were verified using a light microscope by checking 
for the presence of tetrads. A loop of the crossed cells was inoculated in 1 ml of sterile 
water containing 2 μl of Helicase (snail Helix pomatia juice) to digest the ascus wall and 
the solution were then incubated at 37°C overnight. The following day, the sample was 
diluted to reach the dilution of 10-2 and 10-3. 100 μl of each dilution was spread onto 
YEA plates. All plates were incubated at 30°C for 3–5 days (Bähler et al., 1998). 
 
 
33 
 
 
 
2.1.9 Spot test 
After yeast strains were inoculated into YE liquid medium and grown at 30°C 
overnight in a shaking incubator, the cultures were diluted in the same medium to an 
optical density (OD) at 595 nm of approximately 0.2 and reincubated at the same 
conditions for 3 hours to ensure that the cells were in mid-log phase. The OD of these 
cultures was measured again (the cultures were re-diluted if required to ensure that all 
cultures were at the same OD). Ten-fold serial dilutions were made in order to produce 
10-1, 10-2, 10-3 and 10-4 dilutions. From each one of these dilutions, 10 µl of each was 
spotted onto plates containing the different growth media such as YE agar, YNBA agar 
and YNBA agar containing rapamycin and/or NH4Cl. All plates were then incubated at 
30°C for three days.  
2.1.10 Polysome analysis  
To extract polyribosome from S. pombe, it was first necessary to prepare 10–60% 
sucrose gradients in buffer A (20 mM Tris-HCl pH7.5, 50 mM KCl, 1 mM DTT, 10 mM 
MgCl2) containing 100 µg/ml cycloheximide or in buffer B (20 mM Tris-HCl pH7.5, 50 
mM KCl, 1 mM DTT) were prepared in 15-ml polycarbonate tubes. The gradient tubes 
were prepared a day before use by adding 500 µL of 60% sucrose solution. The tubes 
were then frozen in liquid nitrogen for 10 seconds. 1.6 ml of each other concentrations 
of sucrose solution added on top the higher concentration which was frozen in liquid 
nitrogen. The lowest sucrose concentration was added on top. Finally, the tubes were 
covered with parafilm and then stored at 4°C to thaw slowly overnight.    
S. pombe cells were grown at 30°C until they were at OD 0.5. Cells were untreated 
and treated with cycloheximide at the final concentration of 0.1 mg/ml for 10 minutes at 
30°C. Cycloheximide-treated cells were harvested and then resuspended with 0.5 ml lysis 
buffer (20 mM Tris-HCl pH 7.5, 140 mM KCl, 10 mM MgCl2, 1 mM DTT, 0.1 mg/ml 
cycloheximide, 0.2 mg/ml heparin, 1% Triton X-100, EDTA-free protease inhibitor 
(Roche). Untreated cells were also harvested and resupended with the same lysis buffer 
without cycloheximide but containing 2.5 mM EDTA. Cells were lysed by the sonication. 
The supernatant was separated by centrifugation at 13,000 rpm for 5 minutes at 4°C. 400 
µl of each sample was loaded onto the corresponding sucrose gradient tubes. The tubes 
were centrifuged at 38,000 rpm for 130 minutes at 4°C (Beckman SW 40Ti rotor). The 
gradients were then fractionated by upward displacement with 65% sucrose to collect 
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each fraction using a fraction collector. RNA of each sample was measured by the 
OD260 reading.  
2.2 Bacterial methods 
2.2.1 Media 
L-Broth (LB) 
10 g/l tryptone 
5 g/l  yeast extract  
10 g/l  sodium chloride 
8 g/l  agar (for making a solid LB media only) 
2.2.2 Antibiotics 
Bacterial plasmids normally contain one or more antibiotic resistance markers. To 
select bacteria containing particular plasmids, antibiotics were added to media prior to 
use. All antibiotics were kept at –20°C. There were three antibiotics used in this study, 
namely ampicillin (100 µg/ml final concentration), kanamycin (100 µg/ml final 
concentration) and chloramphenicol (50 µg/ml final concentration). 
2.2.3 Bacterial strains 
There were two strains of Escherichia coli (E. coli) that were used in this study.  
1)  NM522, supE, thi-1, Δ(lac-proAB), hsd5 (r–, m–), [F´, proAB, lacIqZΔM15] 
2)  BL21 (DE3), pLysS, F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, Cmr 
2.2.4 Bacterial cloning vectors 
There are many bacterial cloning vectors used in this study (Table 2.2), namely 
pGEM-T Easy (Promega), pET15b (Novagen), pET28a (Novagen), pET28b (Novagen), 
pGEX (Pharmacia) and pCMV6 (OriGene). 
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Table 2.2 Bacterial cloning vectors used in this study.  
Vector Promoter Tag Selection 
pGEM-T Easy T7, SP6 - Ampr 
pET15b T7lac N-terminal 6xHis Ampr 
pET28a T7lac N-terminal 6xHis Kanr 
pET28b T7lac N-terminal 6xHis Kanr 
pGEX tac (trp/lac) N-terminal GST Ampr 
pCMV6 CMV C-terminal myc-Flag Kanr 
2.2.5 Competent cells 
A single colony was grown overnight at 37°C in 5 ml LB (containing the 
appropriate antibiotics). The pre-culture was used to inoculate a larger scale culture in a 
one litre of pre-warmed LB and then was incubated at 37°C with shaking for 2–4 hours 
until OD600 ~ 0.5–0.6. The large culture was chilled on ice for at least half an hour and 
then centrifuged using SLA3000 rotor at 5,000 rpm for 5 minutes at 4°C. The supernatant 
was discarded. The pellet was resuspended in 25 ml of ice-cold TRNS1 solution (100 mM 
rubidium chloride, 50 mM manganese (II) chloride, 10 mM calcium chloride, 35 mM 
sodium acetate, 6.6% glycerol, pH 5.8 was adjusted by 0.2 M acetic acid) and then was 
incubated on ice for an hour. The cells were harvested by centrifugation at 5,000 rpm for 
5 minutes at 4°C. The pellet was resuspended in 12 ml of TRNS2 solution (10 mM 
rubidium chloride, 75 mM calcium chloride, 10 mM MOPS, 6.6% glycerol, pH 6.8 
adjusted with potassium hydroxide). The cell suspension was incubated on ice for 
an hour. 300 µl of the cell suspension was aliquoted into tubes and frozen in liquid 
nitrogen. Competent cells were stored at –80°C. 
2.2.6 Bacterial transformation 
The competent cells, E. coli NM522 or BL21, were thawed on ice. Approximately 
20 ng (1 µl) of plasmid or ligation products was added to tubes containing 100 µl of the 
cells. The mixture was incubated on ice for 20 minutes. Heat shock was performed at 
37°C for 90 seconds. 1 ml of LB medium was directly added to the tubes. The tubes were 
incubated at 37°C for 1 hour. Cells were harvested by centrifugation and the pellet was 
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resuspended with 100 µl of remaining supernatant. The mixture was placed onto LB agar 
plates with specific antibiotic agents to select for transformed cells. 
2.2.7 White-blue selection 
This technique is a screening method which is used to screen ligations in vector-
based gene cloning. This method needs 5-bromo-4-chloro-indolyl-β-D-
galactopyranoside (X-Gal) which is a substrate of the enzyme, β-galactosidase encoded 
by the lacZ gene of the lac operon. In this study, NM522 was normally used as it contains 
lacIq on an F’episome. The transformed cells were screened on a LB agar plate containing 
0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 20 μg/ml X-Gal in DMSO 
or dimethylformamide (DMF). The stock solutions of 0.1 M IPTG and 40 mg/ml X-Gal 
were stored at –20°C. Transformed cells containing non-recombinant vectors will 
produce blue colonies, while cells containing recombinant vectors will form white 
colonies. The white colonies, however, will be further analysed in order to confirm the 
appropriate sequences using other techniques e.g. digestion with restriction enzymes or 
sequencing.  
2.3 DNA methods 
2.3.1 Plasmid DNA Preparation 
A single transformed colony was inoculated and grown in 10 ml of LB medium 
with appropriate antibiotics at 37°C. Plasmid DNA was isolated using a QIAprep® 
Miniprep kit (QIAGEN) according to the manufacturer’s instructions. 
2.3.2 Polymerase chain reaction 
The reaction mixture was generally set up in a final volume of 100 μl. The PCR 
mixture contained 0.2–10 ng plasmid DNA or 20–100 ng of yeast genomic DNA or 
cDNA, 10 µl of 10x ThermoPol Reaction Buffer (NEB), 10 mM of each dNTP, 10 µM 
of each oligonucleotide primer, 2.5 units of a thermostable Pfu DNA Polymerase and 
adjusted with water up to 100 μl. To amplify DNA sequences, the PCR tubes were placed 
on a thermal cycler machine. The PCR was heated to 94°C for 2 minutes. The cycler was 
programmed to cycle between three different temperatures. Typically, 20–25 cycles of 
94°C for 30 second, an appropriate annealing temperature for 1 minute and 68°C for 1–
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2 minutes per a kilobase was performed. The reaction was subsequently heated at 68°C 
for another 10 minutes and kept at 4°C. 
2.3.3 DNA digestion with restriction enzymes 
The reactions for DNA digestion were performed using a final concentration of 1x 
enzyme buffer, 1–20 μg DNA and 1 μl of each of restriction enzymes as well as water up 
to total volume of 50 µl. The reactions were incubated at 37°C for an hour or as 
recommended by the manufacturer. The insert DNA fragments were then purified from 
an agarose gel. In the case of vectors requiring de-phosphorylation, 10 units of calf 
intestine alkaline phosphatase (CIP) was added directly into the reaction for 10 minutes 
at 37°C, prior to DNA purification by QIAquick PCR purification kit (QIAGEN). 
2.3.4 Agarose gel electrophoresis 
To make a 0.8% agarose gel, 2.4 g agarose was added to 300 ml of 1x TBE buffer 
(89 mM Tris base, 2.5 mM EDTA, 89 mM g/l boric acid). The mixture was microwaved 
for 1 minute and mixed gently (these steps were repeated until the agarose had dissolved). 
The agarose was cooled for 30–60 seconds at room temperature. 5 µl ethidium bromide 
was added to the solution, and swirled gently. The solution was poured into a gel cast 
containing a gel comb. The gel was allowed to polymerize for 30 minutes at room 
temperature. To load samples, the comb was removed, and then the agarose gel was 
placed in a gel box containing 1x TBE buffer. Samples were mixed with 6x loading buffer 
(0.25% bromophenol blue, 15% Ficoll-Type 400) and loaded into wells. The sample on 
the gel was run at the voltage of 100–150 V for 30–45 minutes.   
2.3.5 Purification of DNA from agarose gel using Easy Pure kit 
The agarose gel slice containing the DNA fragment was dissolved using 300 μl of 
SALT solution (a chaotropic salt) and 50 μl of MELT solution (guanidine thiocyanate) at 
55°C for 5–10 minutes. 8 μl of bead matrix were added to bind the DNA fragments. The 
contaminants were removed by washing with 1 ml of Easy Pure Wash solution. The 
purified DNA fragments were eluted into water. The eluted DNA was ready to use for 
ligation. 
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2.3.6 Ligation reaction 
DNA ligation was typically carried out in a final volume of 20 μl. The reaction was 
set up with 10 μl of 2x Quick ligation reaction buffer, 50 ng of the linear vector, which 
had been treated with the restriction enzymes and alkaline phosphatase, a three-fold 
molar ratio of the insert DNA fragments and 1 μl of Quick T4 DNA ligase (NEB) 
according to manufacturer’s instructions. The reaction was mixed thoroughly and 
incubated at room temperature for 5 minutes. 
2.3.7 Site-directed mutagenesis by PCR technique  
Unlike the normal PCR technique, this procedure required a forward primer that 
was around 30 bases in length containing the mutant base(s) and a reverse primer that 
was complementary to the forward primer (Kunkel, 1985). The reaction mixture was 
normally set up in a total volume of 50 μl. The PCR mixture contained 0.2–10 ng plasmid 
DNA, 5 µl of 10x ThermoPol Reaction Buffer (NEB), 0.2–0.5 mM of each dNTP, 0.2–
0.5 mM of each oligonucleotide primer, 2.5 units of a thermostable Pfu DNA polymerase 
and adjusted with water up to 50 μl. The PCR tubes were then placed in a thermal cycler 
machine. The PCR was heated to 94°C for 2 minutes. 20–25 cycles were performed with 
denaturing temperature for 30–60 seconds, annealing temperature for 1 minute and 68°C 
(Pfu DNA Polymerase) for 1–2 minutes per a kilobase for extension. Subsequently, the 
mixture was heated at 68°C (Pfu DNA polymerase) for another 20 minutes and kept at 
4°C. The product was digested with DpnI to cleave only at methylated sites of the 
template plasmid. The final reaction was transformed into competent NM522 cells. 
Plasmids were then extracted and sent for sequencing at Source BioScience or GATC.  
2.4 Mammalian cell culture methods 
2.4.1 Mammalian cell culture media, antibiotics and supplements. 
1) Penicillin and streptomycin solution (Sigma-Aldrich) (100x) 
10,000 units  penicillin  
10 mg/ml   streptomycin 
2) L-Glutamine solution (Sigma-Aldrich) (100x) 
200 mM   L-Glutamine 
* These two solutions were frozen at –20°C. They were thawed in a water 
bath at 37°C for at least half an hour prior to use.  
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3) Fetal calf serum (FCS) (Gibco®, Life Technologies) 
This serum was aliquoted and frozen at –20°C. It was thawed at 37°C for at 
least half an hour prior to use.  
4) DMEM medium with high glucose (Gibco®, Life Technologies) 
This 500-ml DMEM medium was supplemented with 5 ml of 200 mM L-
glutamine (100x), 90 ml of FCS and 5 ml of 100x penicillin and streptomycin 
solution.  
5) Coon’s Modified Ham’s F12 medium (Sigma-Aldrich, F6636) 
Nutrient Mixture F-12 Coon's modification powder including 0.292 g/l L-
glutamine and 0.863 mg/l zinc sulphate was added to a litre of water. 2.68 g/l 
sodium bicarbonate (NaHCO3) was added in the solution. This medium was 
prepared according to the manufacturer’s instructions (Sigma-Aldrich). Then 
500 ml of the medium was supplemented with 100x penicillin and 
streptomycin solution and 60 ml of FCS. 
2.4.2 Cell culture 
HeLa, MRC5, MCF7, MDA-MB231 cells were cultured as monolayers in DMEM 
medium supplemented with 15% fetal calf serum (FCS) and incubated at 37°C with 5% 
CO2 for 1–3 days to reach 70–80% confluence. PC3 cells were grown as a monolayer in 
Coons Modified Ham’s F12 medium containing 2mM glutamine and 12% FCS and 
incubated at 37°C with 5% CO2 for 1–3 days to reach 70–80% confluence. Details of 
these cells are shown in Table 2.3. 
 
Table 2.3 Human cell lines used in this study.  
Cell line Organism Origin Cell type Disease 
HeLa* human cervix epithelial adenocarcinoma 
MRC5 human lung fibroblast fibroblast 
MCF7 human breast epithelial adenocarcinoma 
MDA-MB231 human breast epithelial adenocarcinoma 
PC3 human prostate epithelial adenocarcinoma 
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2.4.3 Trypsinization of adherent cells 
To trypsinize the adherent cells, they needed to be at 70–80% confluence. The 
medium was aspirated off in a biohazard hood. The cells were washed twice with PBS. 
0.25% trypsin solution was added. The flask or plate was incubated at 37°C with 5% CO2 
for 5 minutes for trypsin to work. One volume of warm medium was added and the 
mixture was transferred into a sterile tube. The tube was then centrifuged at 1,500 g for 
5 minutes at room temperature. The supernatant was carefully discarded in the hood. 
The pellet was resuspended in an appropriate medium.  
2.4.4 Freezing of mammalian cells  
After cells were trypsinized, they were counted in a haemocytometer. They were 
then pelleted in a conical tube by centrifugation at 1,500 rpm for 5 minutes. The pellet 
was resuspended in freezing medium (10% DMSO, 90% completed media which 
containing FSC) to dilute to a final concentration of 1 × 106 cells/ml. 2 ml of the 
resuspension was aliquoted in each cryotube vial. The tube was kept in a thermal insulated 
box and this was placed in a –80°C for 24 hours. Then the vials was stored in a liquid 
nitrogen container. 
2.4.5 Thawing of mammalian cells 
A vial was taken from the liquid nitrogen container and thawed rapidly by swirling 
in a 37°C water bath. The outside of the tube was sterilized with IMS. Cell solution was 
dropped carefully onto the top of 10 ml of pre-warmed media containing 10% DMSO 
in a new conical tube. The tube was centrifuged at 1,500 rpm for 5 minutes. The 
supernatant was aspirated off and the pellet was resuspended in the growth medium. The 
cells were grown in the same conditions as previously described. 
2.4.6 Arsenite treatment  
60–80% confluent cells were treated with 1 mM sodium arsenite and then 
incubated at 37°C for 30 minutes. 
2.4.7 Radiation sensitivity test 
Cells were irradiated using a [137Cs] gamma source with a dose of 3 Gy, and then 
allowed to recover at 37°C for 30 minutes. 
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2.4.8 Immunofluorescence 
1 × 105 mammalian cells were cultured in 2 ml of the appropriate media in a six-
well plate containing cover slips in each well at 37°C for 48 hours. The cells needed to 
be at 60–80% confluent for treatment with any conditions. The supernatant was aspirated 
off and the cells were washed twice with PBS. The cells were fixed and permeabilized 
with cold absolute methanol for 20 minutes at –20°C. The cells were blocked with 2% 
BSA (bovine serum albumin) in PBS for 30 minutes at room temperature. The BSA 
solution was removed and replaced with appropriate dilution of primary antibody in 2% 
BSA. The primary antibodies were typically used at a 1:50 dilution in 2% BSA. From this 
step on, the cells were kept in a humid atmosphere to prevent them from drying out. The 
reaction was incubated for 1 hour at room temperature after that the cells were washed 
three times with PBS. The 1:200 dilution of specific secondary antibody in 2% BSA was 
then added. The reaction was incubated for at least 40 minutes at room temperature. The 
cells were washed three times with PBS. To mount the cells, 15 µl of ProLong® Gold 
Antifade Reagent with DAPI was dropped on a slide and the coverslip containing the 
cells was mounted upside down and placed on top of the DAPI reagent. The reaction 
was incubated for an hour at room temperature. Slides were kept at 4°C prior to 
examination by wide field fluorescence microscopy (DeltaVision) according to the 
manufacturer’s instructions. 
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Table 2.4 List of primary and secondary antibodies used in 
immunofluorescence assay 
Antibody Source Type Clone Company Dilution 
anti-eIF4G  mouse  primary monoclonal  Santa Cruz 
(sc-373892) 
1:50 
anti-eIF4E rabbit  primary polyclonal In-house 1:100 
anti-eIF4A rabbit  primary polyclonal In-house 1:100 
anti-SUMO1  rabbit  primary polyclonal Santa Cruz 
(sc-9060) 
1:50 
anti-SUMO1  mouse  primary monoclonal Santa Cruz 
(sc-5308) 
1:50 
FITC-anti-
mouse IgG 
goat  secondary polyclonal Sigma (F0257) 1:200 
Cy3-anti-rabbit 
IgG 
sheep secondary polyclonal Sigma 
(C2306) 
1:200 
2.4.9 Two-step transfection of siRNA and plasmids 
A mixture of siRNA was prepared in a 1.5-ml tube by the addition of 50 μl Opti-
MEM (31985-047, Life Technologies), 5 μl HiPerFect transfection reagent (301705, 
QIAGEN) and 10–30 nM siRNA eIF4AII (s4572, Life Technologies). The siRNA 
mixture was incubated at room temperature for 10 minutes. 2 × 105 HeLa cells were 
added in 2 ml DMEM in a six-well plate, followed by the addition of the siRNA mixture, 
then incubated at 37°C for 48–72 hours. The cells needed to be at approximately 70% 
confluent. The cells were washed twice by PBS, and 2 ml fresh medium was added into 
each well. A mixture of plasmid was prepared by the addition of 130 μl Opti-MEM, 6 μl 
FuGENE® HD transfection reagent (e2311, Promega) and 2–3 μg plasmid DNA, then 
incubated at room temperature for 10 minutes. The plasmid mixture was added into the 
six-well plate. This was incubated at 37°C for 24 hours. The cells were harvested for 
further analysis. 
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2.5  Protein methods 
2.5.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS PAGE was carried out using Bio-Rad Mini Protean II apparatus. Protein 
samples were resolved on the various percentage of separating gels, commonly 7.5–
12.5%. Separating gels were prepared by mixing protogel (30% acrylamide: 0.8% 
bisacrylamide) and 4x separating buffer which was polymerised by the addition of 10% 
ammonium persulphate (APS) and TEMED (N,N,N’,N’-tertamethyllethylenediamine). 
The volume added was shown in Table 2.5. The pre-polymerised mixture was poured in 
the 1-mm gap between two glass plates and allowed to set for 30–45 minutes with a layer 
of isopropanol on top to get a level surface. After the gel was set, the isopropanol layer 
was washed off with distilled water. The stacking gel was prepared (usually at 3%) (Table 
2.6), and then poured on top of the separating gel. The gel comb was positioned. After 
the stacking gel was allowed to set for 30 minutes, the comb was removed and the gel kit 
was then assembled. Protein samples were mixed with 5x SDS sample buffer and 
denatured at 95°C for 5–10 minutes. 10–30 μl of protein samples were loaded into each 
well. 8 μl of ColorPlus™ Prestained Protein Ladder (New England Biolabs) was loaded 
into a lane as a size indicator. Gels were run in 1x SDS running buffer at 150 V for 
approximately 1 hour or until the dye front reached the bottom of the gel.  
 
Table 2.5 Separating gel formulation for preparing 2 gels 
Separating Gel (2 gels) 7.5% 10.0% 12.5% 
30% Protogel (ml) 2.5 3.3 4.2 
4x separating buffer (ml) 
(1.5 M Tris-HCl pH 8.8, 0.4% SDS) 
2.5 2.5 2.5 
Distilled water (ml) 5.0 4.2 3.3 
10% APS (μl) 100 100 100 
TEMED (μl) 10 10 10 
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Table 2.6 Stacking gel formulation for preparing 2 gels 
Stacking Gel (2 gels) 3% 6% 
30% Protogel (ml) 0.5 1.0 
4x stacking buffer (ml) 
(0.5 M Tris-HCl pH 6.8, 0.4% SDS) 
1.3 1.3 
Distilled water (ml) 3.3 2.8 
10% APS (μl) 50 50 
TEMED (μl) 10 10 
 
5x Sample buffer:  60 mM  Tris HCl, pH 6.8 
25%   glycerol 
2%   SDS 
14.4 mM  β-mercaptoethanol 
10%   Bromophenol blue 
 
10x SDS-PAGE buffer: 25 mM  Tris HCl, pH 8.3 
192 mM  glycine 
0.1%   SDS 
2.5.2 Coomassie staining 
An SDS-PAGE gel was placed in Coomassie gel stain (1 g/l Coomassie Brilliant 
Blue (Sigma), 45% methanol, 10% glacial acetic acid) at room temperature for 1 hour 
with gentle shaking. The gel was then briefly washed in water and then placed in destain 
solution (10% methanol, 10% glacial acetic acid) overnight with gentle shaking. To dry 
the SDS-PAGE gel, the gel was placed on Whatman 3 MM paper and dried for 1 hour 
on a gel dryer. 
2.5.3 Whole cell extraction 
3–5 × 105 yeast cells or 5–10 × 105 mammalian cells were washed once with pre-
cold PBS. The cell pellet was resuspended with 500 µl of ice-cold water, and then 75 µl 
of lysis solution was added (1.85 NaOH, 7.5%v/v β-mercaptoethanol). The mixture was 
incubated on ice for 15 minutes. Then 75 µl of 50% TCA was added into the lysate tube, 
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and the tube was reincubated on ice for 10 minutes. Denatured proteins were precipitated 
by centrifugation at 13,000 g for 20 minutes at 4°C. The supernatant was aspirated off. 
The tube was re-centrifuged for 1 minute and the remaining supernatant was removed. 
The precipitate was resuspended with 30 µl of 1xSDS sample buffer [if it turned yellow, 
1 µl neutralising buffer (1.5 M Tris-HCl pH 8.8) was added until the sample turned blue]. 
The sample was heated to denature proteins at 95°C for 5–10 minutes. The supernatant 
was collected by centrifugation at 13,000 rpm for 5 minutes. The sample was stored at –
20°C. 
2.5.4 Western blotting  
After SDS-PAGE, proteins were transferred to polyvinylidene difluoride 
membrane (PVDF, Immobilon-P, Millipore). Twelve pieces of Whatman 3MM papers 
were soaked in 1x Semi-dry transfer buffer (48 mM Tris base, 39 mM glycine, 0.04% 
SDS, 20% methanol). The first 6 pieces of the papers were placed on a semi-dry 
electroblotter (Biorad). The PVDF membrane soaked in methanol was placed on top of 
the 6 Whatman sheets. The protein gel was laid on top of the membrane and the 
remaining papers placed on top. Bubbles were removed by rolling a glass tube over the 
stack. The electroblotter was run at 150 mA for 35 minutes per gel. Following blotting 
the PVDF membrane was transferred to a container containing 4% milk (in PBS) and 
was blocked for at least 30 minutes at room temperature with gentle shaking.  
2.5.5 Antibodies used for immunoblotting technique 
Primary and secondary antibodies were required for immunoblotting method 
(Table 2.7). There were several primary antibodies which were specifically used for 
probing the protein of interest, namely specific rabbit anti-eIF4G antisera, rabbit anti-
eIF4A antisera, rabbit anti-eIF4E antisera (kindly provided by Prof Simon Morley), 
mouse monoclonal eIF4G antibody, rabbit polyclonal SUMO1 antibody, rabbit 
polyclonal SUMO 2+3 antibody, mouse monoclonal anti-HA antibody, mouse 
monoclonal anti-c-myc antibody, rabbit polyclonal β-tubulin antibody (Santa Cruz 
Biotechnology), mouse monoclonal anti-FLAG antibody (Sigma) and rabbit polyclonal 
anti-eIF4AII antibody (abcam). For secondary antibodies, there were two types which 
were used in this study, namely polyclonal goat anti-rabbit immunoglobulins/HRP 
(Dako) and polyclonal rabbit anti-Mouse immunoglobulins/HRP (Dako). 
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Table 2.7 List of primary and secondary antibodies used in immunoblotting 
technique 
Antibody Source Type Clone Company Dilution 
anti-eIF4G  rabbit  primary polyclonal In-house 1:10,000 
anti-eIF4G mouse  primary monoclonal  Santa Cruz 
(sc-373892) 
1:2,500 
anti-eIF4E rabbit  primary polyclonal In-house 1:3,000 
anti-eIF4A rabbit  primary polyclonal In-house 1:3,000 
anti-eIF4AII rabbit  primary polyclonal Abcam 
(ab31218) 
1:3,000 
anti-SUMO rabbit  primary polyclonal In-house 1:2,500 
anti-SUMO1  rabbit  primary polyclonal Santa Cruz 
(sc-9060) 
1:2,500 
anti-SUMO1  mouse  primary monoclonal Santa Cruz 
(sc-5308) 
1:2,500 
anti-SUMO2/3 rabbit  primary polyclonal Santa Cruz 
(sc-32873) 
1:2,500 
anti-c-Myc mouse  primary monoclonal Santa Cruz 
(sc-40) 
1:2,500 
anti-HA mouse  primary monoclonal Santa Cruz 
(sc-7392) 
1:2,500 
anti-FLAG mouse  primary monoclonal Sigma (F1804) 1:1,000 
anti-β-tubulin rabbit  primary polyclonal Santa Cruz 
(sc-9107) 
1:2,500 
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2.5.6 PVDF membrane incubated with antibodies 
After the PVDF membrane was blocked in 4% milk (in PBS), the membrane was 
then incubated in 5–10 ml milk containing the primary antibody. The primary antibodies 
were typically used at a 1:2,500 dilution in 4% milk (in PBS) and incubated overnight at 
4°C with gentle shaking. Alterations to this general protocol were made depending on 
the efficiency of the particular antibody (Table 2.7). The membrane was washed three 
times with PBS containing 0.1% Tween-20 (PBST) for 10 minutes each wash. After that 
10 ml of 4% milk (in PBS) was added to the membrane and an HRP-conjugated 
secondary antibody was added to a final dilution of 1:2,500 (Table 2.7). The blot was 
incubated at room temperature for 1–2 hours with gentle shaking. The membrane was 
washed twice with PBST for 5–10 minutes, and another wash with PBS 5–10 minutes, 
respectively. 
2.5.7 Chemi-Luminescent Detection 
The proteins on the PVDF membrane were detected by ECL enhanced 
chemiluminescence. Detection was carried out using ECL Western Blotting substrate 
(Thermo Scientific). The blot was incubated for 1 minute with slight agitation. Then the 
blot was removed onto a transparency wrap or a transparency sheet and then placed in a 
film cassette. In a dark room, the membrane was exposed to X-ray film for varying 
lengths of time depending on the intensity of the signal. The film was developed using a 
LSC50000 machine. 
2.5.8 Bradford assay 
To determine the protein concentration of a sample the Bradford assay reagent 
(Biorad) was diluted 1 in 5 with water. 1 μl protein sample was added to 1 ml of the 
diluted Bradford reagent. The OD595 was measured as compared to a 1 ml reagent only 
‘blank’. The protein concentration of the sample was determined by comparing the 
sample reading against a BSA standard curve. 
2.5.9 In vitro SUMOylation assay 
N-terminally His-tagged Pmt3-GG protein, a C-terminally truncated version of 
Pmt3 and other SUMOylation components were purified as described by Ho et al (Ho et 
al., 2001). The in vitro SUMO modification assay was performed in 50 mM Tris-HCl 
pH7.5, 5 mM MgCl2, 5 mM ATP, 10 mM creatine phosphate, 3.5 U/ml creatine kinase, 
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0.6 U/ml inorganic pyrophosphatase using 3 μg GST-Hus5, 8–10 μg His-SUMO-GG or 
His-SUMO-Tr-GG, 0.4–0.6 μg SAE1 (His-Rad31 and GST-Fub2) and 6.6–15 μg protein 
target. 1 μg His-Pli1 was added to the reaction as optional. The reactions were incubated 
at 30°C for 2 hours and analysed by SDS-PAGE. 
2.5.10 In-solution digestion 
Proteins in any solution were diluted in 25–50 mM ammonium bicarbonate to a 
final concentration of up to 1 mg/ml. Proteins were reduced in 10 mM dithiothreitol, 
25 mM ammonium bicarbonate for 1 hour at 56°C and then alkylated in 55 mM 
iodoacetamide, 25 mM ammonium bicarbonate for 45 minutes at room temperature in 
the dark. Mass spectrometry-grade trypsin (Promega, WI, USA) was added at a ratio of 
1:50 (weight of trypsin: weight of protein) and hydrolysis was allowed to occur at 37°C 
overnight. The reaction was quenched by addition of 0.5% trifluoroacetic acid. Peptides 
were concentrated using SpeedVac® concentrator (Thermo scientific, USA) according to 
the manufacturer’s instructions. 
2.5.11 In-gel digestion 
Bands from polyacrylamide gels were excised and divided into 4–5 small pieces. 
Coomassie-stained bands were destained twice with 50% acetonitrile, 25 mM ammonium 
bicarbonate for 15 minutes at room temperature with agitation, repeated if necessary until 
the gel pieces were destained. Destained gel pieces were dried using vacuum 
centrifugation for 5 minutes. Gel pieces were then rehydrated in 10 mM dithiothreitol, 
25 mM ammonium bicarbonate and reduced at 56°C for 45 minutes. The liquid was 
removed and replaced with 55 mM iodoacetamide, 25 mM ammonium bicarbonate. Gel 
pieces were alkylated for 45 minutes at room temperature in the dark. The supernatant 
was removed and gel pieces were dehydrated twice with 50% acetonitrile, 25 mM 
ammonium bicarbonate for 5 minutes at room temperature with agitation. 25 µg of Mass 
spectrometry-grade trypsin (Promega, WI, USA) was resuspended in 25 µl of 50 mM 
acetic acid resuspension buffer (Promega) and incubated at 30°C for 15 minutes. Trypsin 
solution was then diluted in 25 mM ammonium bicarbonate to give a 25 ng/µl solution. 
Gel pieces were dried and rehydrated in 25 ng/µl trypsin, 25 mM ammonium 
bicarbonate. Excess trypsin solution was removed after 10 minutes, the gel pieces were 
covered with 25 mM ammonium bicarbonate and hydrolysis was allowed to occur 
overnight at 37°C. Trifluoroacetic acid was added to 0.5% and the supernatant was 
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removed to a clean tube. Remaining peptides were extracted from the gel pieces using 
50% acetonitrile with vigorous agitation, repeated if gel pieces were not dehydrated. All 
supernatants were pooled and the volume was reduced using SpeedVac® concentrator 
(Thermo scientific, USA). 
2.5.12 Protein expression from BL21 (DE3) pLysS E. coli cells 
An expression plasmid containing the gene encoding the protein of interest was 
transformed into BL21 (DE3) pLysS E. coli cells, following the bacterial transformation 
protocol (see section 2.2.6). Cells were plated on LA plates containing chloramphenicol 
and the appropriate antibiotics, and then grown overnight at 37°C. A single colony was 
inoculated in 10 ml liquid culture with antibiotic selection and grown overnight at 37°C 
with shaking. The culture was added to one litre of liquid medium with antibiotics and 
incubated at 37°C until the OD600 reached between 0.4 and 0.8. Expression of the 
protein of interest was induced with IPTG at a final concentration of 0.1–0.4 mM (0.15 
mM, commonly used in this study) overnight at 16°C with shaking. The cell pellet was 
harvested by centrifugation at 5,000 rpm for 5 minutes at 4°C. The supernatant was 
discarded and the pellet was scraped into a pre-cooled 50-ml tube. A loop of cells was 
collected to check protein expression using either a Coomassie-stained protein gel, 
western blotting or an activity assay. The rest of the pellet was frozen using liquid 
nitrogen and stored at –80°C overnight or until needed. 
2.5.13 His-tagged protein purification by Ni agarose beads under native 
buffer condition  
A single colony of BL21 (DE3) E. coli cells containing His-tagged expression vector 
was grown overnight at 37°C in L-broth containing chloramphenicol and the selective 
antibiotic. IPTG was added to induce protein expression (see section 2.5.12). The cell 
pellet was resuspended in 15 ml ice-cold Ni2+ binding buffer (20 mM Tris-HCl pH 7.9, 
300 mM NaCl, 5 mM imidazole) containing protease inhibitors (Roche) and 0.1 mM 
PMSF. The cells were lysed on ice by sonication at 27% amplitude for 3 minutes (5 
seconds on and 5 seconds off). The cell debris was removed by centrifugation at 15,000 
rpm for 30 minutes at 4°C. The supernatant was applied to a 5-ml column containing 0.5 
ml of Ni2+-agarose beads equilibrated with Ni2+ binding buffer at 4°C. After all of the 
supernatant flowed through the column by gravity, 10 ml (2x 5 ml) binding buffer was 
applied to the column. To wash the beads, 6 ml of wash buffer (20 mM Tris-HCl pH 7.9, 
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300 mM NaCl, 20 mM imidazole) was added to the column. To elute His-tagged fusion 
protein, 0.3 ml of elution buffer (20 mM Tris HCl pH 7.9, 300 mM NaCl, 250 mM 
imidazole) was added to the column (normally repeated 5 times). Each fraction was 
collected on ice and measured the protein concentration by Bradford assay. The His-
tagged protein was also analysed by SDS-PAGE. Each protein elution was added with 
glycerol at the 10% final concentration in order to store at –80°C 
2.5.14 GST-tagged protein purification under native buffer condition  
A single colony of BL21 (DE3) E. coli cells containing GST-tagged expression 
vector was grown overnight at 37°C in L-broth containing chloramphenicol and the 
selective antibiotic. IPTG was added to induce protein expression (see section 2.5.12). 
The cell pellet was resuspended in 15 ml ice-cold NETN binding buffer (100 mM NaCl, 
1 mM EDTA, 20 mM Tris-HCl pH 8.0, 0.5% NP-40) containing protease inhibitors 
(Roche) and 0.1 mM PMSF. The cells were lysed on ice by the sonication at 27% 
amplitude for 3 minutes (5 seconds on and 5 seconds). The cell debris was removed by 
centrifugation at 15,000 rpm for 30 minutes at 4°C. The supernatant was applied to a 5-
ml column containing 0.5 ml of GST beads equilibrated with NETN binding buffer at 
4°C. After all of the supernatant flowed through the column by gravity, 5 ml of binding 
buffer was applied to the column. To wash the beads, 6 ml of wash buffer (120 mM 
NaCl, 100 mM Tris-HCl pH 8.0) was added to the column. To elute GST-tagged protein, 
0.3 ml of elution buffer (120 mM NaCl, 100 mM Tris-HCl pH 8.0, 1 mM PMSF, 
20 mM glutathione) was added to the column (normally repeated 5 times). Each fraction 
was collected on ice and measured the protein concentration by Bradford assay. The 
GST-tagged fusion protein was also analysed by SDS-PAGE. Each protein elution was 
added with 30 µl of 100% glycerol and then kept at –80°C. 
2.5.15 Protein expression from Sf9 insect cells using Baculovirus 
expression system 
To amplify the P1 recombinant virus, Sf9 insect cells, were diluted in a 35-mm petri 
dish with SF900IISFM medium without antibiotics at a cell density of 1 × 106 cells/ml. 
They were then incubated at 27°C for an hour to adhere to the bottom of the plate, and 
then transfected by adding 2 ml of the P1 Baculovirus under humid conditions at 27°C 
for 3–5 days. Transfected insect cells were monitored every 24 hours to check for 
contamination and for the number of insect cells infected. 5 days after transfection, 2 ml 
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of supernatant was transferred to sterile cryotubes containing 1% heated-inactivated FCS. 
The cryotubes were stored at 4°C in the dark as P2 recombinant virus. Cells were kept 
and whole cell extracts were prepared to check protein expression levels by western 
blotting, and compared with non-transfected cells. P2 recombinant Baculovirus was 
amplified the same ways as above but a six-well plate was replaced to achieve a higher 
amount of P3 recombinant Baculovirus. P4 and P5 recombinant Baculovirus was scaled 
up and collected, respectively. 
Plaque assays were performed to purify virus and determine the viral titre (pfu/ml). 
The P5 viral stock was diluted from 10-5 to 10-7. 100 µl of each viral dilution was added 
into their respective plates containing adherent Sf9 insect cells in SF900IISFM at the cell 
density of 5 × 105 cells/ml and then each plate was incubated at room temperature for 1 
hour. Liquid medium was pipetted off and replaced with 2 ml of 1% agarose containing 
medium. After the agarose had set, 1 ml of medium was added on top of the agarose in 
each plate. Plates were incubated at 27°C for 3–4 days. Cells were stained by adding 1 ml 
of 0.02% neutral red (in PBS) in each plate. Plates were incubated at 27°C in the dark for 
2 hours. All liquid was pipetted off and plates were inverted overnight at room 
temperature in the dark. Plaques were counted for zones of clearing generated by 
infection of Sf9 insect cells. The number of plaques was calculated as a viral titre. 
Efficient protein expression using the Baculovirus system depends on the titre of 
virus, the multiplicity of infection (MOI) and the cell density. These were tested to 
optimize the appropriate volume of recombinant virus used in transfection. To express 
recombinant gene products, a cell density of 1 × 106 to 2 × 106 cells/ml and MOIs of 
0.5 to 10 were commonly employed. The optimized viral volume was added to a 1000 ml 
flask containing insect cells at a cell density of 2 × 106 cells/ml and suspension medium. 
The flask was incubated at 27°C in a humidified incubator for 72 hours. Cells were 
harvested by centrifugation at 2,000 g for 10 minutes at 4°C. The pellet was kept at –
80°C or used immediately. 
2.5.16 Isolation of His/FLAG-eIF4G from Baculovirus-infected insect 
cells 
After 72 hours, Baculovirus-infected insect cells were harvested at 4°C by 
centrifugation at 2,000 g for 10 minutes. The pellet was resuspended in 15 ml of Lysis 
Buffer A [40 mM MOPS (KOH) pH 7.2, 300 mM NaCl, 2 mM benzamidine, 20 mM 
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imidazole, 3.5 mM β-mercaptoethanol, 1% NP40 and protease inhibitor cocktail (Roche, 
Cat. no. 11873580001)]. Cells were sonicated on ice at 27% amplitude, 5 seconds on and 
5 seconds off for 3 minutes and vortexed briefly. The cell lysate was left on ice for 
10 minutes and centrifuged at 9,800 rpm in SS34 Sorvall rotor at 4°C for 20 minutes. The 
supernatant containing His/FLAG recombinant proteins was added to 1 ml of NTA-
agarose, which was washed twice with Binding Buffer B [Lysis Buffer A without 1% 
NP40] in a 50 ml falcon tube. The tube was rotated at 4°C for at least 1 hour. The resin 
was pelleted at 2,000 g for 1 minute in a cooled centrifuge and washed twice with 25 ml 
of the Binding buffer B, followed twice by 25 ml of the Lysis Buffer A. The resin was 
then washed twice with Wash Buffer C [40 mM MOPS (KOH) pH 7.2, 500 mM NaCl, 
2 mM benzamidine, 20 mM imidazole, 3.5 mM β-mercaptoethanol, 1% NP40 and 
protease inhibitor cocktail (Roche)] and washed twice with Binding Buffer B without 
protease inhibitors. The resin was transferred to an ice-cold 2 ml tube. Protein was eluted 
with 500 µl of Elution Buffer D [40 mM MOPS (KOH) pH 7.2, 300 mM NaCl, 2 mM 
benzamidine, 250 mM imidazole, 3.5 mM β-mercaptoethanol] at 4°C on an end-over-
end mixer for 15 minutes. Eluate was removed to a cold tube by centrifugation at 
13,000 rpm for 1 minute and this was repeated 4 times. A Bradford assay was undertaken 
for each sample to check for protein concentration. Each elution was checked by either 
Coomassie-stained protein gel or western blotting. 50 µl of 100% glycerol was added into 
sample tube containing high-yield proteins. The tubes were frozen and stored at –80°C. 
2.5.17 Immunoprecipitation using anti-eIF4G antisera 
Mammalian cells were harvested by trypsinization and washed with PBS. The cell 
pellet was lysed in 100 µl IP Lysis buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 50 mM 
sodium fluoride (NaF), 25 mM β-glycerophosphate, 0.1 mM sodium orthovanadate 
(Na3VO4), 0.2% Triton X-100, 0.3% NP-40, 10 mM N-ethylmaleimide, protease 
inhibitor cocktail (Roche)], and the lysate was then spun at 13,000 rpm for 5 minutes. 
The supernatant was recovered into a new 1.5 ml tube and the protein concentration was 
then measured by Bradford assay. For immunoprecipitation, 1 mg of lysate sample was 
diluted in 1 ml IP Lysis buffer and incubated with 40 μg of anti-eIF4G antisera for 
2 hours at 4°C. The immune complex were then incubated with 20 µl of 50% washed 
Protein A beads with end-over-end mixing for 1 hour. The resin was washed three times 
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with 500 µl of IP lysis buffer. The recovered proteins were eluted with 2x SDS-PAGE 
sample buffer.  
2.5.18 Isolation of eIF4F and associated factors using m7GTP-Sepharose 
4B beads 
Harvested cells were resuspended in 100 µl of MOPS Lysis buffer [20 mM MOPS 
pH 7.2, 75 mM KCl, 2 mM benzamidine, 7 mM β-mercaptoethanol, 25 mM NaF, 2 mM 
magnesium chloride (MgCl2), 25 mM β-glycerophosphate, protease inhibitor cocktail 
(Roche)]. The supernatant was collected and transferred into a new 1.5 ml tube and 
protein concentration was then measured by Bradford assay. 30 µl of pre-washed 50% 
(v/v) m7GTP-Sepharose 4B (GE Healthcare) beads was added into tubes containing 100 
μg of total protein. The samples were gently mixed, placed back on ice and repeated in 
every 5 minutes for 15 minutes. The resins were washed twice with 200 µl of MOPS lysis 
buffer. To elute the factors, the beads were resuspended with 20 µl SDS-PAGE sample 
buffer.  
2.5.19 Ni2+-pulled down under denaturing conditions  
This method is able to be used for both S. pombe and mammalian cells. For 
mammalian cells, cells were grown until 60–80% confluent were harvested and counted. 
6–8 × 106 cells were washed with pre-cold PBS. For S. pombe cells, cells were grown until 
they are at OD 0.5. 1 × 109 cells were harvested and washed with pre-cold PBS. The cell 
pellet was resuspended with 5 ml of ice-cold water, and then 0.8 ml of lysis solution 
(1.85 NaOH, 7.5%v/v β-mercaptoethanol) was added. The mixture was incubated on ice 
for 20 minutes. 0.8 ml of 50% TCA was added into the tube containing the cell lysate, 
and the tube was incubated on ice for 20 minutes. Denatured proteins were precipitated 
by centrifugation at 8,000 g for 20 minutes at 4°C. The precipitate was resuspended with 
1 ml of buffer A (10 mM Tris-HCl, 6 M guanidinium HCl, 0.1 M NaH2PO4, pH 8.0) and 
transferred into a new centrifuge tube. The precipitate was completely solubilised by 
rotating the tube on a wheel for an hour at room temperature. Cell debris was removed 
by centrifugation at 13,000 rpm for 10 minutes, and the supernatant was transferred into 
a new tube containing 30 µl of pre-washed Ni-NTA beads which was washed with buffer 
A and 0.05% Tween-20 three times. The mixture was supplemented with 5 µl of 10% 
Tween-20 and 15 µl of 1 M imidazole. The tube was incubated overnight at room 
temperature on a wheel. Beads were pelleted by centrifugation at 2,000 rpm for 
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2 minutes. The supernatant was pipetted off carefully. The bead pellet was washed twice 
with 1 ml of buffer A containing 0.05% Tween-20. The pellet was then washed twice 
with 1 ml of buffer B (10 mM Tris-HCl, 0.1 M NaH2PO4, pH 6.3, 0.05% Tween-20). 
The pellet was also washed twice with 1 ml of buffer B containing 40 mM imidazole. The 
supernatant was completely removed from the bead pellet. 30 µl of HU buffer (8 M urea, 
200 mM Tris-HCl pH 6.8, 1 mM EDTA, 5% SDS, 0.1% bromophenol blue, 1.5% 
dithiothreitol) was added into the tube containing the beads. To denature proteins, the 
sample was heated at 95°C for 5–10 minutes. The supernatant was obtained by 
centrifugation at 13,000 rpm for 5 minutes. The sample was stored at - 20°C prior to use. 
A whole cell extract sample was needed as a control for the experiment. So 3–
5 × 105 mammalian cells or 4 × 107 S. pombe cells were washed once with pre-cold PBS. 
The cell pellet was resuspended with 500 µl of ice-cold water, and then 75 µl of the same 
lysis solution was added. The mixture was incubated on ice for 15 minutes. Then 75 µl 
of 50% TCA was added into the lysate tube, and the tube was reincubated on ice for 
10 minutes. Denatured proteins were precipitated by centrifugation at 13,000 g for 
20 minutes at 4°C. The supernatant was aspirated off. The tube was re-centrifuged for 
1 minutes and the remaining supernatant was removed. The precipitate was resuspended 
with 30 µl of HU buffer (if it turned yellow, 1 µl neutralising buffer (1.5 M Tris-HCl pH 
8.8) was added until the sample turned blue. The sample was heated to denature proteins 
at 95°C for 5–10 minutes. The supernatant was collected by centrifugation at 13,000 rpm 
for 5 minutes. The sample was stored at –20°C. 
2.5.20 Protein synthesis assay 
50-60% confluent cells were incubated with [35S]-methionine (MP Biomedicals, 
UK; 10 μCi/ml), then reincubated at 30°C. Cells were harvested and then washed with 
pre-cold PBS. Cells were lysed in 100 µl pre-cold lysis buffer [50 mM Tris-HCl pH 7.5, 
150 mM NaCl, 50 mM NaF, 25 mM β-glycerophosphate, 0.1 mM sodium orthovanadate 
(Na3VO4), 0.2% Triton X-100, 0.3% NP-40, 10 mM N-ethylmaleimide, protease 
inhibitor cocktail (EDTA-free Roche), with the addition of 0.5% deoxycholate (DOC)] 
with vortexing. Cell debris was removed by centrifugation at 4°C for 5 minutes. Protein 
concentration was determined and recorded. 5 μl of supernatant was then spotted onto 
Whatman filter papers. Filter papers were soaked in 10% TCA containing 5 mM 
unlabelled L-methionine for 20 minutes, then boiled in 5% TCA. After the papers were 
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cooled at room temperature for 30–45 minute, they were washed in ethanol, then 
acetone, and air dried. Next the papers were placed in liquid scintillation fluid. Protein 
synthesis was measured using a scintillation counter and calculated as cpm/μg protein. 
2.5.21 Identification of SUMOylation sites by mass spectrometry 
Proteins were separated by SDS-PAGE. Gel slices were excised and proteins 
subjected to trypsin digestion (described in section 2.5.11). Peptide fractions were 
analysed by LTQ-Orbitrap XL mass spectrometer (Thermo Scientific). Peptides were 
loaded onto a C18 nanoLC column to be separated using a gradient of acetronitrile. Data 
were analysed using the Human NCBI database in conjunction with the MASCOT search 
algorithm. 
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Chapter 3  
Investigating the role of SUMOylation of S. pombe 
RNA binding proteins 
3.1 Introduction 
One of the studies in the Watts lab to identify SUMOylated proteins in S. pombe 
(described in section 1.9) involved affinity purification of TAP-tagged Ulp2 (SUMO 
protease) and associated proteins (Dr. Min Feng, University of Sussex). Interestingly, the 
TAP-Ulp2 co-purified with a number of proteins, many of which are involved in RNA 
metabolism, protein synthesis or RNA binding. These co-purified proteins included 
translation initiation factors and a number of other proteins e.g. eIF2α, eIF3a, eIF3c, 
eIF3h, eIF4G, eEF1A2 and the La protein homolog (Sla1).  
These preliminary data suggested a link between these proteins and SUMOylation. 
Moreover, a significant number of eukaryotic translation initiation factors (eIFs) in 
budding yeast (S. cerevisiae), plants (A. thaliana), insect cells (D. melanogaster) and 
mammalian cells (human and rat) have been identified in proteomic screens as being 
SUMOylated (Table 1.5). However, most proteins identified in these screens have not 
yet been confirmed as being modified by SUMO. This chapter will focus on determining 
whether the S. pombe La homolog protein and two eIFs, specifically eIF4G and eIF3h, 
are SUMOylated. 
3.2 Background of the S. pombe La homolog protein (Sla1) 
Sla1 is a nuclear RNA-binding phosphoprotein that is encoded by the sla1 gene. It 
is the homologue of the human La gene. The S. pombe La protein, Sla1 contains conserved 
RNA recognition motifs (RRM1 and RRM2) (Tanabe et al., 2003; Cherkasova et al., 2012). 
The protein acts as a molecular chaperone by binding to newly synthesized transcripts of 
RNA polymerase III in order to protect the RNAs from 3’ exonuclease during 
intranuclear maturation (Van Horn et al., 1997; Cherkasova et al., 2012). The La protein 
(Sla1) is non-essential in S. pombe and S. cerevisiae (Lhp1p), but essential in mammals (La). 
For example, S. pombe cells, where the sla1 gene is replaced with the ura4+ gene 
(sla1::ura4+), are able to grow in minimal medium without uracil, indicating that sla1 is a 
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non-essential gene in S. pombe (Van Horn et al., 1997). S. pombe cells with a sla1 deletion 
(sla1Δ) grow slower than wild type cells in Edinburgh minimum medium (EMM), but 
grow relatively well in rich medium (YE). Briefly, a mutated human La protein, which 
lacks a motif required for pre-tRNA processing, when introduced into the sla1Δ cells 
does not rescue the slow growth phenotype (Intine et al., 2000). However, it can be 
rescued by introducing either the wild type human, S. cerevisiae or S. pombe La protein into 
the cells, resulting in a functional pathway of tRNA maturation. This suggests that the 
Sla1-deleted S. pombe grows slowly because of a defect in tRNA metabolism (Van Horn 
et al., 1997; Cherkasova et al., 2012).  
Ammonium chloride (NH4Cl) in EMM is a major component that affects the low 
growth rate of the sla1-deleted cells. It has been shown that adding proline rather than 
NH4Cl supports the growth of the sla1Δ cells in EMM, since proline is a poor nitrogen 
source (Weisman et al., 2005; Weisman et al., 2007). When NH4Cl is added into YE 
medium, growth of the sla1-deleted cells is strongly inhibited. This indicates that sla1Δ 
cells are hypersensitive to NH4Cl and may suggest that Sla1 regulates nitrogen 
metabolism (Van Horn et al., 1997). In addition, it is also found that sla1Δ cells are highly 
sensitive to rapamycin (Cherkasova et al., 2012). 
3.3 Sla1 is endogenously modified by SUMO  
In order to determine whether the La protein homolog (Sla1) is SUMOylated in 
vivo, SUMOylation of Sla1 was investigated following expression of N-terminally HA-
tagged Sla1 from pREP41 (created by Dr. Felicity Watts) and 6xHis-tagged SUMO from 
pREP42 (Dr. Lauren Small, University of Sussex). Those plasmids were transformed into 
wild-type S. pombe, so that both HA-tagged Sla1 and His-tagged SUMO were 
overexpressed. 6xHis-SUMO was pulled out using Ni2+ agarose beads under denaturing 
conditions (see 2.5.19). Figure 3.1 demonstrates that HA-tagged Sla1 is specifically 
recovered in the presence of His-tagged SUMO (lane 1), but not recovered in the absence 
of His-tagged SUMO (lane 2). This indicates that Sla1 is SUMOylated in vivo in S. pombe. 
This is consistent with the fact that the S. pombe La protein homolog interacts with SUMO 
protease Ulp2. 
In addition, to investigate SUMOylation of Sla1 expressed at endogenous levels, 
several attempts were undertaken to C-terminally tag the S. pombe sla1 gene with myc and 
HA epitopes as well as GFP sequences since antibodies against Sla1 were not available. 
 
 
58 
 
 
 
However the gene tagging experiments were unsuccessful, suggesting that addition of a 
C-terminal tag to Sla1 is lethal. 
 
 
Figure 3.1 Western blotting of Ni2+ affinity purification for Sla1.  His-tagged 
SUMO was affinity purified to test for SUMOylation of the La protein homolog (sla1 
product, Sla1). Whole cell extracts (WCE) and pulled down (Ni2+-PD) samples were 
analysed on 10% gels gel. Blots were probed with either anti-HA or anti-SUMO antisera. 
3.4 Sla1 is SUMOylated in vitro on K106 and K263 
Using an in vitro SUMOylation assay, Sla1 has previously been demonstrated to be 
modified by SUMO in vitro (P. Taylor, Watts lab). Mass spectrometric analysis of the 
modified form indicated that Sla1 is SUMOylated on lysines 106 and 263 (Dr. Brenda 
Mercer, University of Sussex). 
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3.5 Creating the SUMOylation mutants of La protein homolog from a 
sla1 base strain 
To investigate the role of SUMOylation of Sla1, strains containing 
unSUMOylatable versions of Sla1 were created. In order to do this, a sla1 base strain was 
first created using the recombinase-mediated cassette exchange system for non-essential 
genes (Watson et al., 2008). The PCR product, loxP-ura4+-loxM3, was amplified from 
the template pAW1 plasmids using a forward primer ‘Sla1 BS F’ and a reverse primer 
‘Sla1 BS R’ (shown in Table 3.1) that consisted of ∼80 bases homology to the upstream 
and downstream genomic target, respectively, plus 20 bases specific to pAW1. The PCR 
product was transformed into a S. pombe wild type strain to obtain the sla1::ura4 base 
strain. To ensure that the integration was successful, genomic DNA was extracted and 
checked using two pairs of primers of ‘Sla1 external F’ and ‘Ura4 R’, another ‘Ura4 F’ 
and ‘Sla1 external R’ shown in Figure 3.2. 
In parallel with the creation of a base strain, the chromosomal sla1 gene along with 
its promoter and terminator was amplified using a pair of primers containing the sites for 
the restriction enzymes SphI (Sla1 ORF Forward primer; 5’ GCATGCAGCAATCTCT
GTTAATCTTTTCAAAAAAAAAAAC 3’) and SalI (Sla1 ORF Reverse primer; 5’GTC
GACATCCATTTTACTCCGAAGCGG 3’) at the 5’ end of the primers. These 
restriction sites are also present in the multiple cloning site (MCS) of pAW8 plasmid into 
which the PCR product was ligated.  
To construct the plasmids containing the mutated residues of sla1 SUMOylation 
sites, the pAW8-sla1 plasmid was then used as PCR template. Site-directed mutagenesis 
was carried out on pAW8-sla1 to mutate lysines at the positions 106 (K106) and 263 
(K263) to arginine using primers ‘Sla 1 K106R F’ and ‘Sla1 K106 R’ thus creating pAW8-
sla1 K106R plasmid and ‘Sla 1 K263R F’ and ‘Sla 1 K263R R’ to create pAW8-sla1 K263R 
plasmid. A doubly mutated plasmid (pAW8-Sla1 K106R, K263R) was also constructed 
using the pAW8-sla1 K106R plasmid as PCR template and the primers ‘Sla 1 K263R F’ 
and ‘Sla 1 K263R R’ instead. All of these plasmids were sequenced using a primer ‘Sla 1 
Seq1 F’.   
 The wild-type and mutated pAW8-sla1 plasmids were then used to transform the 
sla1::ura4 base strain to achieve the sla1.wt strains (non-mutation), two strains containing 
a single lysine mutated to arginine (sla1-K106R and sla1-K263R) and one containing a 
 
 
60 
 
 
 
double mutation (sla1-K106R,K263R or sla1-RR) due to homologous recombination 
between the specific loxP and loxM sites (Figure 3.3). 
 
Table 3.1 Primers involved in the construction of Sla1 strains. 
Name Primer sequences  
Sla1 BS F GTAAAGAATCATAAATAGGAAAACTAAAAGCTACTGCTT
GTCATTATGGTTAAATTGTATCCAGAGCTACATTGTAAGG
CGGATCCCCGGGTTAATTAA 
Sla BS R CCTAATATAACCAATCCGAAAAAGTTTATTTGTCCAGTGT
CTTTGAAGTATTTGTAAAACAAACAAACAAACAAAATTAG
AATTCGAGCTCGTTTAAAC 
Sla1 external F GCTAGGAAATTTGAGGAAGTGGAG 
Sla1 external R GAAATGCAAGCTTGGTCGTACTGG 
Ura4 F TAGCGATATCATCATTGTTGGTCGTG 
Ura4 R CCAATGTCTGCGAATTTGCGATCC  
Sla1 ORF F  GCATGCAGCAATCTCTGTTAATCTTTTCAAAAAAAAAAAC 
    SphI 
Sla1 ORF R  GTCGACATCCATTTTACTCCGAAGCGG 
    SalI 
Sla 1 K106R F CAAACAATTGCTAATTTCAGACGTATGCGTCGTTTTC  
Sla 1 K106R R GAAAACGACGCATACGTCTGAAATTAGCAATTGTTTG 
Sla 1 K263R F CGTTTTGACGCTTTTAGAGAGATGGATCGTCAGC 
Sla 1 K263R R GCTGACGATCCATCTCTCTAAAAGCGTCAAAACG 
Sla 1 Seq1 F GGAAGCTGGAAAAGTAGTAG 
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Figure 3.2 Construction of sla1::ura4 base strain using standard homologous 
recombination techniques (Watson et al, 2008). Plasmid pAW1 was used as PCR 
templates—the loxP-ura4+-loxM3 cassette flanked by pFA6a derivative forward (F) and 
reverse (R) primer sites (Bahler et al., 1998), P = loxP sequence, M3 = loxM3 sequence. 
Sequences of pAW1-specific primers shown in Table 1 (Sla1 BS F and Sla1 BS R) contain 
the upstream and downstream sequences of the sla1 gene, respectively, to generate 
fragments to be used to construct base strains for Cre-mediated cassette exchange. PCR 
product size is approximate 2.0 kb. Green and blue arrows are two sets of primers used 
for checking the replacement of the sla1 gene by the loxP-ura4+-loxM3 cassette. This 
figure was adapted from Watson et al. (2008). 
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Figure 3.3 Schematic representation of Cre recombinase-mediated cassette 
exchange protocol. A) Construction of sla1 base strain using standard homologous 
recombination techniques, B) introduction of Cre-expression plasmid containing sla1 
cassette sequences and C) expression of Cre recombinase resulting in sla1 cassette 
exchange between the plasmid vector and chromosome, sla1::ura4. LEU2 = S. cerevisiae 
leucine selectable marker, ura4+ = S. pombe uracil selectable marker, P = loxP, M3 = 
loxM3, Pnmt = S. pombe nmt41 promoter sequence, S. pombe Tnmt = nmt terminator 
sequence, cre = Cre recombinase coding sequence, IN = S. pombe rad50 intron 1. This 
figure was adapted from Watson et al. (2008). 
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3.6 Phenotypic analysis of sla1 mutants 
The unSUMOylatable sla1 mutants were used for phenotypic analysis and 
compared to wild type (shown in Figure 3.4). This figure includes a number of strains, 
namely (1) S. pombe wild type (wt 501, h-), (2) a sla1 base strain in which sla1 is replaced 
with ura4 (sla1:: ura4, h-), (3) a sla1 wild type strain (sla1-wt, h-) obtained by transforming 
strain (2) with wt-sla1, (4) a sla1 strain containing K106R (sla1-K106R, h-), (5) a sla1 strain 
containing K263R (sla1-K263R, h-) (6) a sla1 strain containing both K106R and K263R 
mutations (sla1-RR, h-), (7) a sla1 base strain with h+ mating type (sla1::ura4, h+), (8) a 
strain containing sla1 replaced with Kan (sla1::kan, h+, a Bioneer library strain). Strain 8 
was crossed with wt 501, h- creating strain (9) with the opposite different mating type 
(sla1::kan, h-). Additionally, the ura4 marker in the sla1 base strain (2) was replaced by 
NAT in order to create (10) sla1::NAT, h- strain. 
These S. pombe strains were exposed to a range of conditions to test for growth at 
30°C and 37°C, sensitivity to rapamycin and/or ammonium chloride (NH4Cl). The 
strains 1–6 were first analysed. Figure 3.4 shows that sla1Δ (sla1::ura4, h-) cells grew well 
in response to all the conditions, compared to wild type and sla1-wt strains. In addition, 
integration of neither of the single sla1 mutations, K106R and K263R, nor the double 
mutation resulted in any alteration in phenotype. However this result was not consistent 
with recent studies by Cherkasova et al. (2012) who have shown that sla1-deleted S. pombe 
(sla1::NAT) grow slower than wild type cells on minimum medium.  
Here, it was questioned whether there are other factors affecting the phenotype of 
the mutants, e.g. mating type or, replacement of sla1 with different gene cassettes. This 
led to the construction of further strains (strains 7, 9–10) and the finding of a Bioneer 
library control strain (strain 8). These strains were grown under the same conditions as 
above. The result shows that different mating types of sla1::ura4 cells (strains 2 and 7) do 
not affect the phenotype. In addition, our sla1Δ strains replaced by ura4 and NAT 
cassette sequences did not have any effect on phenotype. In contrast, the sla1::kan cells 
(strains 8, h+ and 9, h-) had the altered phenotype. This suggests that gene cassettes may 
affect the phenotype of sla1Δ cells, but the mating type does not. The reason for this is 
not known.   
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Figure 3.4 Analysis of the phenotype of unSUMOylatable sla1 mutants. S. pombe wild type and various mutants were determined in 
response to growth temperature, rapamycin and ammonium chloride. 
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3.7 S. pombe eIF4G is SUMOylated in vivo but eIF3h is not 
Since there was no detectable phenotype in unSUMOylatable Sla1 mutants, two 
other proteins were analysed. These were S. pombe eIF4G and eIF3h. Strains containing 
eIF4G and eIF3h tagged with the HA epitope at the C terminus were available for use 
(Dr. Felicity Watts). S. pombe cells containing HA-tagged eIF4G and eIF3h were 
separately transformed with pREP42-6xHis-SUMO (constructed by Dr. Lauren Small, 
University of Sussex). The pull-down experiments demonstrated that HA-tagged eIF4G 
was specifically recovered in the presence of His-tagged SUMO (lane 1 in Figure 3.5 A), 
but HA-tagged eIF3h did not pull down with His-tagged SUMO (lane 1 in Figure 3.5 B). 
This indicates that eIF4G is SUMOylated in S. pombe, but that eIF3h is not. 
 
 
Figure 3.5 Western blotting of Ni2+ affinity purification for S. pombe eIF4G 
and eIF3h. His-tagged SUMO was affinity purified to test for SUMOylation of A) 
eIF4G and B) eIF3h. Whole cell extracts (WCE) and pulled down (PD) samples were 
analysed on 7.5 % gels. Blots were probed with anti-HA and anti-SUMO antisera. 
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3.8 The level of eIF4G modified by SUMO is increased after treatment 
with KCl  
To determine whether SUMOylation of eIF4G was altered in response to different 
stress conditions, transformed HA-tagged eIF4G cells containing either pREP42-6xHis-
SUMO or pREP42 6xHis empty vector were treated with either 100 µg/mL 
cycloheximide (Chx) or 1M KCl for 30 minutes and compared to untreated cells. Figure 
3.6 shows that the level of SUMOylated eIF4G was increased 1.5 fold after treatment 
with 1M KCl, compared to the levels in untreated cells or cycloheximide-treated cells.   
 
 
Figure 3.6 Western blotting of Ni2+ affinity purification for eIF4G in response 
to stresses. His-tagged SUMO was affinity purified to analyse SUMOylation levels of 
S. pombe eIF4G after the treatment with either 100 µg/mL cycloheximide (Chx) or 1M 
KCl for 30 minutes. Whole cell extracts (WCE) and pulled down (PD) samples were 
loaded on 7.5 % gels. Blots were probed with anti-HA and anti-SUMO antisera. 
Normalised ratio was calculated from the SUMOylated ratio of each stress condition 
(UT, Chx and KCl) divided by the SUMOylated ratio of non-treatment (UT). The 
SUMOylated ratio is the individual intensity of PD result (HA blot) which is divided by 
the intensity of its WCE result (HA blot). 
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3.9 S. pombe eIF4G and eIF3h protein are not formed in polysomes 
Following the identification of eIF4G and eIF3h in complexes with Ulp2, gel 
filtration studies were used to confirm that eIF4G and eIF3h are indeed present in Ulp2-
containing complexes (Dr. Felicity Watts) (as shown in Figure 2 in Jongjitwimol et al, 
2014). To begin to identify the nature of these complexes, experiments were undertaken 
to determine whether the complexes were polysomes. Polysomes were prepared as 
described in 2.1.10 and analysis by western blotting. Figure 3.7 shows that Ulp2, eIF4G 
and eIF3h were present in the high molecular weight complexes containing polysomes 
in untreated cells. In cells treated with EDTA (which results in the disruption of 
polysomes), Ulp2 and eIF4G sediment in high molecular weight fractions. This indicates 
that the eIF4G and Ulp2 containing complexes are not polysomes. The identity of this 
complex, however, not known, but may be either stress granules or P-bodies. 
 
 
Figure 3.7 Western blotting of whole cell extracts from Ulp2-myc + eIF4G-HA 
and Ulp2-myc + eIF3h-HA strains. These cells were analysed from polysome 
fractions after treatment of EDTA compared to untreated condition. The fractions were 
loaded on 10 % gels gel. Blots were probed with anti-HA and anti-myc antisera. 
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3.10 Discussion 
In this chapter, I analysed SUMOylation of some RNA-binding proteins in 
S. pombe, namely the S. pombe La homolog protein (Sla1), eIF4G and eIF3h. These three 
proteins are only some of several proteins that were co-purified with SUMO specific 
protease Ulp2. Other proteins (Table 1.4) may need to be further investigated for ability 
to be SUMOylated. It is interesting that these proteins are involved in processes such as 
RNA synthesis or processing, ribosome biogenesis and translation. This is consistent 
with recent studies indicating that a number of proteins required for ribosome biogenesis 
and RNA processing are SUMOylated (Panse et al., 2006; Haindl et al., 2008; Finkbeiner 
et al., 2011). For example, SUMO-specific protease SENP3 has been demonstrated to 
associate with nucleophosmin and to be required for rRNA processing in ribosomal 
biogenesis (Haindl et al., 2008; Finkbeiner et al., 2011). 
To begin with Sla1, it was demonstrated that this protein is modified by SUMO in 
vivo. This is consistent with the fact that the S. pombe La protein homolog interacts with 
SUMO protease Ulp2. To investigate SUMOylation of Sla1 expressed at endogenous 
levels, I undertook several attempts to C-terminally tag the S. pombe sla1 gene with myc 
and HA epitopes as well as GFP sequences since antibodies against Sla1 were not 
available. However the gene tagging experiments were unsuccessful, suggesting that 
addition of a C-terminal tag to Sla1 is lethal in S. pombe. This was unexpected as deletion 
of the sla1 gene was not lethal. In order to identify the SUMOylation sites of Sla1, our 
lab members have undertaken an in vitro SUMOylation assay and mass spectrometry. Sla1 
has previously been demonstrated to be modified by SUMO in an in vitro assay (P. Taylor, 
Watts lab). Mass spectrometric analysis indicated that Sla1 is SUMOylated on lysine 106 
and 263 (Dr. Brenda Mercer, University of Sussex). 
To further phenotypically analyse unSUMOylatable mutants, sla1 base strains 
(sla1::ura4) were created using the recombinase-mediated cassette exchange (RMCE) 
system for non-essential genes (Watson et al., 2008) since Sla1 is a non-essential gene 
(Van Horn et al., 1997). Using another RMCE system, the wild-type and three mutated 
pAW8-sla1 plasmids were then transformed into the sla1::ura4 base strain to achieve the 
sla1-wt strain, two strains containing a single lysine mutated to arginine (sla1-K106R and 
sla1-K263R) and one containing a double mutation (sla1-RR).  
 
69 
All unSUMOylatable sla1 mutants were used for phenotypic analysis and compared 
to wild type strains and sla1-deleted strains (Figure 3.4). The sla1 mutants did not have 
any affect to cell growth in YE (enriched) medium at 30°C. This is consistent with the 
fact that Sla1 is a non-essential gene (Van Horn et al., 1997).  
In response to other conditions (Figure 3.4), all sla1 mutants had also no effect on 
cell growth in the enriched medium, except the kan-replacement sla1-deleted strains both 
h- and h+ mating type (sla1::kan, h- and h+). For example, the sla1::kan strains with h- 
mating type (sla1::kan, h-) is sensitive for growth on YE medium at 37°C and on minimum 
medium, but the sla1::kan h+ strains is not. Both sla1::kan strains are defective in response 
to rapamycin and/or NH4Cl, while others, in particular the sla1Δ strains containing ura4 
and NAT cassette sequences, are not. This suggests that gene cassettes may affect the 
phenotype of sla1Δ cells, but the mating type does not. The reason for this is not known, 
but similar discrepancies have been observed by other members of the GDSC with other 
genes. To conclude, investigating the role of SUMOylation of Sla1 was not possible using 
these mutant strains.   
Next for the analysis of the SUMOylation of other proteins, the role of 
SUMOylation of eIFs has not been well studied even though a number of eIFs have been 
identified in proteomic screens as being SUMO targets (Table 1.5). Here, possible 
SUMOylation of two of the S. pombe eIFs that co-purified with TAP-Ulp2 were studied 
(Table 1.4), specifically, eIF4G and eIF3h. Both proteins are known to be present in high 
molecular weight complexes: eIF4G is part of the eIF4F complex and eIF3h is part of 
the eIF3 complex (Jackson et al., 2010). It is here demonstrated that S. pombe eIF4G, but 
not eIF3h, is SUMOylated in vivo (Figure 3.5). This result is supported by recent studies 
where human eIF4G has been identified in proteomic screens as being SUMOylated 
(Matafora et al., 2009; Bruderer et al., 2011), while to date eIF3h has not been identified 
in these studies. 
There were two obstacles that prevented further investigation of the role of 
SUMOylation of S. pombe eIF4G via the identification of the SUMOylation sites of the 
S. pombe eIF4G using an in vitro SUMOylation assay .The first difficulty occurred at the 
step of cloning the full length S. pombe eIF4G cDNA. This would be needed for in vitro 
SUMOylation assays in order to identify SUMOylated lysine residues using mass 
spectrometry. It has been previously shown that plasmids containing sequences encoding 
the N-terminal region of S. pombe eIF4G are unable to be tolerated in E. coli 
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(Hashemzadeh‐Bonehi et al., 2003). The reason for this is unknown, but is possibly due 
to the presence of a highly repeated sequence within the eIF4G coding sequence. 
Another factor was this highly repeated sequence in S. pombe eIF4G (but which is not 
found in the S. cerevisiae or human proteins). In the S. pombe protein, the highly repeated 
sequence contains 16 repeats of a perfect SUMOylation site consensus motif (AKRE), 
which would be likely to make it difficult to identify the SUMOylation sites, even if the 
full length eIF4G was able to be expressed in E. coli. Because of this, subsequent 
experiments were extended to human eIF4G in order to investigate the role of 
SUMOylation of this translation factors (Chapter 5). 
Here, SUMOylation of S. pombe eIF4G was analysed in response to osmotic stress 
(1M KCl) that induces stress granules in S. pombe. The result (Figure 3.6) indicated that 
the level of SUMOylated eIF4G was increased after treatment with osmotic stress 
conditions compared to the levels in untreated cells or cycloheximide (Chx)-treated cells. 
The role of this modification is not known. However, there are two possibilities. The 
first, is that SUMOylation may be targeting eIF4G for degradation, possibly via the action 
of a SUMO-targeted ubiquitin ligase (STUbL). The second possibility is that 
SUMOylation may be targeting eIF4G to stress granules or P-bodies. Further studies 
conducted (Figure 3.7) here indicated that the eIF4G and Ulp2-containing complexes are 
unlikely to be polysomes. This would be consistent with SUMOylation targeting eIF4G 
to stress granules or P-bodies.  
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Chapter 4  
Characterization of SUMOylation in Human Cell Lines 
4.1 Introduction 
 In vivo studies indicated that S. pombe eIF4G is SUMOylated (Chapter 3). However, 
since it was not possible to clone full length S. pombe eIF4G which is needed for in vitro 
SUMOylation assays to identify modified sites, or for introduction of mutant alleles into 
the genome, attention was directed at mammalian translation initiation factors. Before 
analysis of these factors was analysed, the behaviour of a number of mammalian cell lines 
was analysed. Specifically, protein synthesis and SUMOylation were compared in a range 
of cell lines under different stress conditions, in order to determine whether there are any 
differences in different cell lines.  
The cell lines chosen were HeLa, PC3, MRC5, MCF7 and MDA-MB231 cells. 
MRC5 cells are normal fibroblast cells, being used to represent the normal behaviour of 
human cells. HeLa, PC3, MCF7 and MDA-MB231 cells were chosen as they are cancer 
cell lines three of which are believed to have altered SUMOylation levels. HeLa cells are 
one of most common cell lines used for studying the role of SUMOylation in many 
aspects in vivo e.g Hattersley et al. (2011), Geoffroy et al. (2010), Agbor et al. (2011). PC3 
cells are one of a number of human prostate cancer cell lines. Studies have demonstrated 
that, in prostate cancer cells, SENP1 a SUMO-specific protease is overexpressed, 
compared to normal prostate cells (Cheng et al., 2006b). In addition, recent studies have 
shown that the over-expression of Ubc9, a SUMO-conjugating enzyme, promotes 
tumour growth using MCF7 cells (Mo and Moschos, 2005; Mo et al., 2005), and that this 
also enhances tumour invasion and metastasis using MDA-MB231 cells (Zhu et al., 2010). 
These cells were therefore chosen in order to determine whether there are any alterations 
in SUMOylation levels or localisation in response to stresses. 
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4.2 Ionising radiation does not affect the alteration of global protein 
synthesis levels 
As ionising radiation has been demonstrated to regulate protein synthesis (Lu et al., 
2006; Braunstein et al., 2009). Global levels of protein synthesis were first compared in 
the different cell lines in response to ionising radiation (IR). Each cell line was grown to 
60–80% confluence, and then treated with 3 Gy IR. Subsequently, untreated and IR-
treated cells were incubated with 35S-methionine in order to label newly synthesized 
protein and then allowed to recover for 60 and 120 minutes at 37°C (as previously 
described in section 2.5.20). Untreated and non-labelled cells were used as a baseline. 
Protein synthesis rate was shown as percentage of the rate of the untreated control at 60 
minutes. It was calculated using values in cpm/μg protein of each sample, minus the 
baseline value of untreated non-labelled samples. This becomes the adjusted value. Each 
of them was then divided by the adjusted value of the untreated labelled control at 60 
minutes, then multiplied by 100. Figure 4.1 shows that, in untreated cells, protein 
synthesis approximately doubles after 120 minutes, compared to levels at 60 minutes for 
most cell types. Additionally exposure to IR has little effect on protein synthesis, except 
for MCF7 cells where the level is reduced, compare to that in untreated cells.  
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Figure 4.1 Protein synthesis assay using 35S-methionine labelling. Different cell 
lines were treated and untreated with 3 Gy IR, and then allowed to reincubate for 60 and 
120 minutes. A) Hela cells B) PC3 cells C) MRC5 cells D) MCF7 cells and E) MDA-
MB231 cells. Protein synthesis rate was shown as percentage, compared to the protein 
synthesis rate of the untreated control at 60 minutes after IR treatment. It was calculated 
using values in cpm/μg protein of each sample, minus with the base line value of 
untreated non-labelled samples. Each adjusted value was then divided by the adjusted 
value of untreated-labelled cells after treatment 60 minutes, then multiplied by 100. The 
error bars are of two standard deviations.  
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4.3 Expression levels of SUMO1 and SUMO2/3 in different cell lines 
under stress conditions  
Having analysed levels of protein synthesis in the different cell lines SUMOylation 
levels were then analysed in these cells. Specifically, levels of SUMO1 and SUMO2/3 
conjugation were analysed in order to determine whether there were any differences in 
the cell lines under different stress conditions, namely sodium arsenite (AR) and ionising 
radiation (IR). Cells were grown to 60–80% confluence, and then treated and untreated 
with either 1 mM sodium arsenite or 3 Gy IR, followed by a reincubation for 30 minutes 
(as previously described in 2.4.6 and 2.4.7). Whole cell extracts from each cell line, treated 
and untreated with the different stresses, were analysed on 10% acrylamide gels, followed 
by western blotting with anti-SUMO1, anti-SUMO2/3 and anti-tubulin antibodies. 
Figure 4.2 panel A, indicates that using tubulin levels as controls, the levels of SUMO1 
conjugates in MDA-MB231 are higher than in the other three cell lines. In HeLa cells 
and MRC5 cells, the levels of SUMO1 conjugates are slightly decreased in response to 
IR. AR and IR do not appear to alter the levels in MCF7 cells. Figure 4.2 panel B, 
indicates a difference between the cell types: specifically SUMO2/3 conjugates are 
distinctly different in MDA-MB231 compared to the other cell lines. In particular, low 
molecular weight SUMO2/3 species are present in high levels in MDA-MB231 cells. In 
MRC5 and MCF7 cells the pattern of SUMO2/3 conjugates is similar in untreated and 
IR-treated cells. In MDA-MB231 cells, the patterns of SUMO2/3 conjugates are also 
similar in untreated and IR-treated cells although the levels of high molecular weight 
species increase in response to IR. In response to AR, the pattern of SUMO2/3 
conjugates is somewhat altered in all three cell lines; it is decreased in MCF7 and MDA-
MB231 cells, but increased in MRC5 cells. In contrast, in HeLa cells, SUMO/3 
conjugates are decreased in response to IR. These results indicate that different stress 
conditions affect the levels of SUMOylation, particularly by SUMO2/3, in a range of 
human cell lines.  
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Figure 4.2 Western analysis of whole cell extracts from different human cell 
lines. Different cell lines were treated and untreated (UT) with either 1 mM sodium 
arsenite (AR) or 3 Gy ionising radiation (IR). Samples were analysed onto 10% SDS 
PAGE for western blotting with anti-SUMO1, anti-SUMO2/3 and anti-β-tubulin 
antibodies. 
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4.4 Localisation of SUMO1 in different cell lines after different ranges of 
treatments 
Having analysed SUMO-conjugates, it was next of interest to analyse the 
localisation of SUMO in cells. HeLa, PC3, MRC5, MCF7 and MDA-MB231 cells grown 
to 60–80% confluence were treated with and without either 1 mM sodium arsenite (AR) 
or 3 Gy ionising radiation (IR). Cells were reincubated at 37°C for 30 minutes. For 
microscopic analysis, untreated (UT) and treated cells (AR and IR) cells were incubated 
with mouse anti-SUMO1 antibody, followed by FITC anti-mouse IgG as described in 
section 2.4.8.  
4.4.1 SUMO1 localisation in different cell lines (untreated condition) 
Figure 4.3 shows that, in all untreated cell lines, SUMO1 (green) is present both in 
the nucleus and the cytoplasm, but is mainly present in the nucleus. HeLa, PC3, MRC5, 
MCF7 and MDA-MB231 cells showed very similar patterns of localisation. However it 
is interesting that in MCF7 some of the SUMO1 localises at the nuclear periphery. 
4.4.2 SUMO1 localisation in different cell lines in response to sodium 
arsenite (AR) 
To study the localisation of SUMO1 in response to AR, all cell lines—HeLa, PC3, 
MRC5, MCF7 and MDA-MB231 cells—were incubated with 1 mM sodium arsenite for 
30 minutes (AR) before being stained with antibodies. Microscopic analysis (Figure 4.4) 
shows that SUMO1 (green) is still present in both the nucleus and the cytoplasm. 
However, in arsenite-treated cells, the intensity of SUMO1 staining in the nucleus is 
increased, compared to that in untreated cells. In addition, some of the SUMO1 formed 
foci in the nucleus of HeLa, PC3, MRC5 and MDA-MB231 cells. In PC3, MCF7 and 
MDA-MD231 cells, the SUMO1 foci localise at the periphery of the nucleus. It is 
possible that SUMO1 forms foci in the endoplasmic reticulum (ER) after AR treatment. 
4.4.3 SUMO1 localisation in different cell lines in response to ionising 
radiation (IR) 
HeLa, PC3, MRC5, MCF7 and MDA-MB231 cells were treated with 3 Gy IR and 
then allowed to recover in an incubator for 30 minutes. Figure 4.5 shows that SUMO1 
(green) is mainly present in the nucleus after IR treatment although there is a small 
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amount in the cytoplasm. All of the cell lines formed a number of SUMO1 foci in 
response to IR. These foci were more intense than those in the untreated and arsenite-
treated cells. Unlike AR-treated cells, SUMO1 was not found to localise at the nuclear 
periphery in PC3, MCF7 and MDA-MB231 cells. 
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Figure 4.3 Immunofluorescence of SUMO1 localisation from untreated cells.  
HeLa, PC3, MRC5, MCF7 and MDA-MB231 cells were determined the SUMO1 
localisation without any treatment (UT). 
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Figure 4.4 Immunofluorescence of SUMO1 localisation from AR-treated cells. 
The localisation of SUMO1 from HeLa, PC3, MRC5, MCF7 and MDA-MB231 cells, 
treated with 1 mM sodium arsenite for 30 minutes, was analysed. 
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Figure 4.5 Immunofluorescence of SUMO1 localisation from IR-treated cells. 
The localisation of SUMO1 was analysed from HeLa, PC3, MRC5, MCF7 and MDA-
MB231 cells, treated with 3 Gy ionising radiation.  
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4.5 Discussion 
The aim of this chapter was to analyse protein synthesis, levels of SUMOylation 
and SUMO localisation in a range of cell lines in response to stresses prior to further 
studies. Ionising radiation (IR) and sodium arsenite (AR) were chosen as stresses. IR has 
been demonstrated to regulate protein synthesis (Lu et al., 2006; Braunstein et al., 2009). 
Studies have demonstrated that protein synthesis is induced via the ATM and ERK 
pathway in IR-treated cells (Braunstein et al., 2009). Sodium arsenite inhibits protein 
synthesis (Harding et al., 2000; Souquere et al., 2009). It results in the formation of stress 
granules which are sites where mRNA is stored before being used for reinitiation of 
protein synthesis or being degraded (Anderson and Kedersha, 2006).  
Global levels of protein synthesis were primarily analysed in the different cell lines 
in response to ionising radiation (IR) using protein labelling assay. In all untreated cell 
types at 2 hours, the levels of protein synthesis approximately doubled after 2 hours 
relative to the levels at 1 hour. In most cell types, treatment with IR did not alter the 
levels of overall protein synthesis, i.e. levels again approximately doubles. Exceptionally, 
in IR-treated MCF7 cells reincubated for 2 hours, the rate of protein synthesis is lower 
than the control untreated MCF7 cells. This is consistent with some studies that have 
shown that translational arrest can occur in cells treated with IR. For example, it has been 
shown that IR induces the inhibition of the eIF4E/eIF4G interaction, affecting the cap-
dependent translation pathway (Kumar et al., 2000; Paglin et al., 2005) or IR leads to 
reduced levels of eIF4G (Paglin et al., 2005). To conclude, although no gross changes in 
the levels of protein synthesis after IR treatment, there may be changes in the translation 
of specific mRNAs that are undetectable in this assay. 
SUMOylation levels in a range of human cell lines under different stress conditions 
were next analysed. In the different cell lines, there are small changes in the modification 
levels by SUMO1 and SUMO2 in response to AR and IR. In particular, in HeLa cells, 
the levels of SUMO1 and SUMO2/3 conjugates were decreased in response to IR. In 
MRC5 cells, there was a small decrease of SUMO1 conjugates in response to IR, but an 
increase of SUMO2/3 conjugates in response to arsenite. In contrast, in MCF7 and 
MDA-MB 231 cells, arsenite decreased the levels of SUMO2/3 conjugates while IR 
increased the levels of SUMO2/3 conjugates in MDA-MB231 cells. These results suggest 
that both AR and IR affect the levels of SUMOylation in a range of human cell lines.  
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The SUMO1 localisation was lastly investigated, in order to identify any differences 
in the cell lines following exposure to AR and IR. In all cell lines, untreated and treated 
with either AR or IR, SUMO1 mainly localises in the nucleus but it is also found in the 
cytoplasm. Without any treatment, HeLa, PC3, MRC5, MCF7 and MDA-MB231 cells 
have quite similar patterns of SUMO1 localisation, except MCF7 where SUMO1 
sometimes localises at the nuclear periphery. In most AR-treated cells, except MCF7, 
SUMO1 is predominantly in the nucleus where it is found to form foci. In addition, in 
PC3, MCF7 and MDA-MD231 cells, SUMO1 foci are present at the periphery of the 
nucleus, suggesting that SUMO1 may form foci in the endoplasmic reticulum (ER) after 
AR treatment. There are a number of SUMO1 foci formed in the nucleus of cells exposed 
to IR which is more than in cells exposed to AR. This is consistent with the modification 
of PML by SUMO1 which forms foci (PML bodies) in the nucleus after cells are treated 
with arsenite (Müller et al., 1998; Geoffroy et al., 2010). This is known to result in an 
increase in the colocalisation of PML with a number of proteins in the PML nuclear 
bodies at the sites of DNA damage after IR e.g. TopBP1 (Xu et al., 2003), SUMO1 
(Dellaire and Bazett-Jones, 2004). A similar analysis of SUMO2/3 localisation was not 
undertaken at this time because our anti-SUMO2/3 antibodies cross reacted with other 
epitope(s) in the cells, thus confusing the images.  
In conclusion, the levels of global protein synthesis are not grossly altered in a 
number of human cell lines after exposure to IR, apart from MCF7 cells where a small 
decrease in the rate of global protein synthesis was observed. SUMOylation levels were 
shown to vary, depending on the cell type and treatment. For the SUMO1 localisation, 
SUMO1 mainly localises in the nucleus, and can be found in foci when cells were treated 
with AR or IR.  
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Chapter 5  
Analysis of SUMOylation of Human eIF4G  
5.1 Introduction 
Although it was possible to demonstrate that S. pombe eIF4G is SUMOylated. 
There are a number of factors, described in Chapter 3, that make the identification the 
SUMOylation sites of the S. pombe eIF4G difficult. Briefly, one was the inability to 
express the full length S. pombe eIF4G in E. coli, and another was the presence of a highly 
repeated sequence in the S. pombe protein. Attention was therefore redirected to the 
analysis of the SUMOylation of mammalian initiation factors, in particular human eIF4G 
and eIF4A. 
This chapter focuses on the investigation of SUMOylation of human eIF4G, which 
is one of the proteins identified in proteomic screens as being a SUMOylated target 
(Table 1.5). To confirm that human eIF4G is SUMOylated, two approaches were taken, 
the first was to determine whether eIF4G is SUMOylated in vitro, which would allow 
identification of SUMOylation sites by mass spectrometry, and the second was to 
determine whether it is also SUMOylated in vivo.  
5.2 Expression and purification of SUMO components for the in vitro 
SUMOylation assay  
In vitro SUMO modification assays of protein targets have been developed as an 
effective tool for the analysis of SUMOylation and identification of SUMOylation sites 
(Johnson and Blobel, 1997; Desterro et al., 1998; Okuma et al., 1999; Ho et al., 2001). In 
order to undertake the in vitro assay it was first necessary to purify the components of the 
SUMOylation machinery. The recombinant SUMO components expressed and purified 
in this study were the heterodimeric SUMO-activating E1 enzyme (6xHis-Rad31 and 
GST-Fub2), the SUMO conjugating E2 enzyme (GST-Hus5), the SUMO E3 ligase 
(6xHis-Pli1) and SUMO (6xHis-SUMO-Tr-GG). 
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5.2.1 Isolation of SUMO activating enzyme E1 (SAE; Rad31 and Fub2) 
co-expressed in E. coli system 
The S. pombe SUMO-activating E1 enzyme (SAE) is a heterodimeric protein which 
consists of Rad31 (6xHis-tagged) and Fub2 (GST-tagged). To obtain the complex form 
of the E1 enzyme, pET28a containing Rad31 and pGEX containing Fub2 were co-
transformed and proteins were expressed and purified from a one litre of BL21 (DE3) 
E. coli culture. The heterodimeric enzyme was isolated in a one-step purification using 
Ni2+ agarose beads (see section2.5.13). 300 µl of elution buffer was used to elute the 
recombinant SAE from the agarose beads. The protein concentrations of the 1st–5th 
elution (E1–E5) fractions were measured using a Bradford assay. The protein 
concentrations of the E1–E5 fraction were 1.5, 1.5, 0.1, 0.0 and 0.0 mg/ml, respectively. 
To check the purity of the complex, 10 µl of each fraction was loaded onto a 12.5% 
acrylamide gel. The result in Figure 5.1 indicates the fractions E1, E2 and E3 have a good 
yield of the SAE complex with the recombinant proteins His-Rad31 and GST-Fub2, 
represented by approximately 96 kDa and 36 kDa bands, respectively. To store the 
sample for further use, 30 µl of 100% glycerol was added into the fractions E1–E3. The 
samples were then aliquoted and kept at –80°C. 
5.2.2 Expression and purification of the SUMO conjugating enzyme E2 
(Hus5)  
The SUMO conjugating enzyme E2 (GST-tagged Hus5) was expressed and 
purified from a one litre culture. GST-tagged Hus5 was expressed from the pGEX 
plasmid. The GST fusion protein was purified as previously described (see section 
2.5.14). 300 µl of each fraction were collected during elution. The protein concentrations 
of the fractions E1–E5 were 0.8, 1.8, 0.1, 0.05 and 0.0 mg/ml, respectively using 
Bradford assay. To check the purity and size of GST-tagged Hus5, 10 µl of each fraction 
was loaded onto a 12.5% acrylamide gel. It can be seen in Figure 5.2 that the 44 kDa 
recombinant Hus5 was purified with good purity in fractions E1, E2 and E3. These 
samples were mixed with 30 µl of 100% glycerol. The samples were then aliquoted and 
frozen at –80°C. 
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5.2.3 Expression and purification of the SUMO ligase E3 (6xHis-tagged 
Pli1) 
6xHis-tagged Pli1 was expressed from the pET15b plasmid in a one litre culture 
and then isolated by Ni2+ purification as previously described (see section 2.5.13). 300 µl 
of each elution fraction were collected and the protein concentration was determined 
using a Bradford assay. The purification of the recombinant Pli1 was attempted several 
times but due to the instability of the protein it was difficult to get a high yield with good 
purity (data not shown). Thus the SUMO ligase E3 protein (His-Pli1) used here was a 
kind gift from Dr. Brenda Mercer (University of Sussex).   
 
  
Figure 5.1 Coomassie blue staining for the purification of SAE E1 complex. 
10 µl of each elution fraction was loaded onto a 12.5% acrylamide gel (L = lysate, P = 
cell pellet, FT = the first flow through, E1-E5 = the elution factions 1st–5th). From one 
litre of culture, the protein concentrations of the E1–E5 fractions were purified at 1.5, 
1.5, 0.1, 0.0 and 0.0 mg/ml, respectively. The higher band (~96 kDa) represents GST-
tagged Fub2 of which the molecular weight of Fub2 and GST are 70.6 and ~26 kDa, 
respectively. The lower band (~36 kDa) represents His-tagged Rad31 of which the size 
of Rad31 is 34.7 kDa. 
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Figure 5.2 Coomassie blue staining for GST-tagged Hus5 purified. To observe 
purity and size of the protein purified, 10 µl of each elution fraction (300 µl in total 
volume) was loaded onto a 12.5% acrylamide gel. (L= lysate, FT= the first flow through, 
E1-E5= the eluted faction 1st–5th). The protein concentrations of the E1–E5 fractions 
were 0.8, 2.0, 0.1, 0.05 and 0.0 mg/ml, respectively. The ~44 kDa band represents Hus5 
(17.9 kDa) tagged with GST (~26 kDa).  
5.2.4 Expression and purification of SUMO-Tr-GG  
As one of the aims of using the SUMOylation assay was to identify SUMOylation 
sites, it was necessary to use a modified form of SUMO. Mass spectrometry is an 
important tool for the identification of the specific molecular mass of peptides 
representing as mass-to-charge ratio (m/z). It can be used to detect sites of post-
translational modification. Most proteases recognize a particular amino acid when 
cleaving polypeptide chains. For example, trypsin (commonly used in this study) mainly 
cleaves C-terminal to lysine (K) and arginine (R), except when either is followed by 
proline (P). When protein targets modified by S. pombe wild type SUMO are digested by 
trypsin, the large mass peptide (IRPDQTPAELDMEDGDQIEAVLEQLGG) will 
remain covalently attached to the lysine of the target’s peptide. This may be difficult to 
detect by mass spectrometry as it is quite large already and will be increased in size by 
addition of target sequences. SUMO-Tr-GG is a truncated form of SUMO with a 
diglycine motif (SUMO-GG) at the C-terminal region and a trypsin cleavage site adjacent 
to the motif. If protein targets modified by SUMO-Tr-GG version are digested by 
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trypsin, a smaller mass diglycine (GG) motif instead remains covalently attached to the 
lysine of target’s peptides. This improves the detection by mass spectrometry facilitating 
identification of lysine residues modified by SUMO.  
The SUMO-GG sequence (encoding the mature form of SUMO) in pET15b was 
mutated at amino acid position 109 from leucine (L) to arginine (R), creating SUMO-GG 
L109R or SUMO-Tr-GG, which is a SUMO-GG form with a trypsin cleavage site 
adjacent to the diglycine motif (gift from Dr. Lauren Small, University of Sussex). The 
sequence alignment between SUMO and SUMO-Tr-GG is shown in Figure 5.3.  
SUMO-Tr-GG tagged with 6xHis epitope was expressed in a one litre culture of 
BL21 E. coli. Ni2+-purification was carried out as previously described (see section 2.5.13). 
300 µl of each elution fraction was collected. The protein concentration of 1st–5th elution 
(E1–E5) fraction measured using a Bradford assay were 3.5, 8.0, 2.9, 0.1 and 0.0 mg/ml, 
respectively. To check the purity of the protein, 10 µl of each fraction was loaded onto 
the 12.5% acrylamide gel. The gel was stained with Coomassie blue, shown in Figure 5.4. 
The result shows that the purification of His-SUMO-Tr-GG was good with good yields. 
Samples were preserved in glycerol (10%). Aliquots were frozen at –80°C. 
 
 
Figure 5.3 The alignment between the sequences of S. pombe wild type SUMO 
and SUMO-Tr-GG (SUMO-GG L109R).The blue triangles show the position of 
trypsin cleavage sites where the larger sequences (IRPDQTPAELDMEDGDQIEAVL
EQLGG) of SUMO WT and the smaller diglycine sequences (GG) of SUMO-Tr-GG 
remain covalently attached to the modified lysines of target peptides after digestion of 
the protein targets by trypsin.    
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Figure 5.4 Coomassie blue staining indicating purification of His-tagged 
SUMO-Tr-GG purified. A 12.5% gel was stained with Coomassie bule (L= lysate, FT= 
the first flow through, E1–E5= the elution 1st–5th). The protein concentrations of E1–
E5 fractions were 3.5, 8.0, 2.9, 0.1 and 0.0 mg/ml, respectively.  
5.2.5 Evaluation of the enzymatic activity of all recombinant SUMO 
components in in vitro SUMOylation assay 
To evaluate the enzymatic activity of the SUMOylation components, all purified 
proteins were analysed for ability to form SUMO chains using the conditions described 
Ho et al. (2001). The reaction was incubated at 30°C for 2 hours. Previously prepared 
SUMOylation components (from Dr. Brenda Mercer and Dr. Lauren Small, University 
of Sussex) were used as a set of positive (lane 1–4 in Figure 5.5) and negative controls 
(lane 5). It can be seen that the previously prepared SUMOylation components in lanes 
3 and 4 (containing twice as much SAE E1 as used in lanes 1 and 2) are capable of SUMO 
chain formation as evidenced by the high molecular weight species. The reactions in lanes 
6–11 used the SUMOylation components purified from this study (except Pli1, made by 
Dr. Brenda Mercer).  
The 1st elution of SAE (lane 6 and 7) and the 2nd SAE faction (lane 8 and 9) show 
results similar to those observed with the positive control in lanes 3 and 4. This shows 
that both elutions of SAE enzyme have a good ability to form SUMO chains in an in vitro 
SUMOylation assay. In contrast, the third elution fraction (lane 10 and 11) has very little 
activity, with little SUMO chain formation, being similar to the negative control in lane 
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5 which is in the absence of SAE. This suggests that the first and second elution fractions 
of SAE have good enzymatic activity with or without Pli1.  
The function of the other components (Hus5 and SUMO) was also assayed for 
ability to form SUMO chains (data not shown). Both proteins were shown to be 
functional. 
 
 
Figure 5.5 Assaying the activity of the purified SUMOylation components. 
Western blotting of in vitro SUMOylation assay with anti-SUMO antisera. Lanes 1–5 are 
the previously purified components made by Dr. Mercer and Dr. Small (Sussex), while 
lanes 6–11 are the proteins purified in this study.  
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Table 5.1 The amount of SUMOylation components used in this study 
compared to those used in the study of Ho et al (2001). 
Component Amount used  
by Ho et al (2001) 
Amount used  
in the current study 
SAE (E1) 0.5 μg Elution 1 and 2: 0.6 μg  
Elution 3: 0.4 
Hus5 (E2) 3.0 μg Elution 1 and 2: 3.0 μg 
Pli1 (E3) NA (optional) Dr. Mercer: 1 μg 
SUMO-GG 10.0 μg - 
SUMO-Tr-GG - Elution 1–3: 8.0 μg 
5.3 Human eIF4G expressed in Sf9 insect cells is SUMOylated in vitro  
5.3.1 Expression and purification of His-Flag tagged human full length 
eIF4G performed in Sf9 insect cells 
Sf9 insect cells were infected with Baculovirus encoding human 6xHis-3xFLAG 
tagged eIF4G1 (the recombinant Baculovirus was provided by Prof. Simon Morley, 
Sussex). After His-Flag tagged eIF4G was expressed in Sf9 insect cells in a 400 ml 
suspension culture grown for 72 hours, cells were harvested for the isolation of the 
recombinant protein using Ni2+ agarose beads under native conditions as previously 
described in the section 2.5.16. In the elution step, 500 µl of each elution fraction was 
collected. Bradford assay was used to measure the protein concentration of each fraction 
(E1–E5) which was at 3.30, 1.66, 0.31, 0.03, 0.00 mg/ml, respectively. To check the purity 
of the recombinant protein, 10 µl of lysate (L), flow through (FT), each elution (E1–E5) 
and beads were loaded onto two 10% acrylamide gels, of which the first was stained with 
Coomassie blue and the second was for western blotting. Figure 5.6 demonstrates that 
the recombinant eIF4G was expressed and purified with high yield in the elution 
fractions E1–E3. The presence of lower molecular weight species is likely due to 
proteolysis of eIF4G.  
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5.3.2 Human eIF4G expressed in Sf9 insect cells is SUMOylated in the 
presence of Pli1 in vitro 
 Purified human eIF4G was next assayed for ability to be SUMOylated in vitro. 6.6 
or 13.2 µg of protein purified (from elution 1 = E1 and elution 2 = E2) was incubated 
with SUMOylation components as shown in Table 5.1. Products were analysed by SDS 
PAGE, followed by staining with Coomassie blue and western blotting with anti-eIF4G 
and anti-SUMO antisera (Figure 5.7). Coomassie blue staining and western blotting with 
anti-eIF4G antisera indicate that, in comparison to purified eIF4G (Figure 5.6), there has 
been degradation of the eIF4G protein. Nevertheless, Coomassie blue staining indicates 
high molecular weight species in lanes 6–8, where are not present in the negative control 
lanes 2–3. Western blotting with anti-eIF4G also indicates high molecular weight species 
in lanes 6, 7 and 9. Western blotting with anti-SUMO antisera also indicates high 
molecular weight SUMO-containing species, which are more abundant in the presence 
of Pli1 (lane 7 and 9) than in the absence of Pli1 (lane 6 and 8). These results suggest that 
human eIF4G is SUMOylated in vitro. 
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Figure 5.6 Human eIF4G purification using Ni2+ agarose beads.  Human eIF4G 
tagged with FLAG and 6xHis epitopes at the N terminus was produced in Sf9 insect cells 
using the Baculovirus expression system. The protein concentrations of each fraction 
(E1–E5) were 3.30, 1.66, 0.31, 0.03, 0.00 mg/ml, respectively. 10 µl of each sample 
(L=lysate, FT=flow through, E1–E5= the 1st–5th elution fractions and B=beads) was 
loaded onto a 10% acrylamide gel stained with Coomassie blue (upper part) while another 
10 µl of each sample was loaded onto a gel for western blotting against rabbit anti-eIF4G 
antisera (lower part).  
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Figure 5.7 In vitro SUMOylation of human eIF4G. Full-length human eIF4G 
produced in Sf9 insect cells was used an in vitro SUMOylation assay. 6.6 µg of eIF4G 
fraction 1 (E1) was added in lanes 4–5 and 13.2 µg in lanes 6–7 while 9.9 µg of fraction 
2 (E2) was loaded in lanes 8–9. Other components were used in the same concentration 
as shown in table 5.1. This figure shows staining with Coomassie blue, western blotting 
(WB) with rabbit anti-eIF4G and anti-SUMO antisera.  
5.3.3 Mass spectrometry was unable to identify the SUMOylation sites 
of full length human eIF4G expressed in the insect cells 
Mass spectrometry was undertaken in order to identify which lysine residues are 
used for SUMOylation. Protein species (over 175 kDa) were excised from lanes 6–9 
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(from the Coomassie blue-stained gel in Figure 5.7). Proteins contained in the gel pieces 
were digested with trypsin as described in section 2.5.11. However, using full length 
eIF4G expressed in Sf9 insect cells as a protein target, it was not possible to identify the 
modified lysine(s) with high confidence by mass spectrometry. This may be due to the 
large size of full length eIF4G or because SUMOylation levels were low, making the 
amount of modified peptides insufficient for detection by mass spectrometry. It could 
also be due to the fact that the SUMOylated lysine residues are present on a very large 
tryptic peptide that cannot be detected by mass spectrometry. 
5.4 Human eIF4G expressed in E. coli is SUMOylated in vitro 
5.4.1 Expression and purification of human eIF4G in E. coli system 
To further investigate the SUMOylation in vitro of eIF4G, eIF4G was expressed in 
three truncated forms, an N-terminal fragment from 1 to 532 (N-FAG), a middle 
fragment from 533 to 1176 (M-FAG) and a C-terminal fragment from 1177 to 1600 (C-
FAG). These three fragments of eIF4G relate to the caspase-3-mediated cleavage 
fragments produced during apoptosis (Figure 1.3), called as the apoptotic cleavage 
fragments of eIF4G (FAG). The map of each fragment is shown in Figure 5.8. The ORF 
of each fragment was sub-cloned in pET28b (Prof Simon Morley, Sussex). Thus, these 
proteins could be expressed as N-terminally His-tagged fusion proteins.  
BL21 (DE3) E. coli cells were transformed with pET28b containing ORF encoding 
human 6xHis-tagged N-FAG, M-FAG and C-FAG eIF4G. His-tagged fusion proteins 
(from a one litre culture) were expressed as previously described (see section 2.5.12), and 
cells were harvested for isolation of His-tagged recombinant proteins using Ni2+ agarose 
beads (described in 2.5.13). The concentration of each elution was analysed using a 
Bradford assay. To check the purity of recombinant protein, 10 µl of lysate (L), flow 
through (FT) and each elution (E1–E5) were loaded on a 10% acrylamide gel for 
Coomassie blue staining. Figure 5.9 shows a good yield of C-FAG of eIF4G (purified by 
D. Gunton, final year project student, Sussex). Other purified fragments had a lower yield 
likely because they are present as insoluble protein or in inclusion bodies. However, there 
was enough of each fragment of eIF4G to use in in vitro SUMOylation assays.  
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5.4.2 In vitro SUMOylation analysis of C-FAG eIF4G produced in 
E. coli 
The three fragments of human eIF4G (N-, M- and C-FAG) expressed in E. coli 
were tested in the in vitro SUMOylation assay. 6xHis tagged C-FAG eIF4G contains an 
N-terminal His epitope and the C-terminal eIF4G region of 424 amino acids between 
1177 and 1600. The expected size is around 50 kDa. The amount of protein target was 
varied in the SUMOylation reaction in vitro. As shown in Figure 5.10, 4 µg of C-FAG 
faction 4 used in lane 1 (control lane), 15 µg from elution faction 3 (used in lanes 6, 7) 
and 10 µg from elution 4 (used in lane 8, 9) were added in the reaction according to 
amount shown in Table 5.1. The extra high molecular weight species in lanes 6–9 are 
between 58 kDa and 80 kDa. Theoretically, protein targets modified by a single SUMO 
normally are shifted by approximately 20 kDa. This result suggests that the C-terminal 
fragment of eIF4G (C-FAG) is SUMOylated in vitro. Using similar SUMOylation assays, 
N-FAG and M-FAG were not found to be SUMO modified (data not shown). The 
remainder of the section therefore focusses on the analysis of the SUMOylation sites in 
C-FAG.   
5.4.3 Mass spectrometry shows two lysines of eIF4G SUMOylated in C-
terminal region 
To identify the lysine residues modified by SUMO, the bands corresponding in size 
to those expected to be C-FAG modified by SUMO-Tr-GG, were excised from the gel 
and processed for analysis by mass spectrometry as previously described in section 2.5.11. 
The results of mass spectrometry confirmed that C-FAG is SUMOylated. Mass spectra 
identify with high confidence two lysines attached to diglycine (GG): these are K1386 
and K1588 (Figure 5.11 A and B). Interestingly, the former lysine is located in the eIF4A 
binding region while the latter lysine is in the Mnk binding region (figure 5.11 C). Figure 
5.12 indicates that it should be accessible for SUMOylation. 
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Figure 5.8 Fragments of human eIF4G expressed in E. coli are used for the in 
vitro SUMOylation assay. Schematic structures of eIF4G proteins showing the 
sequences used for expression in this study. This figure also indicates regions involved in 
the interaction with other proteins (PABP= polyA binding protein, 4E=eIF4E, 
4A=eIF4A, 3=eIF3 and Mnk=MAP kinase-interacting kinase 1).  
 
 
 
Figure 5.9 Coomassie blue staining of 12.5% acrylamide gels containing His-
tagged proteins purified. 10 µl each elution fraction of A) His-tagged N-FAG, B) His-
tagged M-FAG and C) His-tagged C-FAG was loaded onto the individual acrylamide gels 
to stain with Coomassie blue. (L= lysate, FT= the first flow through, E1-E5= the elution 
1st–5th). 
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Figure 5.10 The C-FAG of human eIF4G could be SUMOylated in vitro. The 
figures show the effect of adding SUMO components in each reaction and amount of C-
FAG. The expected size of C-FAG is around 50 kDa. The extra high molecular weight 
species in lane 6–9 being between the 58 kDa and 80 kDa, were excised to identify 
SUMOylation sites of C-FAG eIF4G by mass spectrometry.  
 
 
Figure 5.11 Mass spectrophotometry identified two SUMOylation sites on C-
FAG.  A. and B. Mass Spectra of eIF4G peptides modified by GG at K1386 and K1588, 
respectively and C. Schematic diagram of eIF4G indicating position of SUMOylated 
lysines. 
 
98 
 
Figure 5.12 Crystal structures of C-terminal portion of eIF4GI. This figure 
indicates amino acid residues between 1234 and 1572 (PDB ID 1UG3). Thus only K1386 
(green) modified by SUMO is shown in the C-terminal structure (blue) while K1588 is 
not shown in the structure (Bellsolell et al., 2006). Residues in magenta are eIF4A binding 
sites on eIF4GI which are next to Lysine 1386, suggesting that SUMOylation of eIF4G 
on K1386 may affect to the interaction of eIF4G and eIF4A.   
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5.5 SUMOylation of human eIF4G in vivo 
To determine whether human eIF4G is SUMOylated in vivo, two main approaches 
were taken. The first was affinity purification of His-tagged SUMO expressed in 
mammalian cell lines using Ni2+ agarose beads, and the second was alteration of eIF4G 
SUMOylation levels in response to stresses.  
5.5.1 Human eIF4G is SUMOylated in vivo confirmed by Ni2+ affinity 
purification  
HeLa cells that stably express 6xHis-tagged SUMO1 (S1) or 6xHis-tagged SUMO2 
(S2) (a kind gift from Prof Ron Hay, University of Dundee), were used in order to 
investigate SUMOylation of human eIF4G in vivo. Non-transfected HeLa cells (NT) were 
used as a negative control. Cell lysates were prepared under denaturing conditions to 
improve the yield of SUMOylated species as previously described in section 2.5.19. His-
tagged SUMO1 and SUMO2 were affinity purified from the cell extracts by Ni2+ agarose 
beads (Figure 5.13 Panels C and D). It has previously been demonstrated that eIF4E is 
modified by SUMO (Xu et al., 2010). Figure 5.13 (Panel B) shows that, under conditions 
used here, eIF4E is pulled down with both His-SUMO1 and His-SUMO2, confirming 
that eIF4E is SUMOylated. Figure 5.13 (Panel A) indicates that eIF4G is not recovered 
from extracts of cells that do not contain His-tagged SUMO (in PD, NT lane), but is 
isolated from extracts of cells containing His-SUMO1 (in PD, S1 lane) and to a lesser 
extent from cells expressing His-SUMO2 (in PD, S2 lane). This confirms that, like 
S. pombe eIF4G, human eIF4G is SUMOylated. 
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Figure 5.13 Western blotting of Ni2+ affinity purification of eIF4G and eIF4E. 
Whole cell extraction (WCE) and Ni2+ affinity purification (PD) form HeLa cells, non-
transfected (NT) or transfected of either His-tagged SUMO1 or SUMO2 were analysed 
on 7.5% PAGE. Blots were probed with anti-eIF4G (A), anti-SUMO1 (C) and anti-
SUMO2/3 (D) antibodies and blots from 12.5% PAGE was probed with anti-eIF4E 
antisera (B). The results indicate that eIF4G is modified by both SUMO1 and SUMO2. 
eIF4E was included as a positive control.  
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5.5.2 The levels of eIF4G modified by SUMO1 is altered in response to 
ionising radiation 
HeLa cells containing either His-SUMO1 or His-SUMO2 grown to 60–80% 
confluence in T175 flasks, were treated with or without either 1 mM sodium arsenite 
(AR) or 3 Gy ionising radiation (IR). His-tagged SUMO1 and SUMO2 were affinity 
purified from cells extracts using Ni2+ agarose beads under denaturing conditions as 
described in section 2.5.19, and compared to the negative control which was HeLa cells 
untreated (UT). Whole cell extracts (WCE) and affinity purify (PD) samples were loaded 
onto 7.5% acrylamide gels. Western blots were probed with anti-eIF4G antibody. Figure 
5.14 shows that eIF4G was recovered from cell extracts that contain His-tagged SUMO1 
(lanes 2–4) and to a lesser extent from extract containing His-tagged SUMO2 (lane 5–7). 
This confirms that eIF4G is modified by SUMO1 and possibly SUMO2. Interestingly, 
the levels of eIF4G modified by SUMO1 are deceased in response to ionising radiation. 
Figure 5.14 shows that there are degraded species of eIF4G which are also affinity 
purified with SUMO1 and SUMO2. These may be SUMOylated species of eIF4G. Thus 
it is possible that eIF4G (small molecular weight species) modified by SUMO2 are 
increased in response to arsenite. Nevertheless, the amount of eIF4G modified by 
SUMO2 is lower than that of eIF4G modified by SUMO1 which is consistent with Figure 
5.13.   
 
Figure 5.14 Analysis of SUMOylation of eIF4G in response to stresses. Whole 
cell extracts (WCE) and Ni2+ pulled-downs from wild type HeLa cells and HeLa cells 
stably transfected with His-tagged SUMO1 or SUMO2 were loaded onto 7.5% gels. 
Western blots were probed with anti-eIF4G antisera.  
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5.6 Immunofluorescence analysis of human eIF4G and SUMO1  
Because eIF4G is modified by SUMO1, it was of interest to determine whether 
eIF4G and SUMO1 colocalise. HeLa cells were therefore grown to 60–80% confluence 
on cover slides, and then left untreated or treated with either 1 mM sodium arsenite or 
3 Gy ionising radiation. For microscopy, untreated (UT) and treated cells (AR and IR) 
cells were incubated with two primary antibodies, namely mouse anti-eIF4G and rabbit 
anti-SUMO1. FITC anti-mouse IgG and Cy3 anti-rabbit IgG were used against the 
specific primary antibodies as described in section 2.4.8. eIF4E was used as a control.  
The immunofluorescence result (Figure 5.15) shows that eIF4G (green) is mainly 
present in the cytoplasm whereas SUMO1 (red) is mainly in the nucleus, although there 
is a small amount in the cytoplasm. In untreated cells there is a low level of colocalisation 
of eIF4G and SUMO1 in both the nucleus and the cytoplasm (Figure 5.16). Interestingly, 
in arsenite-treated cells most of the eIF4G is observed in stress granules in the cytoplasm. 
At many of the stress granules SUMO1 is found at the edges (Figure 5.17). In IR-treated 
cells, SUMO1 is mainly in foci in the nucleus. In these HeLa cells, there is low, but 
significant level of colocalisation of eIF4G with SUMO1 in the nucleus (Figure 5.18). 
Thus, colocalisation of eIF4G and SUMO1 is increased in cells exposed to both arsenite 
and ionising radiation.  
As it is known that eIF4E is SUMOylated (Xu et al., 2010), HeLa cells were analysed 
for the colocalisation of eIF4E and SUMO1 to see how this compared to the amount of 
colocalisation observed for eIF4G and SUMO1. Figure 5.19 shows that the result is 
similar to that of eIF4G. For example, in untreated cells there is a low level of 
colocalisation of eIF4E with SUMO1 in both the nucleus and the cytoplasm (Figure 
5.20). In arsenite-treated cells most of the eIF4E is observed in stress granules in the 
cytoplasm. At many of the stress granules SUMO1 is found at the edges (Figure 5.21). 
In IR-treated cells, SUMO1 forms more foci in the nucleus and some in the cytoplasm. 
In these cells eIF4E colocalises with SUMO1 in the nucleus (Figure 5.22). 
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Figure 5.15 Immunofluorescence indicating colocalisation of eIF4G and 
SUMO1. HeLa cells untreated (UT) and treated with 1 mM sodium arsenite (AR) or 3 
Gy gamma source (IR). Blue, green and red colours represent the DAPI-stained DNA, 
eIF4G and SUMO1, respectively. The bar scale is 10 µm. The white boxes are shown in 
the expanded versions as Figure 5.16–5.18.  
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Figure 5.16 Expanded version from Figure 5.15. Immunofluorescence of HeLa 
cells untreated (UT). Green and red colours represent eIF4G and SUMO1, 
respectively. The white arrows show sites of colocalisation of eIF4G and SUMO1. 
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Figure 5.17 Expanded version from Figure 5.15. Immunofluorescence of HeLa 
cells treated with 1 mM sodium arsenite (AR). Green and red colours represent 
eIF4G and SUMO1, respectively. The white arrows show sites of colocalisation of eIF4G 
and SUMO1. The small box shows the colocalisation of SUMO1 and eIF4G at the edges 
of stress granules, and this is shown by adjusting higher intensity of red and lower 
intensity of green for presenting the clearer versions of the figure only. 
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Figure 5.18 Expanded version from Figure 5.15. Immunofluorescence of HeLa 
cells treated with 3 Gy ionising radiation (IR). Green and red colours represent 
eIF4G and SUMO1, respectively. The white arrows show sites of colocalisation of eIF4G 
and SUMO1. 
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Figure 5.19 Immunofluorescence indicating colocalisation of eIF4E and 
SUMO1. HeLa cells untreated (UT) and treated with 1 mM sodium arsenite (AR) or 3 
Gy gamma source (IR). Blue, red and green colours represent the DAPI-stained DNA, 
eIF4E and SUMO1, respectively. The bar scale is 10 µm. The white boxes are shown in 
the expanded versions as Figure 5.20–5.22. 
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Figure 5.20 Expanded version from Figure 5.19. Immunofluorescence analysis 
of untreated HeLa cells. Red and green colours represent eIF4E and SUMO1, 
respectively. The white arrows show sites of colocalisation of eIF4E and SUMO1. 
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Figure 5.21 Expanded version from Figure 5.19. Immunofluorescence analysis 
of sodium arsenite-treated HeLa cells. Red and green colours represent eIF4E and 
SUMO1, respectively. The white arrows show sites of colocalisation of eIF4E and 
SUMO1. The small box shows the colocalisation of SUMO1 and eIF4E at the stress 
granules. 
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Figure 5.22 Expanded version from Figure 5.19. Immunofluorescence analysis 
of IR-treated HeLa cells. Red and green colours represent eIF4E and SUMO1, 
respectively. The white arrows show sites of colocalisation of eIF4E and SUMO1.  
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5.7 Discussion 
As an in vitro SUMOylation assay of protein targets has been previously available in 
our laboratory (Ho et al., 2001), it was first used to analyse SUMOylation of eIF4G in 
vitro. The recombinant SUMOylation components of the assay were prepared here and 
were analysed for ability to form SUMO chains using the conditions adapted from Ho et 
al (Ho et al., 2001). The amount of each component used is shown in Table 5.1. All 
components were capable of forming SUMO chains in an in vitro SUMOylation assay. 
Human eIF4G was assayed for ability to be SUMOylated in vitro. The human 
protein was purified from two different sources. One was Sf9 insect cells using the 
Baculovirus system and another was E. coli. Human full length eIF4G purified from in 
insect cells was shown to be SUMOylated in vitro, particularly in the presence of Pli1 
(Figure 5.7), suggesting that human eIF4G may be SUMOylated through a SUMO E3 
ligase-dependent pathway. For the identification of SUMOylation sites of eIF4G, using 
full length eIF4G expressed in Sf9 insect cells as a protein target, it was not possible to 
identify the modified lysine(s) with high confidence by mass spectrometry. This may be 
due to the large size of full length eIF4G or because SUMOylation levels were low, 
making the amount of modified peptides insufficient for detection by mass spectrometry. 
It could also be due to the fact that the SUMOylated lysine residue(s) is/are present on 
a very large tryptic peptide that cannot be detected by mass spectrometry. 
Using an alternative approach, three truncated recombinant proteins were 
expressed in E. coli, namely an N-terminal fragment (N-FAG 1–532), a middle fragment 
(M-FAG 533–1176) and a C-terminal fragment (C-FAG 1177–1600) (Figure 5.8), then 
tested in the in vitro SUMOylation assay (Figure 5.10). Only C-FAG was observed to be 
modified by SUMO in vitro while N-FAG and M-FAG were not. Mass spectrometric 
analysis (Figure 5.11) confirmed that C-FAG is SUMOylated with high confidence on 
two lysines attached to diglycine (GG). These are K1386 and K1588. Interestingly, the 
former lysine is located in the HEAT2 domain while support the second eIF4A binding 
region while the latter lysine is in the HEAT3 domain which supports Mnk1 binding 
region and (Figure 5.12) (Coldwell et al., 2004). K1386 on eIF4G is not in the eIF4A 
contact surface but it is very close to the area (Marintchev et al., 2009). It is possible that 
SUMOylation of eIF4G may change eIF4G conformation which could possibly provide 
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the altered surface in order to interact with eIF4A or interfere the eIF4A binding. 
Likewise, SUMOylation of K1588 on eIF4G may have a role in the binding with Mnk1. 
In order to verify that eIF4G is indeed SUMOylated, it was necessary to 
demonstrate SUMOylation in vivo (Figure 5.13). Human 6xHis-SUMO1 and 6xHis-
SUMO2 were affinity purified using Ni2+ agarose beads under denaturing conditions. As 
a control, eIF4E, which has been previously shown to be SUMOylated (Xu et al., 2010), 
was pulled down with both SUMO1 and SUMO2. This was also the case for eIF4G 
which was isolated with SUMO1 and SUMO2. This confirmed that human eIF4G is 
modified by both SUMO1 and SUMO2. Additionally, in response to IR, the levels of 
SUMO1-modified eIF4G are slightly decreased (Figure 5.14). This suggests that both AR 
and IR affect the levels of SUMOylation of eIF4G.    
I had several attempts to scale up and purify the SUMOylated forms of endogenous 
eIF4G for mass spectrometry in order to identify the SUMOylation sites used in vivo. 
Unfortunately the SUMOylation sites on eIF4G were unable to be identified using mass 
spectrometry (data not shown). This may be because trypsin cleavage of endogenous 
human SUMO produces a large C-terminal fragment (ELGMEEEDVIEVYQEQTGG) 
for mass spectrometry. This would make it difficult to identify the large mass of wild type 
human SUMO cleaved by trypsin on SUMOylation sites of endogenous human eIF4G. 
In further work, this could be solved using human cells containing 6xHis-SUMO 
(SUMO1 or SUMO2) T105R which would encode an alternative human SUMO protein 
with a trypsin cleavage site adjacent to the GG motif.  
Here, it is shown that human eIF4G is SUMOylated in vivo and in vitro. Two 
SUMOylation sites on human eIF4G were identified which are not conserved in fission 
yeast eIF4G. This is because the S. pombe protein does not contain the C-terminal 
domains appeared in human eIF4G.  
Since one of the functions of SUMOylation is to affect protein localisation, eIF4G 
was investigated for colocalisation with SUMO using IF (Figure 5.15). In untreated cells 
(Figure 5.16), SUMO1 is normally found in the nucleus whereas eIF4G is mainly present 
in the cytoplasm although there is a small amount in the nucleus. However, there is a low 
level of colocalisation of eIF4G and SUMO1 in both the nucleus and the cytoplasm. This 
suggests that eIF4G may have a role in regulating RNA processing or localisation in the 
nucleus and translation in the cytoplasm. 
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Interestingly, in arsenite-treated cells (Figure 5.17) most of the eIF4G is observed 
in stress granules in the cytoplasm. Colocalisation of eIF4G and SUMO1 is increased in 
cells exposed to arsenite. At many of the stress granules, SUMO1 is found at the granules’ 
edges where eIF4G colocalise with SUMO1. This suggests that eIF4G and SUMO1 
together may have a role in some aspect of translation when cells are exposed to stress 
conditions. In IR-treated cells (Figure 5.18), SUMO1 is mainly found in foci in the 
nucleus. Colocalisation of eIF4G and SUMO1 is increased in cells exposed to IR. Levels 
of colocalisation of eIF4G with SUMO1 were in the nucleus. This suggests that eIF4G 
may have a role in regulating RNA processing or localisation. 
As the amount of the colocalisation of eIF4G and SUMO1 observed in the cells 
untreated and treated with arsenite and IR is low, compared to their overall levels in cells, 
colocalisation of eIF4E and SUMO1 was also analysed. This was used to evaluate the 
significance of the colocalisation of eIF4G and SUMO1 using immunofluorescence. It is 
found that the amount of the colocalisation of eIF4E and SUMO1 is similar to that of 
eIF4G and SUMO1. For example, in untreated cells (Figure 5.20) there is a low level of 
colocalisation of eIF4E with SUMO1 in both the nucleus and the cytoplasm. In arsenite-
treated cells (Figure 5.21) most of the eIF4E is observed in stress granules in the 
cytoplasm. At many of the stress granules SUMO1 is found at the edges. In IR-treated 
cells (Figure 5.22), SUMO1 forms more foci in the nucleus and some in the cytoplasm. 
In these cells eIF4E colocalises with SUMO1 in the nucleus. These results indicate that 
immunofluorescence is a useful tool for seeing the colocalisation between SUMO1 and 
eIFs.  
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Chapter 6  
Investigation of SUMOylation of Human eIF4A 
6.1 Introduction 
Both eIF4E and eIF4G are components of the eIF4F complex. This complex also 
contains eIF4A, a DEAD-box helicase. Since we know that both human eIF4E and 
eIF4G are modified by SUMO (Xu et al., 2010; Jongjitwimol et al., 2014; Watts et al., 
2014), it was of interest to determine whether human eIF4A is also SUMOylated. Human 
eIF4A has previously been identified as one of the eIFs identified in proteomic screens 
for SUMOylated proteins (Table 1.5), suggesting that this is possible. Specifically, both 
human eIF4AI (Blomster et al., 2009; Bruderer et al., 2011) and eIF4AII (Matafora et al., 
2009) were identified in these screens, but to date the modification of these factors has 
not been confirmed. Therefore, this chapter will focus on an investigation into whether 
human eIF4AI and eIF4AII are modified by SUMO both in vitro and in vivo. In addition, 
the localisation of eIF4A and SUMO in cells has also been analysed.  
6.2 Human eIF4A proteins are SUMOylated in vitro 
6.2.1 Expression and purification of human eIF4A proteins from E. coli  
6xHis-tagged eIF4AI and GST-tagged eIF4AII were expressed in E. coli and 
purified by Robert Baldock (University of Sussex) using Ni2+ agarose purification and 
GST purification, respectively (previously described in section 2.5.13 and 2.5.14). Cells 
from a one litre of culture were harvested for the isolation of the recombinant protein. 
The protein concentration of each recombinant protein was determined using Bradford 
assay. The purity of eIF4As was analysed by SDS PAGE (data not shown). Both 
recombinant eIF4AI and eIF4AII, which have high concentration (1 and 4 mg/ml, 
respectively) with a good purity, were stored in glycerol (10% final concentration). 
Aliquots were frozen at –80°C for further use.  
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6.2.2 Mass spectrometry identifies the lysines of eIF4A that are 
SUMOylated 
To assay for the ability to be SUMOylated, both purified 6xHis-tagged eIF4AI and 
GST-tagged eIF4AII were incubated with SUMOylation components in the in vitro assay 
as described in section 2.5.9 (performed by Robert Baldock, University of Sussex). A 
Coomassie blue-stained gel of eIF4AII is shown in Figure 6.1. To identify the 
SUMOylation sites using mass spectrometry, proteins were excised from lanes 3–4 in the 
region shown Figure 6.1 and from a gel separating SUMOylated eIF4AI species (data not 
shown). Proteins in the gel pieces were digested with trypsin as described in section 
2.5.11. Mass spectra in Figure 6.2 show that K225 of eIF4AI and K226 of eIF4AII are 
modified by the diglycine (GG) motif. The position of the SUMOylated lysines is shown 
on the structures of both eIF4AI and eIF4AII in Figure 6.3. It is clear that both lysine 
residues are located on the outer surface of the molecules (Figure 6.4), consistent with 
them being available for SUMOylation. 
 
 
Figure 6.1 An in vitro SUMOylation of human eIF4AII. This figure shows a gel 
stained with Coomassie blue and indicates the region excised for mass spectrometric 
analysis (R. Baldock, University of Sussex). 
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Figure 6.2 Mass spectra of human eIF4AI and eIF4AII.Both proteins are modified by diglycine (GG) motif with high confidence. Mass 
spectrum of A) eIF4AI and B) eIF4AII peptides modified by GG motif at K225 and K226, respectively. 
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Figure 6.3 Alignment of sequences of eIF4AI and eIF4AII.The SUMOylation 
sites of eIF4AI and eIF4AII indicated in red are K225 and K226, respectively. 
 
 
 
Figure 6.4 Crystal structures of full length eIF4AI and N-terminal eIF4AII. 
Figures A) eIF4AI (PDB ID 2ZU6) and B) eIF4AII (PDB ID 3BOR) show K225 of 
eIF4AI and K226 of eIF4AII located on the outer surface of their molecules. In addition, 
binding surfaces of ATP, RNA and eIF4G are indicated (Oberer et al., 2005). NTD and 
CTD are N-terminal and C-terminal domains of eIF4A proteins. 
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6.3 Human eIF4A is modified by both SUMO1 and SUMO2 in vivo 
To determine whether human eIF4A is modified by SUMO1 or SUMO2 in vivo, 
6xHis-tagged SUMO1 and SUMO2 were affinity purified using Ni2+ agarose beads from 
HeLa cells, which stably express either 6xHis-tagged SUMO1 (S1) or 6xHis-tagged 
SUMO2 (S2) (a kind gift from Prof Ron Hay, University of Dundee). Non-transfected 
HeLa cells (NT) were used as a negative control. Western analysis was carried out using 
anti-eIF4A antisera, which recognises both eIF4AI and eIF4AII (a gift from Prof. Simon 
Morley). Figure 6.5 indicates that eIF4A was recovered from cell extracts that contain 
His-tagged SUMO1 (lane 2) and to a lesser extent from extract containing His-tagged 
SUMO2 (lane 3). The sizes are consistent with mono- and poly-SUMOylated eIF4A. In 
contrast, eIF4A was not isolated from normal HeLa cell extracts (lane 1). This indicates 
that in vivo human eIF4A is modified by both SUMO1 and possibly also SUMO2. 
6.4 The levels of eIF4A modified by SUMO1 and SUMO2 are altered in 
response to different stress conditions 
HeLa cells containing either His-SUMO1 or His-SUMO2 grown to 60–80% 
confluence in T75 flasks, were treated with either 1 mM sodium arsenite (AR) or 3 Gy 
ionising radiation (IR). His-tagged SUMO1 and SUMO2 were affinity purified from cells 
extracts using Ni2+ agarose beads under denaturing conditions as described in section 
2.5.19, and compared to the negative control which was HeLa cells untreated (UT) and 
treated with the same stress conditions (AR, IR). Whole cell extracts (WCE) and affinity 
purify (PD) samples were loaded onto 10% acrylamide gels. Western blots were probed 
with anti-eIF4A antisera. Figure 6.6 confirms that eIF4A is SUMOylated by SUMO1 and 
SUMO2 in untreated cells. Additionally, the eIF4A species in the PD blot represents a 
poly-SUMOylated form similar in size to the smallest band of the poly-SUMO-eIF4A 
shown in Figure 6.5. Figure 6.6 also shows that the levels of eIF4A modified by SUMO1 
are increased in response to sodium arsenite and ionising radiation. The levels of eIF4A 
modified by SUMO2 are also slightly increased in response to ionising radiation.  
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Figure 6.5 Analysis of SUMOylation of eIF4A using Ni2+ affinity purification. 
Whole cell extracts (WCE) and affinity purified samples (PD) from non-transfected 
HeLa cells (NT) and HeLa cells stably transfected with His-tagged SUMO1 (S1) or 
SUMO2 (S2) were loaded on 10% gels. Western blots were probed with anti-eIF4A 
antisera. # represents a mono-SUMOylated eIF4A and * represents the smallest species 
of poly-SUMOylated eIF4A. 
 
 
Figure 6.6 Analysis of eIF4A SUMOylation in response to different stresses. 
Whole cell extracts (WCE) and Ni2+ pulled-downs (PD) from wild type HeLa cells and 
HeLa cells stably transfected with His-tagged SUMO1 or SUMO2 were loaded onto 10% 
gels. Western blots were probed with anti-eIF4A antisera. Normalised ratio was 
calculated from the SUMOylated ratio of each stress condition (UT, AR and IR) divided 
by the SUMOylated ratio of non-treatment (UT). The SUMOylated ratio is the individual 
intensity of PD result which is divided by the intensity of its WCE result.  
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6.5 Human eIF4AII is SUMOylated in vivo 
As anti-eIF4A antisera used in the previous experiment can recognise both eIF4AI 
and eIF4AII, it was of interest to investigate the modification of eIF4AI and eIF4AII 
individually by both SUMO1 and SUMO2. However, as only anti-eIF4AII antibody was 
immediately available in our lab, we focused on the SUMOylation of eIF4AII in vivo. 
Affinity purification using Ni2+ agarose beads was undertaken as in section 6.3 but with 
anti-eIF4AII antibody instead for western blotting. Figure 6.7 indicates that eIF4AII is 
isolated from cell extracts expressing His-tagged SUMO1 (lane 2) and SUMO2 (lane 3) 
in PD blot (indicated in arrows), but not from cell extracts of non-transfected HeLa cells 
(lane 1). This confirms that human eIF4AII is modified by both SUMO1 and SUMO2 
in vivo. Specifically, eIF4AII is modified by a single SUMO1, while it is modified by 
SUMO2 as a mono-SUMO2-eIF4AII and poly-SUMOylated eIF4AII.  
The size of the species purified with His-SUMO1 is consistent with the size 
expected for mono-SUMOylated eIF4AII (SUMO1 is unable to form SUMO chains). 
This size of the mono-SUMOylated eIF4AII (shown as *) may relate to the size of mono-
SUMOylated-eIF4A observed in Figure 6.5. In contrast, the species observed following 
purification of His-SUMO2 likely represent poly-SUMOylated eIF4AII (shown as **). 
These species correlate with the species between 80 and 175 kDa in the S2 lane in Figure 
6.5.  
Unfortunately, this figure also shows that the anti-eIF4AII antibody can recognise 
an 80 kDa non-specific band (indicated as ≠ NS), being present on both blots. This 
suggests that this antibody may not be good enough for further use e.g. localisation of 
eIF4AII in cells.  
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Figure 6.7 Analysis of SUMOylation of eIF4AII using Ni2+ affinity purification.  
Whole cell extracts (WCE) and affinity purified samples (PD) from non-transfected 
HeLa cells (NT) and HeLa cells stably transfected with His-tagged SUMO1 (S1) or 
SUMO2 (S2) were loaded on 10% gels. Western blots were probed with anti-eIF4AII 
antisera. # and  represent unmodified and modified forms of eIF4AII, respectively, * 
and ** represent mono-SUMOylated and poly-SUMOylated forms of eIF4AII, 
respectively.  ≠ shows the non-specific protein recognised by the anti-eIF4AII antibody.  
6.6  Determining the conditions to knock down eIF4AII using siRNA 
and for expression of Flag-myc-tagged eIF4AII in HeLa cells 
To confirm that lysine 226 (K226) of eIF4AII is the residue that is SUMOylated in 
vivo, it is first necessary to knock down expression of endogenous eIF4AII using siRNA 
(Meijer et al., 2013). The siRNA-resistant wild type and unSUMOylatable versions of 
sequences encoding eIF4AII can then be re-introduced into cells for further analysis. 
Thus it was necessary to establish conditions for knocking down eIF4AII expression. 
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6.6.1 The condition of knocking down expression of endogenous 
eIF4AII using siRNA 
4 × 105 HeLa cells in 2 ml were plated on a 6-well plate. 5 µl HiPerFect transfection 
reagent (Qiagen) was added into 50 µl Opti-MEM medium, followed by addition of 
siRNA eIF4AII. The mixtures of eIF4AII siRNA were added to each well to a final 
concentration of 10, 20 and 30 nM. Cells were incubated at 37°C for 48 hours. Whole 
cell extracts (WCE) from each sample were loaded onto a gel and compared to WCE 
from non-siRNA transfected cells (0 nM). A western blot was probed with anti-eIF4AII 
and anti-tubulin antisera (Figure 6.8). The result shows that using 30 nM siRNA is the 
optimal concentration for knocking down expression of endogenous eIF4AII, in that it 
reduces eIF4AII expression approximately three fold.  
 
 
Figure 6.8 Optimisation of siRNA concentration to knock down the 
expression levels of eIF4AII. The blots were probed with anti-eIF4AII and anti-
tubulin antisera. Normalised ratio was calculated from the intensity ratio of eIF4AII to 
tubulin at each siRNA concentration divided by the intensity ratio of eIF4AII to tubulin 
at 0 nM siRNA.  
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6.6.2 Identification of optimal ratio of transfection reagent to DNA 
plasmid 
Plasmid pCMV6 containing eIF4AII (Flag-myc-tagged eIF4AII) was used for 
expression in HeLa cells (a gift from Prof M Bushell). 4 × 105 HeLa cells in 2 ml were 
incubated with 30 nM siRNA for 37°C for 48 hours. Plasmid DNA containing Flag-myc-
eIF4AII was transfected into the eIF4AII knocked-down cells using the ratio of 
transfection reagent (FuGENE® HD) to DNA at 3:1 and 3:2. Transfected cells were 
incubated for a further 24 hours. Whole cell extracts (WCE) were loaded onto a gel, and 
compared to non-siRNA transfected cells (mock siRNA). A western blot was probed 
with anti-eIF4AII and anti-tubulin antibodies (Figure 6.9). The result shows that Flag-
myc-tagged eIF4AII is expressed well using the transfection reagent to DNA ratio of 
both 3:1 and 3:2. However it may be better to use a ratio of 3:1 because this results in a 
similar level of expression as endogenous eIF4AII. 
 
 
Figure 6.9 Western analysis of optimization of transfection reagent to eIF4AII 
DNA plasmid. HeLa cells transfected with mock siRNA and 30 nM eIF4AII siRNA. 
eIF4AII-knocked down cells were then transfected with plasmids containing Flag-myc-
tagged eIF4AII using two different ratios of transfection reagent to plasmid DNA. 
Whole cell extracts (WCE) from those cells were loaded onto 10% gels. A western blot 
was probed with anti-eIF4AII and anti-tubulin antibodies. * refers to the endogenous 
eIF4AII and # refers to the recombinant eIF4AII (Flag-myc tagged). 
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6.7 Investigating the role of eIF4AII SUMOylation after introducing the 
unSUMOylatable eIF4AII into eIF4AII-knocked down cells  
Having identified the optimum conditions for eIF4AII knockdown and subsequent 
expression from a plasmid, the aim was to determine the effect of the K226R mutation 
on SUMOylation of eIF4AII. To address this, it was first necessary to construct a vector 
containing the unSUMOlatable residues (K226R) of eIF4AII. Plasmid pCMV6 
containing C-terminally Flag-myc-tagged eIF4AII-wt (Prof. Martin Bushell) was used for 
mutagenesis using a pair of mutagenesis primers; forward primer 5' GTGTTGGAAGT
GACCAGAAAATTCATGAGAGATC 3' and reverse primer 5' GATCTCTCATGAA
TTTTCTGGTCACTTCCAACAC 3'. The resulting plasmid was sequenced to ensure 
that it contained the correct sequence (data not shown).  
6.7.1 Determination of whether K226 in eIF4AII is important for the 
modification by SUMO1  
To address this, 2.0 × 106 HeLa cells transfected with His-tagged SUMO1 (HeLa 
S1 cells) (Prof. Ron Hay) were incubated with 30 nM siRNA in a 10-cm dish for 37°C 
for 48 hours. 12 µg plasmid DNA containing Flag-myc-eIF4AII (either wild-type or 
mutant version) was transfected into the eIF4AII knocked-down cells using the ratio of 
transfection reagent to DNA at 3:1. Transfected cells were incubated for a further 24 
hours. Cells were harvested for affinity purification using Ni2+ agarose beads (described 
in 2.5.19). Unfortunately, the nonspecific 80 kDa species observed in the PD blot, 
affected visualisation of SUMOylated eIF4AII. The result from affinity purification 
(Figure 6.9) shows that, in the mock control lane (positive control, lane 1 in PD), a 
SUMO1 modified form of eIF4AII is visible. In addition, in the eIF4AII-knocked down 
lane (negative control, lane 2 in PD), there is no equivalent species. In the cells where 
wild type and mutant eIF4AII have been reintroduced, no modified forms are detected. 
The WCE blot indicates that both recombinant proteins are being expressed under 
siRNA-mediated eIF4AII repression as the Flag-myc-tagged proteins are present in 
higher molecular weight than the originally endogenous eIF4AII (untagged eIF4AII). 
The higher molecular weight of the eIF4AII due to the tag would result in SUMOylated 
species migrating at a similar position to the non-specific 80 kDa species, thereby 
interfering with the visualisation of the SUMOylated Flag-myc-eIF4AII. For this reason, 
an investigation of the SUMO2 modification of eIF4AII was initiated, since it is shown 
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in Figure 6.7 that there were three higher molecular weight bands of eIF4AII modified 
by SUMO2. 
6.7.2 Determination of whether K226 in eIF4AII is important for the 
modification by SUMO2  
HeLa cells stably transfected with His-tagged SUMO2 (Prof. Ron Hay) were used 
in order to investigate whether K226 on eIF4AII is important for modification by 
SUMO2. Unfortunately, eIF4AII-knocked down cells transfected with plasmid DNA 
containing the unSUMOylatable version of eIF4AII did not grow well, unlike those cells 
containing eIF4AII-wt, which grew well (Figure 6.11). This implies that K226 in eIF4AII 
may be important and possibly has a role on cell growth. Because the cells containing 
eIF4AII-K226R mutation did not grow sufficiently, it was not possible to obtain enough 
cells for further use in affinity purification using Ni2+ agarose beads. 
 
 
Figure 6.10 Western blotting of Ni2+ affinity purification of eIF4AII. The 
endogenous eIF4AII of HeLa cells stably transfected with His-tagged SUMO1 were 
knocked down using either non-specific siRNA (mock) or 30 nM siRNA eIF4AII for 48 
hours. The eIF4AII-reduced cells were then re-introduced with either wild-type or 
mutant versions of Flag-myc-eIF4AII. Whole cell extraction (WCE) and Ni2+ affinity 
purification (PD) samples were analysed on 10% PAGE. Blots were probed with anti-
eIF4AII antibody. 
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Figure 6.11 Showing cell growth after re-introducing recombinant eIF4AII into the eIF4AII-knocked down HeLa cells containing 
His-SUMO2. Expression of the endogenous eIF4AII of HeLa cells stably transfected with His-tagged SUMO2 was knocked down using either 
non-specific siRNA (mock) or 30 nM siRNA eIF4AII for 48 hours. Wild-type (wt) or mutant versions (K226R) of Flag-myc-eIF4AII was then 
re-introduced into the eIF4A-knocked-down cells for 24 hours. This figure shows that the eIF4AII-knocked down cells containing eIF4AII K226R 
mutation did not grow well (the rightmost photo). From visual inspection, their number and ability to attach to flasks are significantly lower than 
others. 
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6.8 The localisation of SUMO1 and eIF4A in cells exposed to different 
stress conditions 
HeLa cells grown to 60–80% confluence were treated with and without either 1 
mM sodium arsenite (AR) or 3 Gy ionising radiation (IR). For microscopy, untreated 
(UT) and treated cells (AR and IR) cells were incubated with two primary antibodies, 
namely rabbit anti-eIF4A and mouse anti-SUMO1. To observe the colocalisation of 
eIF4A and SUMO1 under a fluorescence microscope, FITC anti-mouse IgG and Cy3 
anti-rabbit IgG were used against the specific primary antibodies as described in section 
2.4.8.  
The immunofluorescence result (Figure 6.12) shows that, as was observed with 
eIF4G, eIF4A (red) is mainly present in the cytoplasm whereas SUMO1 (green) is mostly 
in the nucleus although there is a small amount in the cytoplasm. In untreated cells there 
is a low level of colocalisation of eIF4A with SUMO1 in both the nucleus and the 
cytoplasm (Figure 6.13). In arsenite-treated cells most of the eIF4A is present in stress 
granules in the cytoplasm although there is still some present in the nucleus. 
Colocalisation of these proteins is found at the many of the stress granules, particularly 
at the edges of the granules (Figure 6.14). In IR-treated cells, SUMO1 is present in foci 
in the nucleus. eIF4A is still mainly in the cytoplasm, but unlike the situation with AR is 
not present in the stress granules. In these cells, a small amount of eIF4A colocalises with 
SUMO1 in the nucleus (Figure 6.15). Interestingly, the colocalisation of eIF4A and 
SUMO1 is increased in HeLa cells exposed to both AR and IR, compared to that in the 
untreated cells.  
These results with eIF4A are similar to those of eIF4G and eIF4E. For example, 
in untreated cells there is a low level of SUMO1 colocalisation with either eIF4G or 
eIF4E in both the nucleus and the cytoplasm. In arsenite-treated cells most of 
eIF4A/eIF4E/eIF4G is observed in the cytoplasmic stress granules. In addition the 
colocalisation of these three proteins with SUMO1 is found at the many of the edge’s 
stress granules. In IR-treated cells, a small amount of eIF4A, eIF4E and eIF4G 
colocalises with SUMO1 in the nucleus. 
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Figure 6.12 Immunofluorescence studies indicating the colocalisation of eIF4A 
and SUMO1. HeLa cells were untreated (UT) and treated with 1 mM sodium arsenite 
(AR) or 3 Gy ionising radiation (IR). Blue, red and green colours represent the DAPI-
stained DNA, eIF4A and SUMO1, respectively. The scale bar is 10 µm. The white boxes 
are shown in the expanded versions as Figure 6.13–6.15. 
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Figure 6.13 Expanded version from Figure 6.12. Immunofluorescence studies of 
untreated HeLa cells. Red and green colours represent eIF4A and SUMO1, 
respectively. The white arrows show sites of colocalisation of eIF4A and SUMO1. 
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Figure 6.14 Expanded version from Figure 6.12. Immunofluorescence studies of 
arsenite-treated HeLa cells. Red and green colours represent eIF4A and SUMO1, 
respectively. The white arrows show sites of colocalisation of eIF4A and SUMO1. 
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Figure 6.15 Expanded version from Figure 6.12. Immunofluorescence studies of 
IR-treated HeLa cells. Red and green colours represent eIF4A and SUMO1, 
respectively. The white arrows show sites of colocalisation of eIF4A and SUMO1.  
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6.9 Discussion 
Knowing that human eIF4E and eIF4G are modified by SUMO (Xu et al., 2010; 
Watts et al., 2014) we were prompted to investigate whether eIF4A is also SUMOylated 
since eIF4E, eIF4G and eIF4A are components of the eIF4F complex. Even though 
there are three eIF4A isoforms characterised in human, only eIF4AI and eIF4AII are 
believed to be involved in translation (Andreou and Klostermeier, 2013). The possibility 
of SUMOylation of eIF4A is consistent with proteomic screens, indicating that human 
eIF4AI (Blomster et al., 2009; Bruderer et al., 2011) and eIF4AII (Matafora et al., 2009), 
but not eIF4AIII, have been identified to be SUMO targets. Thus we began our analysis 
of SUMOylation of eIF4AI and eIF4AII in vitro ( Figure 6.1) using our in vitro assay (Ho 
et al., 2001). We found that eIF4AI and eIF4AII are both modified by SUMO in vitro 
(data not shown) on K225 and K226, respectively, using mass spectrometry (Figure 6.2). 
It is interesting that these two lysine residues are conserved in only eIF4AI and eIF4AII 
(Figure 6.3), but not in eIF4AIII. These two lysine residues are located on the outer 
surface of the molecules, consistent with them being available for SUMOylation. It is 
interesting that the SUMOylation sites of eIF4AI and eIF4AII are very close to the ATP 
binding pocket (Figure 6.4), suggesting that SUMOylation of eIF4A proteins may have a 
role in the interaction of eIF4A and ATP molecules. 
Next, it was necessary to confirm that human eIF4A proteins are SUMO modified 
in vivo. Initial observations indicated that eIF4A is modified by SUMO1 and possibly also 
SUMO2 in vivo (Figure 6.5). When this was repeated using cells exposed to arsenite and 
ionising radiation, it was confirmed that SUMO2 modifies eIF4A in untreated cells 
(Figure 6.6). Notably, the levels of SUMO1-modified eIF4A are increased in response to 
arsenite and IR, while the levels of eIF4A modified by SUMO2 are also slightly increased 
in response to IR. This indicates that, in response to arsenite, SUMOylation of eIF4A 
may be involved in the process of stress granule formation. 
Since anti-eIF4A antisera used here can recognise both eIF4AI and eIF4AII, it was 
of interest to investigate which isoforms of eIF4A proteins, eIF4AI and/or eIF4AII, are 
SUMOylated. One of the potential isoforms is eIF4AII, and this was chosen for further 
study since suitable antibodies against eIF4AII were available in our lab. Affinity 
purification of His-SUMO confirmed that human eIF4AII is modified by both SUMO1 
and SUMO2 in vivo (Figure 6.7).   
 
133 
Here, studies were initiated to investigate the role of SUMOylation of eIF4AII. 
This began with determining the optimal conditions of the siRNA eIF4AII concentration 
and the ratio of transfection reagent to DNA plasmid. The optimal concentration of 
siRNA eIF4AII was at 30 nM using HiPerFect transfection reagent, showing that ~70% 
of endogenous eIF4AII was repressed (Figure 6.8). This is consistent with a recent study 
where 30nM siRNA eIF4AII was used to knock down the expression of eIF4AII using 
Dharmafect1 (Meijer et al., 2013). For determining the ratio of transfection reagent 
(Fugene HD) to DNA plasmid, pCMV6 plasmid containing Flag-myc-eIF4All was used 
in this study (provided by Prof. Martin Bushell). The recombinant eIF4AII expressed 
was tolerant to the siRNA eIF4AII, resulting in rescue of the endogenous levels of 
eIF4AII that had been repressed (Meijer et al., 2013). Flag-myc-tagged eIF4AII was 
expressed at good levels using the transfection reagent to DNA ratio of 3:1 and 3:2 
(Figure 6.9). However it may be better to use a ratio of 3:1 since using this ratio the 
expression of the recombinant eIF4AII is similar to that of the endogenous eIF4AII. 
To investigate the role of K226 on eIF4AII to be SUMOylated, the siRNA-
resistant Flag-myc eIF4AII was mutated at lysine 226 to arginine, then re-introduced into 
the siRNA-mediated eIF4AII-repressed cells containing stably transfected His-SUMO1. 
His-SUMO1 pulled down under denaturing conditions using Ni2+ agarose beads. 
Unfortunately, the nonspecific 80 kDa bands were recognised by the anti-eIF4AII 
antibody, affecting the visualisation of the SUMOylated form of recombinant eIF4AII 
(Figure 6.10). This made it impossible to determine whether K226 on eIF4AII was 
modified by SUMO1 since the recombinant eIF4AII is C-terminally tagged with Flag 
and myc sequences, leading to an overall increase in size of eIF4AII. This problem could 
be resolved in a few ways. (1) A new anti-eIF4AII antibody could be used. (2) Anti-Flag 
or anti-myc antibodies could be used instead of eIF4AII. However, this latter approach 
was tried but was not successful as anti-Flag and anti-myc antibodies also recognised a 
number of other non-specific bands (data not shown). (3) Untagged-eIF4AII could be 
the alternative, but it may be difficult to distinguish between the original eIF4AII and the 
re-introduced eIF4AII.  
 From the reasons described above, investigating the SUMO2 modification of 
eIF4AII was thought that it might be easier since it is shown in Figure 6.11 that there 
were three bands of eIF4AII modified by SUMO2. However, there was another difficulty 
with this experiment. HeLa cells containing His-SUMO2 (Prof. Ron Hay) were used for 
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this. The cells transfected with plasmid DNA containing the unSUMOylatable version 
of eIF4AII were sick while those cells containing eIF4AII-wt grew well. This implies that 
K226 on eIF4AII may be important and possibly has a role in cell growth. However, the 
number of the cells containing eIF4AII-K226R was not enough for use in His-SUMO 
purification, but was enough for colocalisation analysis. For the localisation study, using 
anti-eIF4AII, anti-SUMO2/3, anti-Flag and anti-myc antibodies was unsuccessful since 
the antibodies recognised non-specific proteins.  
Work therefore focussed on the localisation of eIF4A proteins and SUMO1 using 
anti-eIF4A and anti-SUMO1 antibodies (Figure 6.12). The result shows that in arsenite-
treated cells SUMO1 colocalises with eIF4A in the cytoplasmic stress granules, especially 
at the edges of the stress granules (Figure 6.14). In contrast, in IR-treated cells (Figure 
6.15), it was found that eIF4A colocalises with SUMO1 more in the nucleus, compared 
to the colocalisation of SUMO1 and eIF4A in untreated cells (Figure 6.13). This is 
consistent with the result that the SUMOylation levels of eIF4A are increased in respond 
to the genotoxic stress. This suggests that the SUMOylation of eIF4A may have a role 
involved in nuclear processes.  
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Chapter 7  
Conclusion 
 
To investigate the SUMOylation of proteins, we have used an in vitro SUMOylation 
assay (Ho et al., 2001) and mass spectrometry in order to identify SUMOylated lysine 
residues on the proteins. In addition, we have analysed SUMOylation of the proteins in 
vivo. However, it is found that there were several limitations to the investigation of the 
role of SUMOylation of the proteins studied, particularly of S. pombe eIF4G, human 
eIF4G and human eIF4A. 
7.1 Limitations encountered during this study  
The limitations cover a number of aspects. First, in studying SUMOylation of 
proteins in vivo, it was difficult to identify and isolate SUMO conjugates from cell extracts 
even though SUMO protease inhibitors e.g. N-ethylmaleimide (NEM) were added to 
immunoprecipitation lysis buffers, which involved the purification of proteins under 
native conditions. This led to analysis of SUMOylation of proteins using only Ni2+ 
affinity purification, which was undertaken using denaturing conditions which would 
prevent the activity of SUMO proteases.  
For studying SUMOylation of S. pombe proteins, it was first necessary to tag the 
proteins with epitopes or sequences because specific antibodies against all proteins were 
not available. Fortunately, S. pombe containing eIF4G tagged with HA epitopes has been 
available (made by Dr. Felicity Watts), so there was no problem on the specific antibody 
to S. pombe eIF4G.  However, another difficulty was at the step of cloning the full length 
S. pombe eIF4G cDNA which would be needed for in vitro SUMOylation assays in order 
to identify SUMOylated lysine residues using mass spectrometry. Hashemzadeh‐Bonehi 
et al. (2003) have shown that plasmids containing sequences encoding the N-terminal 
S. pombe eIF4G are unable to be tolerated in E. coli. The reason for this is unknown, but 
is possibly due to the presence of a highly repeated sequence within S. pombe eIF4G (this 
is not found in the S. cerevisiae or human proteins). Additionally, the highly repeated 
sequence of S. pombe eIF4G contains 16 repeats of a perfect SUMOylation site consensus 
motif (AKRE), which would be likely to make it difficult to identify the SUMOylation 
sites, even if the full length eIF4G was able to be expressed in E. coli.  
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Unlike antibodies against S. pombe proteins, most specific antibodies to human 
proteins are commercially available. However, some antibodies used in this study were 
able to recognised non-specific epitopes or sequences. For example, Figure 6.7 shows 
that anti-eIF4AII antibody was able to recognise an 80 kDa non-specific protein in both 
whole cell extract and affinity purification blots. Additionally, in localisation studies, anti-
SUMO2/3, anti-Flag and anti-myc antibodies were used to represent SUMO2/3 and 
Flag-myc-eIF4AII in cells, but they all recognised other non-specific epitopes (data not 
shown), thus confusing the images.   
7.2 Conclusions 
Here, this study has shown that S. pombe eIF4G and Sla1 are SUMOylated in vivo, 
but eIF3h is not.  In addition, the level of SUMOylated eIF4G was increased after 
treatment with osmotic stress conditions (1 M KCl, a stress granule inducer) compared 
to the levels in untreated cells. The role of this modification is not known. However, 
there are two possibilities. The first, is that SUMOylation may be targeting eIF4G for 
degradation, possibly via the action of a SUMO-targeted ubiquitin ligase (STUbL). The 
second possibility is that SUMOylation may be targeting eIF4G to stress granules or P-
bodies. Further studies conducted here indicated that the eIF4G and Ulp2-containing 
complexes are unlikely to be polysomes. This would be consistent with SUMOylation 
targeting eIF4G to stress granules or P-bodies. For further work for studying the role of 
S. pombe eIF4G, it might be worth another attempt to clone full length eIF4G ORF or 
truncated versions of eIF4G. The expressed protein could be used for in vitro 
SUMOylation assays in order to identify SUMOylated lysine residues using mass 
spectrometry. 
Next, human eIF4G is SUMOylated in vivo and in vitro. Two SUMOylation sites on 
human eIF4G, K1386 and K1588, were identified which are not conserved in the fission 
yeast eIF4G. This is because the S. pombe protein does not contain the C-terminal 
domains present in human eIF4G. SUMO modification on these sites in human eIF4G 
may affect interactions of eIF4G with eIF4A and Mnk1. As previous described, eIF4A 
is a DEAD-box protein that is involved in translation initiation. It binds to eIF4G 
(Sonenberg and Hinnebusch, 2009; Jackson et al., 2010) in order to unwind secondary 
structure in the 5’ UTR of mRNAs as being an ATP-dependent RNA helicase. The 
activities of eIF4A (both an RNA-dependent ATPases and an ATP-dependent RNA 
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helicase) are enhanced by its interaction with two domains on eIF4G, locating at the 
middle and C-terminal domains (Sonenberg and Hinnebusch, 2009; Jackson et al., 2010). 
Results here suggest that SUMOylation of eIF4G may affect the interaction with eIF4A, 
possibly leading to the regulation of translation initiation. Mnk1 is a kinase which can 
bind the C-terminal eIF4G. It has a role in the translational regulation through 
phosphorylation of eIF4E at Ser209 (Pyronnet et al., 1999; Sonenberg and Hinnebusch, 
2009; Jackson et al., 2010). Phosphorylated eIF4E has been shown to be modified by 
SUMOylation on five lysine residues, leading to the formation of eIF4F complex and 
specific protein synthesis (Xu et al., 2010). It is possible that the SUMOylation of eIF4G 
at K1588 may prevent the binding of Mnk1 to eIF4G and reduce phosphorylation of 
eIF4E. If it is the case, SUMOylation of eIF4E and the formation of eIF4F complex may 
be interfered, leading to decrease the translation of specific mRNA.  
Like human eIF4G, human eIF4A is also SUMOylated in vivo and in vitro. The 
SUMOylation sites on human eIF4AI and eIF4AII were K225 and K226, respectively. 
These sites are highly conserved in both isoforms because these two isoforms share 90-
95% sequence identity which is mostly different at the N’ terminus. Interestingly, the 
SUMOylation sites of both eIF4A isoforms are close to the ATP binding pocket. It 
suggests that SUMOylation of eIF4A may have a role in the interaction of eIF4A and 
ATP. However, the role of SUMO1 modification of K226 on eIF4AII was further 
analysed since eIF4AII is thought to involve in a miRNA-mediated translational 
repression (Meijer et al., 2013). One of our collaboration also has an assay in order to 
determine the role of SUMOylation of eIF4AII in the context of the miRNA-mediated 
translational repression. As one of the limitations was described above, the nonspecific 
80 kDa bands were recognised by anti-eIF4AII antibody, affecting the visualisation of 
the SUMO1-conjugated form of recombinant eIF4AII.  Thus, investigating the SUMO2 
modification of eIF4AII might be easier since there were three bands of eIF4AII 
modified by SUMO2 (Figure 6.7). However, there was another difficulty since eIF4AII-
knocked down HeLa cells containing His-SUMO2 were sick when they contained the 
unSUMOylatable version of eIF4AII. This implies that K226 on eIF4AII may be 
important and possibly has a role on cell growth. In addition, the number of the cells 
containing eIF4AII-K226R was not enough for use in His-SUMO purification. These 
results suggest that the unSUMOylatable eIF4AII may have a ‘dominant negative’ effect 
in cells. 
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Colocalisation of human eIF4A/eIF4G and SUMO1 was then analysed in cells. It 
shows that, in arsenite-treated cells, SUMO1 colocalises with eIF4A and eIF4G 
(including eIF4E) in the cytoplasmic stress granules, especially at the edges of the stress 
granules. In contrast, in IR-treated cells, it is found that eIF4G/eIF4A colocalises with 
SUMO1 more in the nucleus, compared to the colocalisation of SUMO1 and 
eIF4G/eIF4A in untreated cells. This suggests that eIF4G/eIF4A and SUMO1 may have 
a cellular role in some aspects in response to arsenite and ionising radiation. To address 
this, further works need to be done. 
From the results described above, we conclude that, like human eIF4E, human 
eIF4G and human eIF4A are modified by SUMO1. We also show that these three 
proteins in the eIF4F complex are modified by SUMO2.  
7.3 Further work 
In order to fully determine, the role of SUMOylation of eIF4G, eIF4AI and 
eIF4AII further work needs to be undertaken. For example, more specific anti-
SUMO2/3 may be necessary, in particular, in the study of the localisation of these 
translation factors with SUMO2/3 in cells. Specific anti-eIF4AI antibody could be used 
in order to investigate the role of SUMOylation of eIF4AI. Anti-eIF4AII antibody, which 
is more specific than the antibody here, is also needed in order to determine whether 
K226 in eIF4AII is important for the modification by SUMO1 and SUMO2. 
Additionally, it would be very interesting to investigate why eIF4AII-knocked down cells 
containing the unSUMOylatable version of eIF4AII did not grow well while those cells 
containing eIF4AII-wt grew well (Figure 6.11).  
It may also be interesting to have clones of other cell types which have been stably 
transfected with either His-SUMO1 or His-SUMO2 e.g. MCF7 and MDA-MB231 cells. 
Since, in those cell types, the levels of SUMOylation has been altered in response to 
arsenite and ionising radiation. 
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Appendix 
A1 SUMO1 modification of endogenous eIF4G observed by 
immunoprecipitation (IP) technique  
HeLa cells were cultured until 70–80% confluence in T-75 flasks. Then, cells were 
treated either with or without the following stress conditions: (i) heat shock (HS), at 42°C 
for 15 minutes and re-incubation at 37°C for 30 minutes, (ii) 3 Gy ionising radiation (IR), 
followed by re-incubation at 37°C for 30 minutes and (iii) 10 µM MG-231 (MG) 
proteasome inhibitor for 30 minutes. Cells were harvested and used for 
immunoprecipitation using anti-eIF4G antisera and protein A agarose beads as 
previously described in section 2.5.17. The result in figure A1 shows both unmodified 
(*) and modified (***) bands of eIF4G. It is clear that eIF4G is modified by SUMO1 
when expressed at the endogenous levels. It also confirms that eIF4G is not recovered 
by protein A beads alone in the absence of anti-eIF4G antisera. However, there is no 
change of SUMOylation level of eIF4G in response to different stress conditions. 
 
 
Figure A1  Western blotting of immunoprecipitation (IP) using anti-eIF4G 
antisera and protein A beads. IP samples were loaded onto 7.5% gels. HeLa cells, 
untreated (UT) and treated with either heat shock (HS), 5 Gy IR or 10 µM MG132 (MG), 
were immunoprecipitated with and without anti-eIF4G antisera. The blots were probed 
with anti-eIF4G antisera and anti-SUMO1 antibody. (* indicating unmodified form of 
eIF4G, *** indicating SUMOylated eIF4G)  
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A2 Purification of eIF4F complexes using m7GTP Sepharose beads 
The eIF4F complex which contains several eIF3 subunits was partially purified 
using m7GTP Sepharose beads. Western blotting with anti-eIF3 antisera, anti-SUMO1 
and anti-SUMO2/3 antibodies shows that there are numerous SUMOylated species in 
the preparation. Interestingly, SUMO1 appears to modify the smaller eIF3 subunits in 
both MRC5 and MCF7 cells, while SUMO2/3 is present in higher molecular weight 
species. This could represent that small molecular weight proteins are SUMOylated as 
single by SUMO1. Moreover, SUMO modification of these subunits decreases in 
response to IR, particularly in MCF7 cells. Interpretation of these results is difficult 
because eIF4F complexes consist of several factors – eIF4G, eIF4E, eIF4A – so that 
identification of individual proteins that are SUMOylated is difficult. However, it could 
be repeated in order to observe SUMOylation of other eIFs e.g. eIF4G, eIF4E and/or 
eIF4A as specific antisera are available for these proteins. It could also be extended to 
study SUMOylation of eIFs in response to the stresses as above. 
 
 
Figure A2  Western analysis of partial purification of eIF4F complexes using 
m7GTP Sepharose. Blots were probed with anti-eIF3 antisera, anti SUMO1 and 
SUMO2/3 antibodies. 
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A3 Characterisation of anti-eIF4A and anti-eIF4AII antibodies 
This aimed to determine whether the antibodies, eIF4A (in-house antibody made 
by Prof Simon Morley) and eIF4AII (sc-137147) are able to distinguish between eIF4AI 
and eIF4AII. The recombinant eIF4A proteins, His-tagged eIF4AI and GST-tagged 
eIF4AII were expressed in E. coli and then purified under denaturing conditions 
(performed by Robert Baldock, University of Sussex). These samples were loaded on 
10% acrylamide gels. Blots were then incubated with either anti-eIF4A or anti-eIF4AII 
antibodies. Results in Figure A3 show that anti-eIF4A antibody recognises both eIF4AI 
and eIF4AII isoforms while anti-eF4AII antibody is able to specifically recognise 
eIF4AII isoform. This suggests that anti-eIF4AII antibody (sc-137147) is good enough 
to distinguish the different isoforms of eIF4A effectively.  
 
 
Figure A3  Western analysis for characterisation of anti-eIF4A and anti-eIF4AII 
antibodies. His-eIF4AI and GFP-eIF4AII were expressed and purified from 
E. coli.This figure indicates that anti-eIF4A antisera can recognise both eIF4AI and 
eIF4AII isoforms, but anti-eIF4AII antibody can recognise only eIF4AII. 
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Introduction
Sumoylation is a post-translational protein modification that is
required for numerous processes within cells, including transcrip-
tion, chromosome segregation, DNA damage responses, cell
signalling and meiosis (reviewed in [1–7]). At the molecular level
it functions by altering the surface of target molecules to affect
protein-protein interactions e.g. of PCNA (proliferating cell
nuclear antigen) and Srs2 (a DNA helicase) [8,9], by altering the
intracellular localisation of proteins e.g. of RanGAP [10], or by
changing the conformation of target proteins (e.g. in the case of
thymine DNA glycosylase [11]). SUMO chains attached to target
proteins can also be ubiquitinated and thus result in proteolysis of
the target.
SUMO is a small ubiquitin-like modifier that is attached to
lysine residues in target proteins. The yeasts Schizosaccharomyces
pombe and Saccharomyces cerevisiae both have a single gene for
SUMO: pmt3 and SMT3, respectively, while mammals have four,
SUMO-1, -2, -3 and -4 (although the role of SUMO-4 is not well
defined). SUMO-2 and -3 are 97% identical to each other and
about 50% identical to SUMO-1 (reviewed in [1]). SUMO is
produced as a precursor protein that needs to be cleaved into the
mature form in order to act as a substrate in the sumoylation
reaction. Processing of SUMO requires a specific SUMO-protease
[12–14], and involves the removal of a small number of amino
acids from the C-terminus of precursor SUMO to reveal a Gly-
Gly motif. Mature SUMO is then activated by the formation of a
thioester bond between the C-terminal glycine residue and a
cysteine residue in one subunit of the SUMO activating enzyme
(E1). From here SUMO is passed to the SUMO conjugating
enzyme (E2), where it again forms a thioester bond with another
cysteine residue. SUMO can then be attached to one or more
lysine residues in the target protein. In some cases, one of a small
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e94182
number of SUMO ligases (E3) is required for conjugation. In
many cases the lysine is contained within the consensus motif
yKxE, where y is a hydrophobic amino acid, and x is any amino
acid. SUMO can be added to target proteins as a monomer or as
poly-SUMO in the form of chains. The removal of SUMO from
target proteins or dismantling of SUMO chains occurs via the
action of SUMO-specific proteases [14,15].
In S. cerevisiae there are two SUMO proteases, Ulp1 and Ulp2,
both of which can deconjugate SUMO from target proteins, but
which have different target specificities [12]. Only Ulp1 is capable
of processing precursor SUMO to the mature form [12,15]. Ulp1
and Ulp2 are differently localised within the cell: Ulp1 is located at
nuclear pores, while Ulp2 is located mainly within the nucleus
[15]. Mammalian cells have six SUMO-specific proteases
(SENPs). These are also differentially localised within cells and
have different abilities to cleave precursor SUMO and to
deconjugate SUMO from targets e.g. [16,17]. The S. pombe Ulp1
protease has been characterised and shown to process SUMO to
the mature form, and like S. cerevisiae Ulp1, to be located at the
nuclear periphery [13]. However, little is known about Ulp2 in this
organism.
Translation initiation factors, which play key roles in cell
survival and oncogenesis [18–22], can be modified by sumoylation
[6,7,23–31]. Protein synthesis is carried out in three stages
(initiation, elongation and termination), with the initiation stage
of translation generally accepted as a major site of regulation of
gene expression in mammalian cells [18–22]. This step in protein
synthesis is regulated by a family of proteins, the initiation factors
[18,21,22] which interact with each other and the mRNA. These
proteins modulate the binding of mRNA to the ribosome, a
process facilitated by the assembly of the cap binding protein
(eIF4E), a helicase (eIF4A) and a scaffold protein (eIF4G), to form
the eIF4F complex (eIF4E/eIF4A/eIF4G). The eIF4G scaffold
protein possesses domains that interact with eIF4E, eIF4A, eIF3
and the poly(A) binding protein (PABP) [18,20–22]. The activity of
the eIF4F complex is regulated by a family of proteins, the eIF4E
binding proteins (4E-BPs). Using a conserved motif, 4E-BPs
compete with eIF4G for a common surface on eIF4E and inhibit
eIF4F assembly. In mammalian cells, activation of the mechanistic
target of rapamycin (mTORC1) leads to the multi-site phosphor-
ylation of 4E-BP1 [18,22,32] preventing 4E-BP1 from binding to
eIF4E and thereby allowing formation of the eIF4F initiation
complex and ribosomal recruitment of mRNA [18,21,22]. More
recently, phosphorylated human eIF4E has been shown to be
modified by sumoylation on five lysine residues [33]. Consistent
with a role in modulating protein-protein interactions [34],
sumoylation did not interfere with mRNA recognition but
enhanced eIF4F complex level assembly on the mRNA cap,
promoting the expression of ornithine decarboxylase, c-myc and
Bcl-2, thereby driving the anti-apoptotic and oncogenic activity of
eIF4E [33].
Since the majority of SUMO in cells is present in the nucleus,
much of the work undertaken to understand the role of
sumoylation has focussed on its role in regulating events associated
with DNA metabolism, such as the maintenance of chromatin
structure, recombination and DNA damage responses [3,5,8,9].
More recently it has been demonstrated that sumoylation is
required in the nucleolus to regulate ribosome biogenesis e.g. [35].
In order to obtain a fuller understanding of the role of sumoylation
we have begun to investigate the protein-protein interactions and
localisation of the mostly uncharacterised S. pombe SUMO
protease, Ulp2. Our results from gel filtration and immunofluo-
rescence studies indicate that Ulp2 is present in at least two high
Mr complexes, which are distinct from the nuclear pore complex
that contains Ulp1. We demonstrate that it co-purifies with a
number of proteins, many of which are involved in RNA
metabolism or protein synthesis. We have investigated whether
two of these proteins, eIF4G and eIF3h, are sumoylated, with the
result that we observe SUMO modification of eIF4G but not
eIF3h. Exposure of cells to conditions that lead to the formation of
stress granules, results in increased sumoylation of eIF4G, and
partial co-localisation of eIF4G and SUMO in the cytoplasm.
Finally, we demonstrate that human eIF4G is sumoylated in HeLa
cells, by both SUMO-1 and SUMO-2.
Materials and Methods
Strains and plasmids
The strains used in this work are described in Table 1. The
strains containing myc-, HA or TAP-tagged ulp1, ulp2, pli1, eIF4G
and eIF3h were created using the method of Bahler et al [36].
pREP41-His-SUMO was constructed by cloning the pmt3 ORF
into pREP41-His (created in this study). The S. pombe and human
eIF4G and eIF4GI constructs, Sp C-term, N-FAG, M-FAG and
C-FAG contain different fragments of the eIF4G/eIF4GI Orfs
cloned into pET15b [37]. HeLa cell lines stably transfected with
His-SUMO-1 and His-SUMO-2 were gifts from Prof R Hay
(University of Dundee) [38,39].
Ulp2 expression and assay
The ulp2 ORF was amplified from cDNA, by PCR and cloned
into pFastBacHTa (GibcoBRL). Recombinant baculoviruses were
generated according to GibcoBRL instructions. 50 ml infected
cells were lysed in 50 mM Tris HCl pH 8, 5 mM b-mercapto-
ethanol, 1% nonidet, 1 mM PMSF. Ulp2 protein was purified
using Talon resin. Ulp2 activity assays were conducted as
described for Ulp1 [13].
Protein purification methods
His-tagged SUMO was recovered from S. pombe and human
whole cell extracts under denaturing conditions with Ni2+ agarose
beads. Cell extracts were prepared as follows: 108 cells (S. pombe) or
6–86106 cells (Hela) were washed in ice cold water before being
lysed by vortexing in 1.85 M NaOH, 7.5% v/v b-mercaptoeth-
anol. The lysate was incubated on ice for 20 min after which TCA
was added to a final concentration of 25%. Following a further
20 min incubation on ice, precipitated proteins were collected by
centrifugation and resuspended and solubilised in 1 ml buffer A
(6 M guanidinium HCl, 0.1 M NaH2PO4, 10 mM Tris-HCl,
pH 8). Insoluble material was removed by centrifugation. The cell
extract was then incubated with Ni2+ agarose (Novagen) in Buffer
A in the presence of 0.05% Tween-20, 150 mM imidazole.
Purification on Ni2+ agarose was carried out according to the
manufacturer’s instructions. Samples were analysed by SDS-
PAGE and Western blotting. His-tagged S. pombe and human
eIF4GI fragments for in vitro sumoylation assays were purified from
E. coli using Ni2+ agarose according to the manufacturer’s
instructions.
For gel filtration, 200 ml logarithmically growing cells were
harvested, washed and then broken in 1 ml ice cold lysis buffer
(45 mM HEPES pH 7.8, 300 mM KCl, 5 mM MgCl2, 5 mM
EDTA, 5 mM EGTA, 12 mM NaF, 10% glycerol, 80 mM b-
glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM PMSF,
1 mM DTT, supplemented with Roche complete protease
inhibitor). The extract was clarified by two rounds of centrifuga-
tion at 20,000 rpm for 10 min. 1.5 mg protein was loaded onto
either a Superdex 200 or Superose 6 column pre-equilibrated in
S. pombe Ulp2
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lysis buffer. 0.5 ml fractions were collected and 15 ml of each was
analysed by SDS PAGE.
For TAP-purification, 60 l ulp2-TAP cells were grown to mid-log
phase, harvested and frozen at 280uC until required. Ulp2-TAP
was purified using a modification of the method described by
Seraphin et al. [40]. Specifically, the cells were broken in a 6850
freezer mill in 20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 1 mM
DTT, 0.5 mM EDTA, 2 mM MgCl2, 0.1 mM NaF, 0.1%
Nonidet NP40, 1 mM PMSF, 5 mM sodium orthovanadate,
80 mM b-glycerophosphate, 10 mM N-ethylmaleimide, supple-
mented with Roche complete protease inhibitor. All subsequent
procedures were carried out at 4uC. The cell extract was
centrifuged twice for 1 h at 10,000 rpm. Samples were pre-
cleared by incubation with 200 ml Dynabeads for 30 min to
remove proteins that bound non-specifically to the beads. The
extracts were incubated with 300 ml IgG-coated Dynabeads for
2 h. The beads were collected and washed extensively before
being resuspended in TEV buffer (50 mM Tris-HCl pH 8.0,
0.5 mM EDTA, 1 mM DTT) with 250 units AcTEV protease
(Invitrogen) for 3 h. The IgG-coated Dynabeads were removed
from the preparation and Ulp2-TAP containing complexes were
snap frozen in liquid nitrogen.
In vitro sumoylation assay
Recombinant His-tagged S. pombe eIF4G and human eIF4GI
fragments were purified from E. coli and tested for sumoylation in
an in vitro sumoylation assay as described elsewhere [41]. SUMO-
TRGG (Pmt3-L109R,GG: the mature form of S. pombe SUMO
containing a trypsin cleavage site immediately upstream of the
diglycine motif) was used in the assay to facilitate the identification
of the sumoylation sites by mass spectrometry.
Immunological methods
Western analysis was carried out as described previously [13].
Production of anti-SUMO and anti-eIF4GI (against the KRERK
epitope) antisera has been described elsewhere [41,42], anti-myc
antibodies for immunofluorescence were purified from cell
supernatant (cell line CRL1729, from ATCC) using protein G-
sepharose or were from Santa Cruz (sc-40), anti-HA antisera were
from Santa Cruz (sc-7392) and monoclonal anti-tubulin antibodies
were from Sigma (T5168). Immunofluorescence was undertaken
as described in Moreno et al. [43]. Cells were observed using an
Applied Precision Deltavision Spectris microscope using deconvo-
lution software.
Mass spectrometry
Complexes purified by purification of TAP-Ulp2 were analysed
by SDS PAGE. Protein bands were visualised by staining with
colloidal Coommassie, excised and subjected to trypsin in-gel
digestion essentially as described by Schevchenko et al. [44]. The
supernatant from the digested samples was removed and acidified
to 0.1% TFA, dried down, and reconstituted in 0.1% TFA prior to
LC MS/MS analysis. Each sample was loaded and desalted at a
flow rate of 5 ml/min on a C18 trap column (200 mm ID x 1 cm,
5 mm PepMap 100, Dionex) in buffer A (acetonitrile (2% v/v):
water (97.9% v/v): formic acid (0.1% v/v)). The tryptic peptides
were fractionated on a C18 reverse phase column (75 mm ID x
25 cm, 3 mm PepMap 100, Dionex) using an Ultimate U3000
nano-LC system (Dionex) and a 2 hr linear gradient from 95%
buffer A to 50% buffer B (acetonitrile (95% v/v): water (4.9% v/v):
formic acid (0.1% v/v) at a flow rate of 300 nl/min. Eluted
peptides were directly analysed by tandem mass spectrometry
using a LTQ Orbitrap XL hybrid FTMS (ThermoScientific)
operated in parallel acquisition IDA mode with nominal resolution
of 60,000 (FWHM) at m/z 400 for MS1 and the top six most
abundant multiply charged ions being selected for CID fragmen-
tation in the linear ion trap followed by dynamic exclusion for
90 secs.
Derived MS/MS data were searched against the S. pombe subset
of the UniProt Knowledgebase release 15.13 database using
Sequest version SRF v. 5 as implemented in Bioworks v 3.3.1
(Thermo Fisher Scientific), assuming carboxyamidomethylation
(Cys), deamidation (Asn and Gln) and oxidation (Met) as variable
modifications and using a peptide tolerance of 10 ppm and a
fragment ion tolerance of 0.8 Da. One missed cleavage was
allowed and filtering criteria used for positive protein identifica-
tions were Xcorr values greater than 1.9 for +1 spectra, 2.2 for +2
spectra and 3.75 for +3 spectra and a delta correlation (DCn) cut-
off of 0.1.
Table 1. List of strains.
Strain Genotype Reference
Sp.011 ade6-704, leu1-32, ura4-D18, h2 [72]
Sp.611 ulp1-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.614 ulp2-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.658 ulp1::ura4, ade6-704, leu1-32, ura4-D18, h2 [13]
Sp.723 pli1-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.874 pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
sp.851 ulp1::ura4, pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
sp.855 ulp2::ura4, pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.1470 ulp2-TAP, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2047 eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h+ This study
Sp.2048 ulp2-myc:kan, eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2068 ulp2-myc:kan, eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2085 ulp2::kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2088 eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h+ This study
doi:10.1371/journal.pone.0094182.t001
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For the identification of sumoylation sites, reduction and
alkylation were instead performed using TCEP and MMTS
respectively as previously described [45] and bioinformatics
analysis following conversion of LTQ-Orbitrap (.raw) raw data
files to Mascot generic format (MGF) via Mascot Distiller (Matrix
Science) performed essentially as described by Chicooree et al.
[46] using the MASCOT search engine with the UniProt
Knowledgebase release 15.13 database with the S. pombe subset
as selected taxonomy. Precursor ion tolerances were again set at
10 ppm and MS/MS peptide ion tolerance to 0.8 Da, and the
same variable modifications assumed. However, two missed
trypsin cleavages were allowed.
Following trypsin digestion, cleavage of the SUMO moiety was
expected to leave a Gly-Gly isotag on modified residues. The GG
isotag (on lys) was accordingly also searched as a variable
modification. Following MASCOT searches, putative sites of
SUMOylation were noted and the relevant raw MS/MS spectra
subsequently examined manually to confirm presence of the
modification (the GG isotag).
Results
Biochemical characterisation of S. pombe Ulp2
A comparison of the S. pombe Ulp2 sequence was made with
those of the two S. cerevisiae SUMO proteases, Ulp1 and Ulp2 [47].
Since S. pombe Ulp2 more closely resembles S. cerevisiae Ulp2
(required solely for deconjugating SUMO from high Mr SUMO-
containing species) than it does Ulp1 (which is required for both
processing and deconjugating), it is likely that the main activity of
S. pombe Ulp2 is in deconjugating SUMO from sumoylated targets
rather than in processing SUMO to the mature form. Before
proceeding to analyse the localisation or protein-protein interac-
tions of Ulp2, we first confirmed its proposed biochemical activity.
His-tagged Ulp2 was purified from insect cells as described in
Materials and Methods. Using assays we described previously [13],
we demonstrate that Ulp2 is significantly less able than Ulp1 to
process SUMO to the mature form (Figure 1A, lane 2 (Ulp1) and
lane 3 (Ulp2)), but is capable of deconjugating SUMO from high
Mr species in an N-ethylmaleimide- (NEM)-dependent manner
(Figure 1B). These results confirm that like S. cerevisiae Ulp2, S.
pombe Ulp2 is a cysteine protease whose main function is in
deconjugating SUMO from target proteins.
Deletion of the ulp2 gene results in a severe growth
defect and sensitivity to a range of stresses
Deletion of pmt3 (which encodes SUMO), hus5 (the gene
encoding the SUMO-conjugating enzyme, E2), rad31 (which
encodes one sub-unit of the SUMO activating enzyme, E1) or ulp1
(another SUMO-specific protease gene) results in severe growth
and morphological abnormalities [13,48–50]. We therefore wished
to determine whether disrupting the ulp2 gene has any effect on
cell growth or viability. Disruption of the gene is not lethal.
However, ulp2-d cells form very small colonies and show distinct
morphological abnormalities resembling hus5 and rad31 mutants
(data not shown). Comparison of SUMO-containing species in
ulp1-d and ulp2-d cells (Figure 1C, lanes 3 and 4) supports the
notion that the main function of Ulp2 is in the removal or
dismantling of high Mr SUMO-containing species, rather than in
processing precursor SUMO. Provision of the mature form of
SUMO (Pmt3-GG) in ulp1-d cells (lane 5) results in the
incorporation of SUMO into high Mr species (unlike the situation
in ulp1-d cells, lane 3), while in ulp2-d cells (lane 6), the level of high
Mr species is slightly increased.
To begin to identify cellular processes involving Ulp2, we tested
whether ulp2-d cells are sensitive to the DNA synthesis inhibitor,
hydroxyurea (HU) and other stresses (Figure 1D), and compared
these responses to those of ulp1-d,pmt3-GG cells (where the mature
form of SUMO is provided, so that cells are only defective in the
deconjugating activity of Ulp1). Since ulp2-d and ulp1-d,pmt3-GG
cultures contain a high proportion of dead cells, it was necessary to
plate more cells for these strains compared to wild type
(approximately 10 fold). These data indicate that ulp2-d cells are
temperature sensitive, unlike the ulp1-d,pmt3-GG strain, but similar
to the S. cerevisiae ulp2D strain [51], and sensitive to the DNA
synthesis inhibitor, hydroxyurea (HU, 2 mM). They are also
sensitive to the protein synthesis inhibitor, cycloheximide (CHX,
10 and 20 mg/ml) and KCl (1 M) indicating that Ulp2 likely has
roles in numerous cellular processes.
Ulp2 is present in high molecular weight complexes
Throughout most of the cell cycle, Ulp1 is associated with the
nuclear envelope [13], and specifically with the nuclear pore
complex [52,53]. To determine whether Ulp2 is also part of a high
Mr complex we undertook gel filtration analysis. Figure 2A
indicates that, as expected, Ulp1 elutes in the void volume,
consistent with it being present in a high Mr complex. Ulp2 also
elutes in the void volume like Ulp1, but additionally, it is present in
fractions corresponding to an approximate Mr of 670 kDa. This
suggests that Ulp2 is likely to be present in at least two different
complexes. In contrast to the results obtained for Ulp1 and Ulp2,
Pli1, an E3 SUMO ligase [54], does not elute in these high Mr
fractions, implying that it likely exists in cells as a monomer or
possibly a dimer.
Ulp2 is located in both the nucleus and cytoplasm, but is
predominantly nuclear
Since a proportion of Ulp2 co-elutes with Ulp1 in the void
volume, we wished to determine whether some or all of the Ulp2
co-localises with Ulp1 in cells, i.e. is at the nuclear periphery. We
therefore analysed the localisation of Ulp2. Figure 3 indicates that
Ulp2 is present in foci that are predominantly nuclear, with a small
proportion in the cytoplasm. Little if any Ulp2 is located at the
nuclear periphery. Thus the location of Ulp2 is distinct from that
of Ulp1 [13], indicating that it is unlikely to be part of nuclear pore
complexes. In many cases, Ulp2 co-localises with SUMO. Ulp1
undergoes distinct changes in localisation during the cell cycle, its
localisation changing from the nuclear periphery where it is for
most of the cell cycle, to the region between the separating DNA
masses during mitosis [13]. In contrast, the location of Ulp2
appears to be relatively unchanged in cells at different cell cycle
stages. For example, during mitosis (Figure 3, TRITC panel, cells
labelled 4), a time when Ulp1 relocalises, the distribution of
intranuclear Ulp2 foci is very similar to that observed at other
times in the cell cycle (cells labelled 1–3) and is unchanged.
Ulp2 co-purifies with proteins associated with RNA
metabolism and protein synthesis
To begin to identify the nature of the complexes observed in
Figure 2, we C-terminally-tagged Ulp2 with TAP in the genome
(ulp2-TAP) and isolated the tagged protein and associated proteins
as described in Materials and Methods. Protein complexes were
analysed by SDS PAGE (Figure 4) and fractions excised from the
gel for mass spectrometric analysis. As shown in Table S1 and
Table 2, the majority of the proteins identified are associated with
RNA metabolism, such as RNA processing, ribosome biogenesis
or initiation of translation. To ensure that these proteins co-
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purified specifically with Ulp2, a parallel purification was
undertaken using Rad9-TAP, and from cells expressing the TAP
tag alone (Figure S1). Rad9 is a member of the 9-1-1 complex
required for the DNA integrity checkpoint [55], and would not be
expected to interact with a the same proteins as those that interact
with Ulp2. Very little protein co-purified with the TAP-tag alone,
while purification of Rad9-TAP yielded a quite different set of
bands. Most of the proteins co-purifying with Rad9 were
associated with DNA metabolism as expected (data not shown)
and only one protein, glyceraldehyde 3-phosphate dehydrogenase,
was common to the Ulp2-TAP and Rad9-TAP preparations.
A number of proteins required for ribosome biogenesis,
including some of those we identified by mass spectrometry, have
recently been demonstrated to be sumoylated (Table 2) [6,7,23–
27,56–58]. However, little is known about the effect of sumoyla-
tion on the function of translation factors. We therefore selected
two translation initiation factors, eIF4G and eIF3h for further
study. The analysis of some of the other factors will be described
elsewhere. eIF4G has been well characterised in S. cerevisiae and
mammalian cells [18,22] and to some extent in S. pombe [59].
eIF4G acts as a scaffold protein as part of the eIF4F complex to
recruit mRNA to the ribosome for translation [21], while eIF3h is
a non-core subunit of the eIF3 complex linking eIF4F/mRNA to
the ribosome in mammalian cells [60]. Gel filtration analysis of
whole cell extracts from cells containing Ulp2-myc and either
eIF4G-HA or eIF3h-HA indicates that the majority of eIF4G co-
elutes with Ulp2 (Figure 2B). In contrast, eIF3h elutes in multiple
Figure 1. Analysis of Ulp2 function. A. Assay for SUMO-processing activity. Lanes 1–4 contain full length SUMO, lane 5 SUMO-GG. Lanes 1,5,
unincubated controls, lanes 2–4 were incubated at 20uC for 2 h following addition of 0.72 mg Ulp1 (lane 2), 2.32 mg Ulp2 (lane 3) or 2 ml buffer (lane
4). Proteins were analysed by SDS PAGE followed by staining with Coommassie Brilliant Blue. B. Assay for de-conjugating activity. S. pombe cell
extracts were prepared using standard native extraction procedures. Extracts were incubated at 20uC for 2 h (lanes 1–6), lane 1 5 ml of fraction from
extract from E. coli cells transformed with empty vector, equivalent in volume to the Ulp2-containing fraction from ulp2-transformed cells, lane 2
0.6 mg Ulp2, lane 3 1.2 mg Ulp2, lane 4 2.4 mg (5 ml) Ulp2, lane 5 4.8 mg Ulp2, lane 6 1.2 mg Ulp2 pre-incubated with 5 mM NEM, lane 7 total cell extract
without incubation at 20uC. Assays were analysed by Western blotting with anti-SUMO antisera. C. Western analysis of total cell extracts using anti-
SUMO antisera. Both the separating and stacking gels (6% polyacrylamide in the stacking gel) were blotted. D. Ten microlitre of 10 fold serial dilutions
of cells were plated onto YEP agar plates with or without additives as indicated. 10x amount of cells of ulp2-d and ulp1-d,pmt3-GG were used
compared to wild type.
doi:10.1371/journal.pone.0094182.g001
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Figure 2. Ulp2 is present in high Mr complexes. Analysis of complexes by gel filtration. A. Total cell extracts from ulp1-myc, ulp2-myc or pli1-myc
strains were analysed on a Sephadex 200 column, and fractions were western blotted with anti-myc antibodies. B. Total cell extracts from ulp2-
myc,eIF4G-HA and ulp2-myc,eIF3h-HA strains were analysed on a Superose 6 column, fractions were western blotted with anti-myc and anti-HA
antibodies.
doi:10.1371/journal.pone.0094182.g002
Figure 3. Ulp2 is localised predominantly within the nucleus. A. Cells containing myc-tagged ulp2 as the sole copy of the ulp2 gene were
incubated with anti-myc antisera (mouse monoclonal) and anti-SUMO antisera (rabbit polyclonal) followed by TRITC-conjugated anti-mouse IgG
antisera, FITC-conjugated anti-rabbit IgG antisera and DAPI. Merge = overlay of TRITC (red), FITC (green) and DAPI (blue) staining. 1: early G2 cells,
2,3: late G2 cells, 4: mitotic cells, 5: S phase cells. Bar = 5 mm.
doi:10.1371/journal.pone.0094182.g003
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fractions, suggesting it is present in several different sized
complexes.
eIF4G, but not eIF3h, is sumoylated in S. pombe
One possibility to explain the interaction of eIF4G and eIF3h
with the SUMO protease Ulp2 is that they are themselves
modified by SUMO. In order to determine whether this is the
case, cells containing genomic copies of HA-tagged eIF4G or
eIF3h were co-transformed with pREP41-His-SUMO. His-tagged
SUMO was purified on Ni2+ agarose. Denaturing conditions (with
6 M guanidinium HCl in the binding buffer, followed by 6 M
urea, 300 mM imidazole washes) were used to ensure that
sumoylation of the individual proteins was being observed, rather
than that of other components of the eIF4F or eIF3 complexes).
Figure 5A, shows that eIF4G is specifically recovered in the
presence of His-tagged SUMO (lane 1), but not in the absence of
His-tagged SUMO (lane 2), indicating that it is sumoylated in S.
pombe. In contrast, eIF3h is not recovered in either the absence or
presence of His-tagged SUMO (Figure 5B), indicating that this
translation factor is not sumoylated in fission yeast. Its co-
purification with Ulp2 may thus be through the interaction of
Ulp2 with other member(s) of the eIF3 complex.
Conditions that induce stress granules affect the
localisation and sumoylation of eIF4G
Since one of the functions of sumoylation is to affect protein
localisation, we next investigated whether eIF4G and SUMO co-
localise. Figure 6 shows that in untreated cells, as has been shown
previously [61], the majority of eIF4G is cytoplasmic as expected
for a translation initiation factor. As has been observed in S.
cerevisiae and human cells [62,63], a small amount of eIF4G is also
present in the nucleus, where it is proposed to couple RNA
processing events in the nucleus with translation in the cytoplasm.
In contrast to the situation with eIF4G, the majority of the SUMO
protein is present in the nucleus (Figures 3 and 6). We observe that
a significant proportion of the nuclear eIF4G co-localises with
SUMO, suggesting sumoylation of eIF4G may have a role in
regulating RNA processing or localisation.
Protein synthesis can be inhibited by a variety of factors. For
example, cycloheximide (CHX) interacts with ribosomes and
inhibits the elongation step, while exposure of S. pombe cells to 1 M
KCl inhibits protein synthesis by the sequestration of translation
initiation factors and mRNA into cytoplasmic stress granules [64].
Following treatment with CHX, eIF4G staining is slightly more
punctate than in untreated cells, while the pattern of SUMO
staining is unchanged. In these cells, there is a low level of
colocalisation of eIF4G and SUMO in the nucleus. Interestingly,
exposure of cells to CHX results in distorted nuclei. The reason for
this is not known, but it could be due to disruption of RNA
processing and/or localisation by CHX.
In S. pombe and mammalian cells eIF4G and eIF4GI respec-
tively, are among the translation factors present in stress granules
[61,65,66]. To investigate stress granule formation in S. pombe, we
exposed cells to 1 M KCl. In these cells, eIF4G is present in fewer,
but quite bright, punctate cytoplasmic foci (Figure 6). This pattern
of staining is similar to what has been observed for stress granules
in S. pombe, and in particular, what has previously been observed
for eIF4G in this organism [61,64]. In these cells, there was
occasional co-localisation of the two proteins in the cytoplasm and
this appeared to reflect the appearance of eIF4G and SUMO in
the same granule.
Figure 4. Purification of Ulp2-TAP. SDS-PAGE of Ulp2-Tap and
associated proteins. TEV = TEV protease, used to cleave Ulp2 from TAP
tag. Numbers refer to gel slices analysed by mass spectrometry.
doi:10.1371/journal.pone.0094182.g004
Table 2. Summary of proteins identified by mass spectrometry that co-purified with TAP-Ulp2.
Function Protein
Translation eIF2a, eIF2b, eIF3a, eIF3b, eIF3c, eIF3c, eIF3h, eIF4G, EF1a EF2B, eEF3B, EF2, Pabp
RNA synthesis Rpa1, Rpa2,
RNA processing Rrp5, SPAC694.02, Exo2, Dhp1, Upf1, SPBC19G7.10C, Nop2, Dbp2, Prp19, Sla1,
Ribosome biogenesis aconitate hydrolase/mitochondrial ribosomal protein subunit L49, SPAC22G7.05, SPAC1142.04(Noc2 predicted), Hsc1/Sks2, Rpl301,
Rpl302, Rml2
DNA metabolism Tcg1, Rfc5,
Other Pfk1, SPBC16h5.12C, glutamate 5-kinase (predicted), Gpd1, Gpd3
Data from [6,7,23–26,56–58].
doi:10.1371/journal.pone.0094182.t002
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Another protein known to be present in stress granules is polyA-
binding protein (PABP) [61]. We therefore compared the
localisation of eIF4G and PABP in cells exposed to 1 M KCl.
We observe PABP in large cytoplasmic granules, which are
different to those we observe in cells only containing HA-tagged
eIF4G-HA (Figure S2A and Figure 6). Curiously, in some of the
cells that contain both eIF4G-HA and PABP-RFP, eIF4G is now
also present in large granules where it co-localises with PABP.
Further analysis of PABP-RFP containing cells indicated that a
proportion of the SUMO is mislocalised to the cytoplasm (Figure
S2B). This suggests that C-terminal RFP-tagging of PABP may
affect its function and/or localisation.
Following exposure to 1 M KCl, we noticed that there was less
staining of both eIF4G and SUMO compared to that in untreated
cells. Western analysis of eIF4G and SUMO levels indicates that
in response to 1 M KCl the levels of both proteins are significantly
reduced (Figure 5C). The reason for this is unknown, but may be
due to the fact that a proportion of the eIF4G and SUMO is
insoluble and not recovered in the extract. Alternatively, and in
our view the more likely explanation, we propose that in response
to this stress, there is increased proteolysis of both proteins.
We next investigated whether sumoylation of eIF4G is affected
by exposure of cells to either CHX (100 mg/ml) or KCl (1 M).
Figure 7A indicates that there is an increase in sumoylation in
response to KCl, with levels of sumoylation unaffected by exposure
to CHX, when compared to levels in untreated cells (with relative
levels being 1:1:1.5; wt, CHX-treated, KCl-treated, respectively).
These data suggest that sumoylation of eIF4G may be associated
with stress granule formation and/or proteolysis of the translation
initiation factor.
Human eIF4GI is sumoylated
In order to analyse the role of sumoylation of S. pombe eIF4G we
investigated the possibility of testing the protein for ability to be
sumoylated in our in vitro sumoylation assay, as this could help us
identify the sumoylated lysine residue(s). However, two factors
make this identification difficult. Firstly, in order to purify protein
for an in vitro sumoylation assay, we would need to clone the full
length S. pombe eIF4G cDNA. We have previously observed that
Figure 5. eIF4G, but not eIF3h, is sumoylated. His-tagged SUMO was expressed in cells containing genomically tagged (HA) copies of eIF4G (A)
and eIF3h (B). WCE = whole cell extract, PD = Ni2+-agarose pull down. Blots were probed with anti-HA or anti-SUMO antisera. C. Western blot of
whole cell extracts from cells containing genomically tagged eIF4G-HA. UT = untreated, C, K = incubated for 30 min with 100 mg/ml CHX (C) or 1 M
KCl (K).
doi:10.1371/journal.pone.0094182.g005
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plasmids containing the N-terminus of the S. pombe eIF4G coding
sequence cannot be tolerated in E. coli [59], so that full length
eIF4G cannot be expressed in E. coli. The reason for this is
unknown, but may be due to the presence of a highly repeated
sequence within the eIF4G coding sequence. Secondly, this highly
repeated sequence (present in the coding sequence in the S. pombe,
but not in the S. cerevisiae or human proteins) contains 16 repeats of
a perfect sumoylation site consensus motif (AKRE), which would
likely make identification of the site(s) difficult, even if we were able
to express the full length protein. We therefore expressed a C-
terminal fragment (comprising aa 970–1403), which contains
eIF4E, eIF4A and eIF3 binding sites (Figure 7B) and tested this in
our in vitro sumoylation assay. We did not observe any sumoylation
of this fragment, implying that sumoylation likely occurs in the N-
terminus of the protein.
To further analyse the role of sumoylation we set out to
determine whether human eIF4GI is sumoylated and if so, to
identify the sumoylation site(s) in this protein. We used HeLa cell
lines stably transfected with either His-SUMO-1 or His-SUMO-2
[38,39]. His-tagged SUMO was recovered from cell extracts
prepared under denaturing conditions. Figure 7C indicates that
eIF4GI is not recovered from extracts of cells that do not contain
His-tagged SUMO (lane1), but is isolated from extracts of cells
containing His-SUMO-1 (lane 2) and to a lesser extent from cells
expressing His-SUMO-2 (lane 3). This confirms that, like S. pombe
eIF4G, human eIF4GI is sumoylated.
We next sought to identify the sumoylation sites on human
eIF4GI. In order to facilitate our analysis, we used three different
human eIF4G fragments, N-FAG, M-FAG and C-FAG (Figure 7B,
[37]). These protein fragments were purified from E. coli and tested
in our in vitro sumoylation assay (data not shown). Slow migrating
forms of eIF4G were excised from gels and analysed by mass
spectrometry. Two sumoylation sites were identified: K1368 and
K1588 (Figure 7D). These map to two domains of eIF4GI which
interact with eIF4A and the protein kinase, Mnk1, respectively
[18,21,22]. These results suggest that sumoylation may affect the
interaction of eIF4GI with these two proteins.
Discussion
In order to analyse the role of S. pombe Ulp2, we purified Ulp2-
TAP-containing complexes. We identified proteins involved in
RNA synthesis or processing, ribosome biogenesis and translation.
This is consistent with recent reports that a number of proteins
required for ribosome biogenesis and RNA processing are
sumoylated [6,67,68]. While this manuscript was in preparation,
Figure 6. Effect of cycloheximide and KCl on localisation of eIF4G and SUMO. Cells containing eIF4G-HA, untreated (UT) or exposed to CHX
(100 mg/ml) or KCl (1 M) as indicated, were incubated with anti-SUMO antisera (green) and anti-HA antisera (red). Bar = 5 mm. Bottom panel, regions
indicated by boxes in panel above. Arrows indicate sites of colocalisation of SUMO and eIF4G.
doi:10.1371/journal.pone.0094182.g006
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a global analysis of the SUMO system interactome in S. cerevisiae
identified a range of proteins including a number required for
ribosome biogenesis and rRNA processing that interact with Ulp2
[69]. Additionally, the nucleolar SUMO-specific protease, SENP3,
has been demonstrated to reverse the SUMO modification of
nucleophosmin to be required for rRNA processing [70].
Although a number of translation factors, required for both the
initiation and elongation steps of protein synthesis, have been
identified in global screens as being sumoylated e.g. [23–28,30,31],
little is known about the role of sumoylation of these proteins. This
is in contrast to the situation with the role of sumoylation in
ribosome biogenesis. We therefore focussed our attention on two
S. pombe translation initiation factors in our list of Ulp2-interactors:
Figure 7. Human eIF4G is sumoylated. A. S. pombe cells containing His-tagged SUMO and HA-tagged eIF4G as indicated were treated with CHX
(100 mg/ml) or KCl (1 M), and His-tagged SUMO pulled down, and analysed as in Figure 5. B. Comparison of human and eIF4G proteins, indicating
protein binding domains: PABP= polyA binding protein, 4E = eIF4E, 4A = eIF4A, 3 = eIF3, Mnk = MAP kinase-interacting kinase 1. C. Whole cell
extracts (WCE) and Ni2+ pull-down (PD) from extracts of HeLa cells stably transfected with His-tagged SUMO-1 (S1) or SUMO-2 (S2) or nothing (-).
Western blots probed with anti-eIF4GI (KRERK epitope) antisera. D. Representative eIF4G ion mass spectra (MS/MS spectra) showing identification of
the in vitro sites of sumoylation.
doi:10.1371/journal.pone.0094182.g007
S. pombe Ulp2
PLOS ONE | www.plosone.org 10 May 2014 | Volume 9 | Issue 5 | e94182
eIF4G and eIF3h. Both proteins are known to be present in high
Mr complexes, with eIF4G being part of the eIF4F complex while
eIF3h is part of the eIF3 complex [22]. We demonstrate here that
eIF4G, but not eIF3h is sumoylated in vivo. These results are
supported by the genome-wide analyses of sumoylated proteins
that have been undertaken, that indicate that eIF4G is sumoylated
[24,28] but which have not to date identified eIF3h as a
sumoylation target.
As the most prominent role of translation initiation factors is in
cytoplasmic protein synthesis, we began by investigating whether
Ulp2 is associated with polysomes. However, we observed that
while Ulp2 migrated at the same position in sucrose gradients as
polysomes, it was still present in these fractions under conditions
(2.5 mM EDTA) where polysomes were disrupted, indicating that
the majority of Ulp2 is not associated with actively translating
polysomes (data not shown). This result confirms our gel filtration
analysis and localisation studies, and indicates that Ulp2 is present
in very high molecular weight complexes, but discounts the
possibility that Ulp2 is associated with actively translating
polysomes.
The role of sumoylation of translation factors has not been well
studied, apart from that of eIF4E [29,33]. eIF4E is an mRNA cap-
binding protein, and one of the proteins that interacts with eIF4G
to form the eIF4F complex [22]. eIF4E is regulated by
phosphorylation and by interaction with eIF4E-binding proteins
(4E-BPs). Sumoylation of eIF4E on five lysines is promoted by its
phosphorylation at S209, and results in its dissociation from 4E-
BP1. Sumoylation did not interfere with mRNA recognition but
enhanced eIF4F complex assembly on the mRNA cap, promoting
the expression of ornithine decarboxylase, c-myc and Bcl-2,
driving the anti-apoptotic and oncogenic activity of eIF4E [33]. As
phosphorylation of eIF4E has been shown to play a role in
selective nuclear export of mRNA [71], it is likely that sumoylation
of eIF4E occurs in the nucleus and/or as it emerges into the
cytoplasm
We have shown that in response to osmotic stress (1 M KCl),
conditions that induce stress granules in fission yeast, the overall
levels of SUMO and eIF4G are reduced. We have also shown that
under these conditions, there is increased sumoylation of eIF4G.
The role of this modification is not known. Our results suggest two
possible scenarios: the first being that sumoylation is targeting
eIF4G for degradation, possibly via the action of a SUMO-
targeted ubiquitin ligase (STUbL). The second possibility is that
sumoylation may be targeting eIF4G to stress granules. Further
work is needed to distinguish between these two possibilities.
The two sumoylation sites in human eIF4GI that we have
identified are not conserved in fission yeast eIF4G, as this protein
lacks the C-terminal domains present in human eIF4GI
(Figure 7B). Their positions suggest that sumoylation of this
protein may be affecting interactions of eIF4GI with eIF4A and
Mnk1. eIF4A is a DEAD-box protein that participates in
translation initiation and binds to eIF4GI [18,21,22]. Functioning
as an ATP-dependent RNA helicase, eIF4A is believed to unwind
secondary structure in the 59-untranslated region of mRNAs to
enable ribosome scanning. The RNA-stimulated ATPase and
ATP-dependent helicase activities of eIF4A are enhanced by its
interaction with two domains on eIF4GI, one in the C-terminus
and one in the middle domain [18,22]. Interaction and subsequent
recycling of eIF4A from the eIF4G/eIF4A complex stimulates the
eIF4A helicase activity required for the mRNA scanning process.
It is possible that sumoylation of eIF4GI either directly or
indirectly affects the interaction with eIF4A, thereby regulating
translation initiation. Mnk1 is a kinase which binds at the extreme
C-terminus of eIF4GI and regulates the phosphorylation of eIF4E
at Ser209 [18,21,22]. Phosphorylated eIF4E has been shown to be
modified by sumoylation on five lysine residues [33] promoting
eIF4F complex formation and specific protein synthesis [33].
Sumoylation of K1588 on eIF4GI could prevent the binding of
Mnk1, reduce eIF4E phoshorylation and thereby abrogate
sumoylation of eIF4E and specific mRNA translation. As
phosphorylation of eIF4E is associated with tumour cell formation
and increased resistance of tumour cells to apoptosis, sumoylation
of eIF4GI at this site could provide a novel and undiscovered
mechanism to regulate cell growth and proliferation in mamma-
lian cells. Further work needs to be done to address this.
In conclusion, our results demonstrate that S. pombe and human
eIF4GI are both sumoylated, and that in S. pombe this modification
is increased under conditions that promote the formation of stress
granules. We have also identified the target lysine residues that are
used for sumoylation in vitro in human eIF4GI. It will be of interest
to determine whether these sites are also used in vivo, and to
identify the role of this sumoylation.
Supporting Information
Figure S1 Comparison of proteins co-purifying with
Ulp2-Tap and Rad9-Tap. Extracts from cells expressing Ulp2-
Tap, Rad9-Tap (Methods S1) or Tap alone were subjected to the
same purification procedure and analysed by SDS-PAGE followed
by staining with colloidal coommassie.
(TIF)
Figure S2 Colocalisation of eIF4G with PABP. A. Strain
containing eIF4G-HA and PABP-RFP stained with anti-HA and
anti-RFP antisera. Secondary antisera: anti-rabbit FITC conju-
gated, anti-mouse TRITC-conjugated. B. Strains containing either
eIF4G-HA or Pabp-RFP (Methods S1) as indicated, stained with
anti-SUMO antisera.
(TIF)
Table S1 Identity of proteins co-purifying with Ulp2-
TAP. Proteins identified by LC MS/MS (Methods S1).
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Regulation of protein synthesis is of fundamental
importance to cells. It has a critical role in the control of gene
expression, and consequently cell growth and proliferation.
The importance of this control is supported by the fact that
protein synthesis is frequently upregulated in tumor cells. The
major point at which regulation occurs is the initiation stage.
Initiation of translation involves the interaction of several
proteins to form the eIF4F complex, the recognition of the
mRNA by this complex, and the subsequent recruitment of
the 40S ribosomal subunit to the mRNA. This results in the
formation of the 48S complex that then scans the mRNA for
the start codon, engages the methionyl-tRNA and eventually
forms the mature 80S ribosome which is elongation-
competent. Formation of the 48S complex is regulated by the
availability of individual initiation factors and through speciﬁc
protein-protein interactions. Both of these events can be
regulated by post-translational modiﬁcation by ubiquitin or
Ubls (ubiquitin-like modiﬁers) such as SUMO or ISG15. We
provide here a summary of translation initiation factors that
are modiﬁed by ubiquitin or Ubls and, where they have been
studied in detail, describe the role of these modiﬁcations and
their effects on regulating protein synthesis.
Introduction
Initiation of protein synthesis
Protein synthesis is of fundamental importance in cells and its
regulation is crucial for the continued viability of organisms. The
process comprises 3 stages: initiation, elongation and termina-
tion. Of these, initiation is generally considered to be one of the
major regulatory steps of gene expression in mammalian cells.
Initiation requires the function of a number of translation initia-
tion factors (Fig. 1), several of which have key roles in cell sur-
vival and oncogenesis. These proteins modulate the binding of
mRNA to the ribosome, a process facilitated by the assembly of
the cap binding protein (eIF4E), a helicase (eIF4A) and a scaffold
protein (eIF4G), to form the eIF4F complex (eIF4E/eIF4A/
eIF4G).1-3 The eIF4G scaffold protein possesses domains that
interact with eIF4E, eIF4A, eIF3 and the poly(A) binding pro-
tein, PABP.1-4 PABP itself is regulated by interaction with other
proteins; binding of Paip1 to PABP stimulates protein synthesis
while interaction with Paip2 is inhibitory to translation.5,6 The
activity of the eIF4F complex is regulated by a family of proteins,
the eIF4E binding proteins (4E-BPs). Using a conserved motif,
4E-BPs compete with eIF4G for a common surface on eIF4E
and inhibit eIF4F assembly. In mammalian cells, activation of
the mechanistic target of rapamycin (mTORC1) leads to phos-
phorylation of 4E-BP1 in a hierarchical manner. This promotes
protein synthesis by releasing eIF4E and enabling eIF4F complex
assembly on the m7GTP cap of mRNA, mediating 40S ribo-
somal subunit binding by a bridging interaction between eIF4G
and eIF3.1-3
In most organisms there is more than one isoform of most of
these translation initiation factors. For example, there are 3 iso-
forms of eIF4A, eIF4G and PABP.7-9 In some cases the functions
of the isoforms are indistinguishable, in others there are indica-
tions that the different isoforms display mRNA-specific regula-
tion.7-9 Further work will be required to uncover the full range of
functions and specificities of these isoforms.
Ubiquitin like proteins
Ubiquitin-like proteins (Ubls) comprise a family of structur-
ally related proteins. The different members of the family share
sequence similarities, and in particular the proteins contain a
conserved b-grasp fold consisting of 5 b sheets and one a helix.10
Ubiquitin is a 76 amino acid protein and is the most highly con-
served member of the Ubl family, with 96% identity between
yeast and human ubiquitin. SUMO (small ubiquitin-like modi-
fier) is less conserved between species and contains a longer,
more variable N-terminal extension than ubiquitin being around
100–110 amino acids in total length.11 ISG15, between 155–
165 amino acids in length, contains 2 ubiquitin-like domains.12
It was the first member of the family to be identified and, unlike
ubiquitin and SUMO, is present only in vertebrates. The gene
was so named because it was observed to be an interferon stimu-
lated gene encoding a 15 kDa protein.13 Most members of the
Ubl family are synthesized as precursor proteins that need to be
processed to a mature form to reveal a di-glycine motif at the
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Figure 1. For ﬁgure legend, see page e959366-3.
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C-terminus that is required for activation and subsequent con-
jugation of the Ubl to target proteins. The exception to this
is ISG15 in fish and bovine species where the protein is syn-
thesized in the mature form.14 Ubls are attached to one or
more lysine residues in target proteins. There are no known
consensus sequences for conjugation sites for ubiquitin and
ISG15. However SUMO is frequently, although not always,
attached to lysine residues present within the consensus
sequence cKxE, where c D a hydrophobic amino acid and x
is any amino acid.11
Ubiquitylation
Ubiquitin can be covalently attached to lysine residues in tar-
get proteins as a monomer or in the form of chains. This occurs
via the activity of a number of proteins, the E1 (ubiquitin acti-
vating enzyme), E2 (ubiquitin conjugating enzyme) and E3
(ubiquitin ligase) proteins (Fig. 2). In most organisms there is a
single E1, around 40 E2s and hundreds of E3s (reviewed
in15,16). Ubiquitin is produced as a precursor protein that is
processed to the mature form by one of a small number of spe-
cific ubiquitin proteases, to reveal a diglycine motif at the C-ter-
minus. Ubiquitin is then activated in an ATP-dependent
manner, by the formation of a thioester bond between the C-ter-
minal glycine residue and a cysteine residue on the E1 activating
enzyme. From here it is passed to an E2 ubiquitin conjugating
enzyme, again, via the formation of a thioester bond between the
C-terminal glycine residue and a cysteine residue. Attachment of
ubiquitin requires one of a large number of E3 ubiquitin ligases,
which in many cases interact directly with target proteins, but
which in some instances interact with targets via an adaptor pro-
tein. In the main, the E3s provide the specificity for the modifi-
cation. Ubiquitin chain formation occurs via lysine residues
within ubiquitin itself, and also requires the activities of the E1,
E2 and E3 enzymes. The most common linkages are via K11,
K48 and K63.17,18 Ubiquitin can be removed from targets by
the actions of deubiquitinating enzymes (DUBs). Ubiquityla-
tion has 2 main roles: targeting of proteins for proteolysis and
modification of protein function. The best studied role of ubiq-
uitylation is its targeting of proteins for proteasome-mediated
degradation. This involves the recognition of K11- and K48-
linked ubiquitin chains by the 26S proteasome.19 However,
there is a rapidly expanding literature on other roles for ubiqui-
tylation. For example ubiquitylation of PCNA is required for
the recruitment of an error-prone polymerase to undertake
translesion DNA synthesis e.g,20 while ubiquitylation of mem-
brane proteins is required for endocytosis and ubiquitylation of
PIN2 is required for vacuolar sorting (reviewed in21). In these
cases the modification involves a single ubiquitin or K63-linked
chains.
Sumoylation
The process of sumoylation is very similar to that of ubiqui-
tylation, involving SUMO-specific E1 (SUMO activating
enzyme), E2 (SUMO conjugating enzyme) and E3 (SUMO
ligase) proteins.11 There is a single E1 (a heterodimer), a single
E2 (Ubc9) and to date around 12 E3s have been identified.
Unlike ubiquitylation, an E3 is not always required for modifi-
cation, as the E2 is in some cases sufficient, and can provide a
degree of target specificity.22 Like ubiquitin, SUMO can be
attached to proteins either as a monomer or in the form of
poly-SUMO chains.11 Sumoylation affects protein-protein
interactions,23,24 protein activity25 and protein localization.26
In addition, SUMO chains interact with STUbLs (SUMO-tar-
geted ubiquitin ligases) that bring about ubiquitylation of the
target protein and associated SUMO chains, resulting in pro-
teasome–mediated proteolysis.27
ISGylation
ISG15 is conjugated to target proteins in a manner similar to
that of ubiquitin and SUMO.28 ISG15 expression and modifica-
tion (ISGylation) are activated by Type I interferon (IFN), which
is one of a number of critical cytokines in the innate immune
response. As is the case for ubiquitin and SUMO, there are pro-
teases that are specific for processing ISG15 and deconjugating it
from target proteins (e.g., USP43,29) and a specific E1 enzyme
for ISG15.29 However, some of the E2s (e.g., UbcH8) and E3s
(e.g., Efp—the partner of UbcH8, and HHARI—the human
homolog of Drosophila ariadne) involved in ISGylation also
appear to be involved in ubiquitylation.30,31
Identiﬁcation of Ubl Attachment Sites and the Roles
of Modiﬁcation
Early methods for the identification of modified sites involved
site-directed mutagenesis of individual lysine residues in target
proteins, followed by analysis in vitro or in vivo to determine
whether modification still occurred. While this has been success-
ful in some cases (e.g.,32) in many cases it has been problematic
since other lysine residues are frequently used instead of the nor-
mal sites in the mutant proteins. More recently, mass spectrome-
try has been used successfully for site identification (e.g.,33). This
involves the cleavage of modified proteins by trypsin or other
suitable protease to release peptides from the target. This method
is facilitated by having a protease cleavage site close to the C-ter-
minal diglycine motif attached to the target, so that only a few
extra amino acids remain attached to the modified site. Modifica-
tion sites are thus detected by the identification of peptides that
are increased in Mr by an amount dependent on the position of
the cleavage site within the Ubl.
Figure 1. (See previous page). Formation of the 48S preinitiation complex. eIF1, 1A and 3 interact with the 40S ribosomal subunit. This then interacts
with eIF5 and the ternary complex (eIF2-GTP-Met-tRNA) to form the 43S complex. In parallel, eIF4E and eIF4A are recruited by eIF4G to form the eIF4F
complex. The availability of eIF4E is controlled by 4E-BP1, which in turn is regulated by phosphorylation by mTOR. The eIF4F complex binds to the cap
on mRNA along with Poly(A)-binding protein (PABP) and eIF4B. PABP is regulated via interactions with 2 PABP proteins, PAIP1 and PAIP2. The 43S com-
plex then binds close to the cap from where it can scan the mRNA for the start codon.
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Analysis of the role of the modifications is hampered by the
fact that frequently, only low levels of modified forms are
observed in cells. The reason for this could be that the modifica-
tions are transient, are labile, or as in the case of poly-ubiquityla-
tion and poly-sumoylation, are targeting the protein for
proteasome-mediated destruction. It is also possible that modifi-
cation may be confined to target molecules in a particular cellular
location. Additionally, it is proposed that this form of post-trans-
lational modification is not like modifications such as phosphory-
lation—i.e., an on/off switch. For example, in the case of
SUMO, it is proposed that in some cases modification results in
a change in conformation of the target protein that is maintained
even after desumoylation occurs. Thus analysis of the roles of
these modifications has lagged behind analysis of the function of
other types of modifications.
Identification of the roles of the modifications has been under-
taken, in the main using in vitro assays to look at relative binding
abilities of wild type and unsumoylatable mutant proteins for
their binding partners e.g.,32 or by introduction of mutant cod-
ing sequences into cells to determine the effect of inability to
modify a particular protein. This is relatively straightforward in
yeast where a mutant copy can be integrated in the genome as
Figure 2. Ubiquitylation pathway. E1 D Ubiquitin activating enzyme, E2 D ubiquitin conjugating enzyme, E3 D ubiquitin ligase, DUB D deubiquitylating
enzyme. Ubiquitin is activated by the formation of a ubiquitin-adenylate before forming a thioester bond with a cysteine residue in the E1 ubiquitin acti-
vating enzyme. Ubiquitin is passed to an E2 ubiquitin conjugating enzyme, again forming a thioester bond. Target proteins are recognized by E3 ubiqui-
tin ligases, either directly or via an adaptor, and ubiquitin is attached via the formation of an e-amino bond. Ubiquitin can be attached to target proteins
either as a monomer, or in the form of ubiquitin chains. Ubiquitin can be removed from target proteins by the action of one of a number of DUBs.
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the sole copy of the coding sequence e.g.,34 In mammalian cells,
the mutant sequence can be introduced by transfection, but is
dependent on having cells where the gene has been knocked out
or where siRNA depletion is efficient. Depletion of the any of
the enzymes in the conjugation pathway would be likely to affect
multiple targets and would not be appropriate.
Role of Modiﬁcation by Ubiquitin or Ubls
in Translation Initiation Factors
A series of recent proteomic screens have identified numerous
translation initiation factors that are modified by either ubiquitin
or SUMO, or in many cases, by both (Table 1). Additionally,
some of the screens have identified the lysine residues required
for the modification. Early studies involved the overexpression of
the modifier, but recently more refined methods using diGly cap-
ture techniques have been used to identify sites when the
modifier is expressed at endogenous levels e.g.35,36 These studies
use mass spectrometry to identify diGly-modified peptides
obtained by trypsin digestion of cellular proteins. A list of modi-
fied sites can be found at PhosphoSitePlus37 (http://www.
phosphosite.org/home). In many cases, individual lysine residues
are identified as a single ‘hit’, making them less likely target sites
than lysine residues that are highly represented, as for example is
observed in eIF4A and eIF4G proteins.
More detailed studies on the role of modification of a number
of the individual proteins by ubiquitin, SUMO and in one case,
ISG15 have also been reported. We summarize here what is
known about the roles of these post-translational modifications
and how they might affect translation rates in mammalian cells.
eIF4E
Regulation of eIF4E levels is important for normal cell
growth, as disruption of its expression or its over-production
leads to aberrant cell growth or oncogenesis.38 Additionally,
Table 1. Proteins identiﬁed in proteomic screens as being modiﬁed by ubiquitin or SUMO
Initiation factor Ubiquitin SUMO Reference
eIF1A Hs Ubiquitin*Mm Ubiquitin Rn SUMO-3 35,36,58,59
eIF2A Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2*At SUMO 35,55,59,80
eIF2a Hs Ubiquitin*Mm Ubiquitin Dm SUMO 36,56,59
eIF2B-b Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1/2 36,59,81
eIF2b Hs Ubiquitin*Mm Ubiquitin At SUMO*Sc SUMO-1 36,59,80,82
eIF2 subunit 1 Hs Ubiquitin*Mm Ubiquitin Rn SUMO-3 35,58,59
eIF2g Hs Ubiquitin*Mm Ubiquitin Dm SUMO*Hs SUMO-1*Hs SUMO-2/3*Sc SUMO 35,36,56,57,59,82,83, *
eIF5B* Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2*Hs SUMO-1* 55,59,61(A)
eIF3A Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin Hs SUMO-2*Hs SUMO-1 36,55,59,61(B)*
eIF3B Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2 35,55,59
eIF3C Hs Ubiquitin*Mm Ubiquitin Hs SUMO 1/2 35,59,81
eIF3D Hs Ubiquitin*Mm Ubiquitin Rn SUMO-3 35,58,59
eIF3E Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1/2 35,59,81
eIF3F Hs Ubiquitin*Mm Ubiquitin 59,74(C)
eIF3G Hs Ubiquitin*Mm Ubiquitin 35,36,59
eIF3H Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin 35,36,59(D)*
eIF3I Hs Ubiquitin Sc SUMO*Hs SUMO-1/2 35,36,59,60,82–84
eIF3J Hs Ubiquitin*Mm Ubiquitin 36,59
eIF3K Hs Ubiquitin*Mm Ubiquitin 35,36*
eIF3L Hs Ubiquitin*Mm Ubiquitin 35,59
eIF3M Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1 35,59,83
eIF3X Hs SUMO-2 55
eIF4A1 Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin Dm SUMO*Rn SUMO-3*Hs SUMO-1/2*At SUMO 35,36,55–62(D)
eIF4A2 Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1 35,59,61
eIF4E Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1 36,46,59
eIF4GI Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1/2 36,57,59,61
eIF4GII Hs Ubiquitin 35
eIF4GIII Hs Ubiquitin*Mm Ubiquitin 35,36
eIF5A Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin Hs SUMO-1/2 35,59,83(D)
PABP1 Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2*Sc SUMO 35,55,57,59,85
PABP4 Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2 35,55,59
Hs: human, Rn: rat, Mm: mouse, Sc: S. cerevisiae, At: Arabidospsis. (A) (2010) CST Curation Set: 9913; Year: 2010; SILAC: N; Biosample/Treatment: AMO-1(cell
line)/Velcade; Disease: -; Speciﬁcity of Antibody Used to Purify Peptides prior to MS2: anti-UbK Antibody Used to Purify Peptides prior to MS2: Ubiquitin
(D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoafﬁnity Beads Cat#: 1990. (B) (2008) CST Curation Set: 3970;
Year: 2008; SILAC: N; Biosample/Treatment: brain(tissue)/untreated; Disease: -; Speciﬁcity of Antibody Used to Purify Peptides prior to MS2: anti-UbK.
(C) (2009) CST Curation Set: 8668; Year: 2009; SILAC: N; Biosample/Treatment: RPMI-8266(cell line)/Velcade; Disease: -; Speciﬁcity of Antibody Used to Purify
Peptides prior to MS2: anti-UbK Antibody Used to Purify Peptides prior to MS2: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin
Branch Motif (K-e-GG) Immunoafﬁnity Beads Cat#: 1990. (D) (2007) CST Curation Set: 3578; Year: 2007; SILAC: N; Biosample/Treatment: brain(tissue)/ischemia
and Reperfusion; Disease: -; Speciﬁcity of Antibody Used to Purify Peptides prior to MS2: anti-UbK.
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eIF4E protein levels increase during differentiation e.g.,39 eIF4E
is both mono- and poly-ubiquitylated40,41 and this has been
demonstrated to occur mainly on K159.40 This modification is
enhanced by the E3 ubiquitin ligase, Chip (carboxy terminus of
Hsp-70 interacting protein) which is known to have a role in reg-
ulating protein quality control.42 A mutant form of eIF4E that is
unable to interact with eIF4G or 4E-BP1 is more highly ubiqui-
tylated than wild type eIF4E. This results in increased degrada-
tion by the proteasome of the mutant form, consistent with a
role for ubiquitylation of eIF4E in a quality control process,
removing inactive forms of the protein from the cell.40 A role for
ubiquitylation in quality control is supported by a number of
observations. First, that binding of eIF4E to 4E-BP1 (eIF4E
binding protein that is also regulated by ubiquitylation—see
below) suppresses ubiquitylation and degradation and that only
non-ubiquitylated eIF4E binds eIF4G. Second, overexpression of
4E-BP1 prevents ubiquitin-mediated degradation of eIF4E.
Third, heat shock (45C 10 min, conditions that would result in
a degree of protein misfolding) also induces ubiquitylation of
eIF4E, as does exposure to another form of stress, cadmium
chloride.41
While poly-ubiquitylation clearly has a role in targeted
destruction of eIF4E, little work has been performed to deter-
mine whether there is a different role for mono-ubiquitylation in
regulating levels or subcellular localization of eIF4E. In contrast,
the biological significance of eIF4E phosphorylation and its effect
on translation have been studied over many years; however, the
role of phosphorylation in modulating the activity of the protein
is still not completely understood, although enhanced levels of
eIF4E phosphorylation are associated with a number of human
tumors.43,44 Biophysical studies have suggested that phosphoryla-
tion of eIF4E decreases its affinity for the mRNA cap of mRNA,
possibly allowing rapid recycling of eIF4E between competing
mRNAs.45 However, it has also been suggested that phosphoryla-
tion of S209 causes a retractable salt bridge to form with K159
(the ubiquitylation site) which leads to increased binding of
capped mRNA.40 Mutation of K159 to alanine but not arginine,
reduces association with cap analogs, indicating that a positive
charge is required at this position. Despite the fact that the
K159R mutant cannot be ubiquitylated, it has been proposed
that mono-ubiquitylation may stabilize the distance between
S209 and K159, or that ubiquitin itself may form part of the
bridge between S209 and K159.40
eIF4E is also modified by SUMO,32,46 in a process that is pro-
moted by HDAC2 (histone deacetylase 2).46 Sumoylation occurs
on several lysine residues, namely K36, 49, 162, 206 and 212.
Interestingly, unlike what has been observed with a number of
other proteins, such as IkBa and PCNA,34,47 sumoylation and
ubiquitylation of eIF4E do not occur on the same lysine residues.
Sumoylation of eIF4E is dependent on phosphorylation, but the
reverse is not true: inability to sumoylate eIF4E does not affect
its ability to be phosphorylated.32 Sumoylation results in the
induction of translation of a subset of mRNAs required for cell
proliferation and apoptosis. A mutant form of eIF4E that cannot
be sumoylated is still able to bind m7GTP, indicating that cap-
binding is unaffected. However, compared with wild type
protein, the mutant form binds significantly better to 4E-BP1
than it does to eIF4G, and is unable to form stable eIF4F com-
plexes. It has been suggested that sumoylation induces a confor-
mational change in eIF4E producing a change in interaction
surfaces resulting in release from 4E-BP1 and promoting interac-
tion with eIF4G. The inability of the mutant protein to be
sumoylated results in an increase in the amount of eIF4E inter-
acting with 4E-BP1.32 While overexpression of wild type eIF4E
in NIH-3T3 cells results in increased expression of eIF4E-
regulated genes, this is not observed when unsumoylatable eIF4E
is overexpressed.32 At this time is unclear whether sumoylation of
eIF4E has any effect of global rates of translation or rates of
export of specific mRNAs from the nucleus.
4EHP
4EHP, also known as eIF4E2, binds to the m7GTP cap in a
manner similar to that of eIF4E. However, unlike eIF4E, it does
not bind eIF4G and therefore does not allow ribosome recruit-
ment. It thus competes with eIF4E for the mRNA and prevents
translation.48 It is targeted for ubiquitylation49 and interestingly,
also for modification with another Ubl, ISG15.50 Curiously, the
E3 ligase HHARI, which has recently been shown to be a marker
of cellular proliferation,51 stimulates both ubiquitylation and
ISGylation of 4EHP.49,50 Proteomic studies have identified
K239 as a ubiquitylation site, but this has not been verified in a
detailed study. In contrast, ISGylation, which occurs on K134
and K222, has been analyzed in some detail.50 Binding studies
indicate that ISGylated 4EHP has a higher affinity for m7GTP
than the unmodified form. It has been proposed that this modifi-
cation is used by cells to inhibit translation of specific mRNAs in
innate immune responses. Interestingly, despite its similarity to
4EHP, eIF4E is not ISGylated.
4E-BP Family
The eIF4E binding proteins (4E-BPs) are key regulators of
protein synthesis.1-3 As their name suggests, they function by
interacting with eIF4E. This inhibits eIF4E function by prevent-
ing it from interacting with eIF4G to form the mature eIF4F
complex. The 4E-BP proteins are phosphorylated following acti-
vation of mTORC1, in response to changes in growth condi-
tions, and interaction of eIF4E with 4E-BP1 and -2 occurs with
the hypophosphorylated form.1-5 A key factor in the regulation
of translation initiation is that the relative levels of eIF4E and
4E-BP1 and -2 are highly controlled.52 The hypophosphorylated
form, but not the hyperphosphorylated form, of 4E-BP1 is unsta-
ble if not bound to eIF4E. Under these conditions, 4E-BP1 is
ubiquitylated and targeted for proteasome-mediated proteoly-
sis.52,53 The role of ubiquitylation was identified following some
rather unexpected results obtained when knockdown of eIF4E
using shRNA was demonstrated to have no effect on protein syn-
thesis.52 This was subsequently shown to be due to concomitant
degradation of 4E-BP1, which resulted in the release of eIF4E
molecules to compensate for the loss brought about by the
reduced expression. K57, a lysine residue conserved between all 3
4E-BPs, was identified by the Sonenberg lab as the ubiquitylation
site in 4E-BP1,52 and a screen of an siRNA library identified the
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KLHL25-CUL3 as the E3 ubiquitin ligase responsible for 4E-
BP1 degradation. Knockdown of KLHL25 resulted in a decrease
in translation, consistent with it having a role in controlling levels
of 4E-BP1.52
Proteasome activity (presumed to be a result of poly-ubiquity-
lation) has also been demonstrated to be required for the forma-
tion of a truncated form of 4E-BP1 (tr4E-BP) in murine erythro-
leukemia (MEL) cells containing activated p53.54 This truncated
form is 3 kDa smaller than full-length protein, is unphosphory-
lated and relatively stable. It also binds to eIF4E in preference to
the full-length protein. It has been proposed that the production
of this p53-induced form may be contributing to the ability of
p53 to regulate apoptosis and malignancy.
eIF4A
Two isoforms of eIF4A have been identified in proteomic
screens as being modified by ubiquitin and SUMO.35,36,55-62 In
contrast to what is observed with some of the other initiation fac-
tors, modified peptides from both eIF4A1 and eIF4A2 are highly
abundant in the proteomic screens designed to identify ubiquity-
lation sites, implying that modification is likely to have a key role
(s) in the regulation of the function of these 2 proteins. In the
ubiquitin screens, most of the modified sites identified in the
human eIF4A proteins were also observed in the mouse proteins,
suggesting that they are likely to be true ‘hits’ and not false posi-
tives. Interestingly, eIF4A2 (but not eIF4A1) and translational
repression have both been shown to be essential for miRNA-
mediated gene regulation.63 However, the post-translational
modification of these proteins by ubiquitin or Ubls has not been
analyzed in detail and to date there are no reports on whether it
affects the activity of the eIF4A protein or miRNA-mediated
translational control.
In a role unrelated to its function in translation, ubiquityla-
tion of Drosophila eIF4A has been shown to be linked with
Decapentaplegic (Dpp) signaling.64 Additionally, rice DRM2
(required for RNA-directed DNA methylation) interacts with
eIF4A via its ubiquitin associated (UBA) domain, (although
whether this occurs with a ubiquitylated form has not been
analyzed).65
eIF4G
There are 3 isoforms of the scaffold protein, eIF4G, eIF4GI-
III. As observed with eIF4A, diGly-modified peptides from these
proteins are abundant in proteomic screens designed to identify
ubiquitylation sites,35,36,57,59,61 and again most are observed in
both the human and mouse proteins. In eIF4GI these sites (6 in
total, 4 common to both human and mouse) map to lysine resi-
dues occurring between amino acids 593–925 which map close
to, or in the region of, the eIF4E and eIF4A/3 binding sites. The
abundance of these modified tryptic fragments and their position
in the protein suggests that this post-translational modification is
likely to be important for regulating the functions of these pro-
teins, possibly by affecting the interaction of eIF4G with other
members of the eIF4F complex. Again, these modifications have
not been analyzed in detail and to date there are no reports on
whether they affect the activity of eIF4GI. In addition to this
modification by ubiquitin, eIF4GI has been shown to be sumoy-
lated in both fission yeast and human cells.66 Sumoylation of S.
pombe eIF4G is increased following exposure of cells to 1 M KCl
or arsenite, conditions which result in the formation of stress
granules. In vitro sumoylation studies have identified 2 sumoyla-
tion sites in mammalian eIF4GI, K1368 and K1588, residing in
the eIF3/4A binding site and the Mnk-binding domain, respec-
tively. (Mnks (MAP kinase-interacting kinases) are kinases which
bind to the C-terminus of eIF4G and phosphorylate eIF4E
which is bound to the N-terminus of eIF4G.67) These data sug-
gest that sumoylation may be affecting interactions of eIF4GI
with associated proteins, e.g., eIF4E, and possibly the assembly
of eIF4G into stress granules.
Paip2
Poly(A)-binding protein (PABP) is regulated through the
interaction with 2 proteins, Paip1 and Paip2.5,6 Paip1, which
also interacts with eIF3g, is eIF4G-like and is stimulatory for
translation, while Paip2 represses PABP function by decreasing
the affinity of PABP for polyadenylated mRNA, thus inhibiting
translation. Paip1 and Paip2 both have 2 domains, PAM1 and
PAM2 which interact with PABP. This interaction occurs
through RRM-1 and PABC domains, respectively.68 Addition-
ally, PAM2 is capable of interacting with EDD (a member of the
HECT domain family of E3 ubiquitin ligases) which also con-
tains a PABC domain.69 In cells where levels of PABP are
depleted, Paip2A is ubiquitylated in an EDD-dependent manner
prior to proteasome-mediated degradation.70 Interestingly, the
affinity of the PAM2 domain of Paip2 for the PABC domain of
PABP is greater than that of the affinity for the PABC of EDD.
Thus, it is proposed that interaction of PABP with Paip2 com-
petes with EDD for interaction with PAM2 on Paip2, and that
this normally prevents ubiquitylation of Paip2.70 However, in
apparently contradictory work, it has been demonstrated that
during human cytomegalovirus infection PABP levels rise con-
comitantly with the levels of both Paip2 and EDD1. The reason
for this is not known, but it has been proposed that it may pro-
vide cells with a process to allow rapid changes in protein levels if
necessary.71 Paip2B is also polyubiquitylated, although at a
somewhat lower level that Paip2, and is hence more stable.72
eIF3
Proteomic studies have identified many of the eIF3 subunits
as targets for ubiquitylation and/or sumoylation. However, inde-
pendent of these studies, eIF3f is the only eIF3 subunit where the
function of these modifications has been studied in any detail.
eIF3f is a non-core subunit of the eIF3 complex. It can act both
as a repressor and as an enhancer of translation (reviewed in73).
Its role as a translational enhancer came to light in a study on
muscle atrophy.74 Here, eIF3f is ubiquitylated by the MAFbnx/
Atrogin1 protein which is a muscle-specific F-box protein ubiq-
uitin E3 ligase.75 This E3 is upregulated and essential for acceler-
ated muscle protein loss in a number of disorders.76
Ubiquitylation of eIF3f occurs on multiple (6) lysines in the C-
terminus74 and results in its ubiquitin-mediated proteolysis in
myotubes undergoing atrophy. Under these conditions both
www.landesbioscience.com e959366-7Translation
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 Su
sse
x L
ibr
ary
] a
t 0
3:5
9 1
0 F
eb
ru
ary
 20
15
 
MAFbnx and eIF3f are detected in the nucleus.75 It has been pro-
posed that this ubiquitylation may be associated with the rapid
downregulation of certain proteins during muscle atrophy. eIF3f
also interacts with the ubiquitin E3 ligase TRC8 to inhibit pro-
tein synthesis. The mechanism by which this occurs is unknown,
but it has been proposed that TRC8 targets an eIF3 subunit for
ubiquitylation.77 Unrelated to its role in translation, eIF3f can
act as a deubiquitylating enzyme (DUB). In this capacity it is
capable of deubiquitylating, and thus contributing to the activa-
tion of, the Notch signaling receptor in Drosophila.78
Interestingly, recent work has shown that eIF3e is involved in
eIF4E phosphorylation; Mnk1 binding to eIF4F is dependent on
eIF3e, and eIF3e is sufficient to promote Mnk1-binding to
eIF4G.79 As eIF3e is modified by both ubiquitylation and
sumoylation, it would be interesting to know if these modifica-
tions of eIF3e also have a role in controlling eIF4E
phosphorylation.
Summary
In conclusion, despite the fact that numerous translation initi-
ation factors have been shown to be ubiquitylated and/or sumoy-
lated in proteomic screens, relatively little is known about the
effects of the modifications on the functions of individual pro-
teins. In part this is due to the transient nature of these modifica-
tions, e.g., in many cases of sumoylation, less than 5% of a
particular protein is modified at any one time, and the sumoy-
lated species appear to be very labile in certain organisms due to
highly active SUMO-specific proteases. Additionally, since ubiq-
uitylation targets proteins for destruction, analysis of ubiquity-
lated proteins, other than in the presence of a proteasome
inhibitor, is difficult.
The recent use of proteomic screens to identify modified pro-
teins and the modified site(s) suggests that there are many more
cases where post-translational modification by ubiquitin or Ubls
is likely to affect translation initiation factors. For example,
sumoylation of eIF4A1/2 might have a role in regulating both
the unwinding of mRNA secondary structure and the ability of
eIF4A2 to mediate miRNA-dependent gene expression in mam-
malian cells. Further work on these modifications is required to
fully elucidate their effect on individual proteins and on transla-
tional control of gene expression as a whole.
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